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Abstract 
The influx of over one million Syrian refugees to Lebanon brought enormous demands 
on the country’s health system. Despite some success in facilitating access to care for highly 
prevalent non-communicable diseases (NCDs), evidence is needed to tailor interventions to meet 
chronic health needs of Syrian refugees and host communities in Lebanon. To this end, this 
dissertation assesses healthcare utilization and medication adherence for hypertension and 
diabetes among Syrian refugees and host communities in Lebanon. 
Paper 1 assesses care-seeking, spending, and medication adherence using data from a 
2015 household survey of Syrian refugees and Lebanese host communities. Papers 2 and 3 
explore care visit frequency and medication adherence, respectively, in greater depth using 
baseline data from a longitudinal cohort study of care-seekers at primary health facilities in 
Lebanon.  
Descriptive analyses reveal material gaps between refugees and host communities in care 
utilization, out-of-pocket costs, and medication interruption. At the population level, care-seeking 
and uninterrupted medication adherence for hypertension and diabetes are high. Qualitative 
findings reveal potentially insufficient GP training and uncertainty about the NCD care quality at 
primary health facilities. Despite low rates of medication interruption for two weeks or longer in 
quantitative findings, non-adherence was widely reported during focus group discussions for 
shorter durations than captured quantitatively and suggest refinements to improve the quantitative 
measure’s reliability in this context. 
Few refugee household characteristics were associated with individuals’ care-seeking and 
medication adherence. Individual level analyses among refugees indicate that for diabetes, older 
age and housing stability are associated with higher care-seeking and lower odds of medication 
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interruption. For hypertension, housing stability was also associated with higher care-seeking 
rates and reduced odds of medication interruption. 
Although care-seeking is high, there are opportunities to improve service utilization and 
medication adherence by these populations. Current programs may sustain high care-seeking 
rates; however, continued efforts are needed to inform refugees of available services. Expansion 
of alternative payment arrangements, increased use of community health workers and refugee 
outreach volunteers, and quality improvement via large-scale health provider training and 
collaborative care models could strengthen current initiatives to improve NCD management in 
Lebanon.  
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Chapter 1. Introduction 
Since its start in March 2011, the Syrian conflict has generated widespread displacement. 
More than half of Syria’s pre-conflict population has been displaced. By mid-2018, an estimated 
6.2 million individuals were displaced within Syria and an additional 6.5 million refugees fled to 
other countries, accounting for one-third of the global refugee population.1 The majority of these 
refugees are hosted in neighboring countries throughout the region. As of late 2018, an estimated 
1.5 million Syrians were hosted in Lebanon, 950,000 of whom were registered with the United 
Nations High Commissioner for Refugees (UNHCR), making it host to the largest number of 
refugees per capita globally.2,3 Given the substantial burden of non-communicable diseases 
among both Syrian refugees and the host communities within which they are settled, 
humanitarian actors and the Government of Lebanon face immense challenges in addressing 
health needs for chronic conditions, which are often difficult and expensive to manage and 
require continued monitoring and adherence to prescribed treatment over time to mitigate long-
term complications.4-6 
1.1. Research Aims and Objectives 
The objectives of this dissertation are to assess healthcare utilization and medication 
adherence for hypertension and type 2 diabetes among Syrian refugees and host communities in 
Lebanon, and to identify factors associated with care-seeking behaviors and medication 
adherence for these conditions among refugees. The specific research objectives are: 
1. To compare health service utilization, out-of-pocket spending, and interrupted 
medication adherence between Syrian refugees and host communities at the 
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population level and assess whether refugee household characteristics are associated 
with care-seeking and interrupted medication adherence. 
2. To characterize health service utilization patterns for hypertension and type 2 
diabetes among Syrian refugees and host community patients receiving care at select 
primary health facilities in Lebanon, and to identify factors associated with refugees’ 
utilization of general and specialist physician care. 
3. To compare the prevalence of interrupted medication adherence among Syrian 
refugees and host community patients receiving care at select primary health facilities 
in Lebanon, and to characterize determinants of interrupted adherence among Syrian 
refugees. 
1.2. Organization of the Dissertation 
This dissertation is presented in eight chapters, organized as follows: 
• Chapter 2 provides a background overview of the Syrian crisis, affected populations in 
Lebanon, and the organization of the Lebanese health system and provision of health 
services to Syrian refugees in Lebanon. 
• Chapter 3 is a literature review of hypertension and type 2 diabetes treatment, care 
utilization, and the measurement, role, prevalence, and determinants of medication 
adherence.  
• Chapter 4 details the conceptual framework, study design, and analytical methods 
utilized. 
• Chapter 5 examines care-seeking, utilization of health services, out-of-pocket spending, 
and adherence to medication for hypertension and diabetes among Syrian refugees and 
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host communities in Lebanon at the population level, including analyses of household 
level determinants of care-seeking and medication adherence for Syrian refugees (Paper 
1). 
• Chapter 6 characterizes care utilization for hypertension and type 2 diabetes among 
Syrian refugees and Lebanese patients receiving care at select primary health facilities in 
Lebanon and explores clinical and demographic factors associated with utilization of 
health care provided by general practitioners and/or specialist physicians (Paper 2).  
• Chapter 7 focuses on medication prescription and adherence for hypertension and type 2 
diabetes among Syrian refugee and Lebanese primary care patients and examines 
individual and household level determinants of interrupted medication use by Syrian 
refugees (Paper 3).  
• Chapter 8 summarizes key findings from chapters five through seven, outlines areas for 
further research, and provides recommendations for ongoing and future programming. 
 
Additional information about parent study methods is provided in Appendices A and B. 
Supplemental analysis methods and results are included in Appendices C, D, E, F, and G. 
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Chapter 2.  Background and Study Context 
2.1. Syrian Crisis 
The conflict in Syria, which began in March 2011, has produced widespread 
displacement with more than 6.5 million Syrians internally displaced and an exodus of refugees 
to countries throughout the region. In July 2015, over four million Syrian refugees were 
registered or awaiting registration with UNHCR, a figure that has grown to reach more than 5.5 
million in July 2019, in addition to an unregistered population unknown in size.7,8 The largest 
Syrian refugee populations are in Turkey, Lebanon, Jordan, and, to a lesser extent, Iraq and 
Egypt.  
As of mid-2015 when data for this study were collected, there were over 1.17 million 
Syrian refugees registered with UNHCR in Lebanon. Though there is no reliable data on the 
number of unregistered refugees in Lebanon, 2014 estimates placed this figure between 2,000 and 
4,000 individuals.9 Lebanon kept its border open to Syrians fleeing the unrest through 2014; 
however, restrictions on the entry of Syrian refugees were tightened in early 2015. There are no 
formal Syrian refugee camps in Lebanon; rather, refugees reside in a variety of settings ranging 
from rented accommodations to informal settlements, other transitional housing, or staying with 
host families. As the Syrian refugee population has grown, Lebanon’s absorption capacity has 
become increasingly strained. The impact of the refugee influx on Lebanon’s economy, 
demographics, political stability, and security is pervasive since, with an estimated 183 refugees 
per 1,000 inhabitants at the end of 2015, the country is host to the largest number of refugees in 
relation to its host population worldwide.10 
With direct and indirect effects of the Syria conflict on Lebanon’s economy estimated at 
US$7.5 billion at the end of 2014, the stability of Lebanon’s economy and institutions continue to 
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face severe threats.11 In addition to the Syrian refugee crisis unfolding, a second crisis has 
emerged with the tremendous effect on Lebanese host communities. An overwhelming 86% of 
Syrian refugees in Lebanon reside in communities already hosting 66% of the most vulnerable 
Lebanese populations.12 In response, the 2015-16 Lebanon Crisis Response Plan (LCRP), an 
integrated humanitarian and stabilization guide to responding to the Syrian refugee crisis 
developed jointly by the humanitarian community and the Government of Lebanon, focuses on 
national and local capacities with two of its three objectives seeking to (i) “strengthen the 
capacity of national and local delivery systems to expand access to and quality of basic public 
services” and (ii) “reinforce Lebanon’s economic, social, environmental, and institutional 
stability.”13 The US$77.9 million applied to “support service delivery, institutional capacity 
building, and enhance societal resilience and stability” in public institutions through the LRCP in 
2014 more than doubled to over US$170 million in 2015.14   
Despite priority setting and investment in local and national stability, numerous studies 
have noted a continued sense of dissatisfaction within Lebanese host communities.15,16 This 
discontentment is driven by resource scarcity, perceived deterioration of living conditions, 
economic competition, and historical tensions between Syrians and Lebanese, among many other 
factors.15,16 Perceptions of inequitable distribution of aid and access to basic services in favor of 
refugees only further these tensions, contributing to community instability and challenges to 
international assistance actors and the Lebanese government alike.  
2.2. Population Overview 
Lebanese Population 
Due to the longstanding power struggle between Lebanon’s 18 recognized religious sects 
and a multitude of other political reasons, most Lebanese demographic data is either outdated, 
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extrapolated, or extensively modeled from outdated sources, rendering most figures unreliable.17 
The last official census conducted in Lebanon was in 1932; however, more recent estimates place 
the Lebanese population around or just above four million, exclusive of more than one million 
Syrian refugees, 450,000 Palestinian refugees, 7,000 Iraqi refugees, and an estimated, though not 
precisely known, foreign worker population between 300,000 and 400,000 also residing in 
Lebanon.18-22 It should be noted that a sizeable population of Syrian migrant workers (estimated 
between 300,000 and 500,000 before the start of the crisis) have had a consistent seasonal 
presence in Lebanon for decades, just one example of the complex historical relationship between 
the two countries’ populations.23,24  
Among the most densely populated countries in the world, Lebanon has an average of 
400 people per square kilometer.25 Approximately 88% of Lebanon’s population resides in urban 
areas, largely in the capital of Beirut, a figure not likely to decline in the near future given 
Lebanon’s 3.2% annual increase in urbanization.26 A middle-income country, Lebanon’s 
economic growth has been inconsistent and unequal, and disparities in socioeconomics and 
access to social services throughout the country are great.27 Despite these disparities, Lebanon 
ranked 67th out of 188 countries in the Human Development Index in 2014, placing it in the “high 
human development” category.28  
Lebanon’s population is representative of a mid-demographic transition, with sizeable 
young and aging populations (Figure 2-1).With a median age of 29.9 years and average life 
expectancy at birth of 77.6 years (76.3 years for males and 78.9 years for females), Lebanon’s 
population growth rate is 0.85%, ranking 129th out of 235 countries on which data is reported in 
the U.S. Central Intelligence Agency’s World Factbook.26 Lebanon ranks similarly with regard to 
birth rate (14.4 births per 1,000 population/ranked 134th) and total fertility rate (1.73 children 
born per woman if she was to pass through child-bearing age/ranked 169th), though higher with 
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regard to death rate (4.90 deaths per 1,000 population per year/ranked 193rd).26 The elderly (65 
years and older) represent 6.6% of the Lebanese population and Lebanon’s elderly dependency 
support ratio, a measure of individuals 65 years and older as a share of the working-age 
population (15 to 64 years), is estimated at 12%.26  
Syrian Population 
The most recent official estimates published prior to the start of the crisis in 2011 based 
on civil registration records estimated the Syrian population to be 24.5 million, approximately 21 
million of whom were estimated to live in the country at the end of 2011.29,30 Due to complex 
political motivations and access challenges, demographic data since 2011 varies widely and most 
figures reflect source biases and/or the inaccessibility of much of the country for proper data 
collection. July 2016 Syrian population figures estimated a decrease of 7.5 million people to just 
over 17 million, after accounting for deaths and the vast number of Syrians refugees that fled the 
country as a result of the conflict.31 Substantially geographically larger than Lebanon, Syria’s 
2016 population density was 101.1 people per square kilometer.31 More than half (57.7%) of 
Syria’s population lives in urban areas, and the urban population reportedly grew by an average 
of 1.4% annually from 2010-2015. Catastrophic drought beginning in late 2006/early 2007 
prompted urban migration of as many as 1.5 million people from herding and agriculturally-
dependent families from rural areas.31,32  
Syria has an overall younger population than Lebanon, with a median age of 24.1 years, 
and is suggested to be in early mid-demographic transition owing to its growing aging population 
(Figure 2-2).31 Both the total fertility rate (3.0 live births per woman) and birth rate (21.7 births 
per 1,000 population) are higher than in the Lebanese population and research among Syrian 
refugee populations in neighboring countries has shown that the conflict and challenges 
 
 8  
 
associated with displacement are not leading to a decreased desire for more children. A 2015 
report by the United Nations Population Fund (UNFPA) found that family planning is not a 
priority for Syrian refugee youth in Lebanon, rather, child-bearing is a “valued and necessary 
achievement” and 46% of married refugee couples reported intending to have children.33 Rather 
than deterring families from having more children, the conflict is leading many to marry off 
young girls to reduce economic hardship or to protect girls from growing threats of sexual 
assault.34 Moreover, half of the youths interviewed by UNFPA agreed with the statement, “it is 
important to have children under these circumstances since we are losing many people in wars.”33 
Of the 13.5 million people in Syria estimated to be affected by the crisis, 4.1 million are women 
and girls of reproductive age, 360,000 (or eight percent) of whom are estimated to be pregnant, 
indicating a likelihood for the continued growth of the young Syrian population.33 Among the 
more than one million Syrian refugees in Lebanon, 265,272 are women and girls of reproductive 
age, 7.2% of whom are estimated to be pregnant.33,35 The elderly (65 years and older) represented 
an estimated 4.1% of the population in Syria in 2016 for an elderly dependence ratio (6.9%), 
almost half that of the Lebanese population.31 Life expectancy at birth in Syria in 2016 was 74.9 
years (77.4 for females and 72.5 for males), and the death rate was four deaths per 1,000 
population per year; little evidence has been published on changes to this since the start of the 
current conflict.31 While concrete evidence is lacking, many posit that death rates among Syrian 
refugees are higher than among local populations due to poor living conditions and access to 
health services.36  
Trends from the period of 1950-1955 through 2005-2010 indicated that Syria was 
progressing through mid-demographic transition. In this period, Syria’s total fertility rates fell 
from 7.2 to 3.2 children per woman and the crude birth rate declined substantially from 50.8 
births per 1,000 population to 26.3.37 Accompanying a decreased crude death rate from 19.2 to 
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3.5 deaths per 1,000 population, Syria’s life expectancy at birth rose from 70.8 to 74.4.37 Despite 
clear evidence of Syria’s demographic transition pre-crisis, demographic changes since 2011 
likely serve to offset the population’s movement through the full transition model, though there is 
little recent evidence of such trends in either direction. 
2.3. Non-Communicable Diseases Among Syrian Refugees and Host Lebanese 
With increased urbanization, population growth, aging populations, and rises in 
behavioral risk factors, hypertension and diabetes have grown as worldwide public health crises 
in recent decades. Global prevalence of hypertension rose from 600 million (13.5% of the global 
population) in 1980 to 1 billion (14.9% of the global population) in 2008.38,39 Over 17 million 
deaths each year are attributable to cardiovascular disease and over 9 million of these deaths are 
the result of complications of hypertension.40 Not only is hypertension prevalence higher in low- 
and middle-income countries, but it goes undiagnosed or untreated more often in these countries 
than in high-income nations.41  
Diabetes prevalence has also risen in recent decades from 108 million (2.4% of the global 
population) in 1980 to over 400 million adults (5.6% of the global population) in 2014.39,42 In 
2012, 1.5 million deaths were attributed to diabetes and an additional 2.2 million deaths were 
attributed to cardiovascular diseases, chronic kidney disease, and tuberculosis related to higher-
than-optimal blood glucose.42 Diabetes is a notable cause of many long-term health 
complications, including kidney failure, lower limb amputation, and blindness, among others.42 
From 2005 to 2015, diabetes rose from the eighth leading cause of years lived with disability 
(YLD) to the sixth. Similarly, diabetes climbed from the 24th leading cause of disability-adjusted 
life years (DALY) worldwide in 1990 to the 11th in 2015. In many countries, the number of 
observed DALYs caused by diabetes in 2015 exceeded the expected number based on the Global 
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Burden of Disease Study’s (GBD) Socio-demographic Index, a composite indicator based on 
countries’ income per capita, average years of schooling, and total fertility rate.43 
Like many countries in the region, Lebanese and Syrian populations are in the mid to late 
stages of the epidemiologic transition from communicable, maternal, neonatal, and nutritional 
conditions to non-communicable diseases (NCDs).44-48 Diabetes prevalence has been estimated at 
7.4% in Syria and 14.4% in Lebanon; in other studies of the Lebanese population, it ranges from 
7% to 15.8%, and according to World Health Organization (WHO) 2018 NCD country profiles, it 
was 13% in both countries in 2014.40,49-56 Data from the WHO STEPwise approach to 
Surveillance (STEPS) survey conducted in Lebanon in 2009 showed raised blood glucose 
(defined as either plasma venous value: ≥ 7.0 mmol/L or capillary whole blood value≥ 6.1 
mmol/L) in 11.2% of adults age 25-64, an overall average fasting blood glucose result of 104.0 
mg/dl, and 5.9% of adults reporting known diabetes diagnoses.57 Neither plasma venous nor 
capillary whole blood values were reported in an earlier (2003) STEPS survey in Syria, but blood 
sugar measures of 110 or higher were reported for 19.8% of the population with an overall 
average fasting blood glucose result of 98.2 mg/dl and 4.8% of adults reporting known diabetes 
diagnoses.58 In the 2016-2017 Lebanon STEPS survey, a smaller proportion (10.5%) of Lebanese 
respondents had raised fasting blood glucose or were currently on medication for raised blood 
glucose as compared to the 2009 survey, with an average fasting blood glucose of 99.7 mg/dl, and 
6.3% reporting known diabetes diagnoses in 2016-2017.59  
Variations in prevalence reporting are likely a result of different methodologies and 
demographic characteristics of study samples, but the overwhelming majority of published 
estimates remain higher than the 2013 estimated global prevalence of diabetes (8.3%).60 From 
1990 to 2010, the number of DALYs caused by diabetes more than doubled based on the GBD 
estimates.61 According to the 2015 GBD, diabetes was the third leading cause of DALYs and 
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YLDs, and the fifth leading cause of Years of Life Lost (YLL) in Lebanon.43,62,63 The number of 
DALYs caused by diabetes similarly increased in Syria from 1990 to 2010 and though it was not 
among Syria’s leading ten causes of DALYs or YLLs during the same year, diabetes was the 
eighth leading cause of YLD in 2015.61,62  
Though evidence of the burden of hypertension in Syria and Lebanon is not as widely 
available as diabetes estimates, previous literature has estimated regional prevalence of 
hypertension at 29.5%, prevalence in Syria at 24.9%, and 28.8% in Lebanon.64-67 The prevalence 
of raised blood pressure in adults 18 years and older reported in the WHO’s 2018 NCD country 
profiles were 20% in Lebanon and 19% in Syria.55,56 High blood pressure was reported in 12.7% 
of adults in the 2008 STEPS survey in Lebanon and 28.8% in Syria in 2003; mean systolic and 
diastolic blood pressure, respectively, were 124.3 mmHg and 77.3 mmHg in Lebanon and 126.0 
mmHg and 77.1 mmHg in Syria.57,58 Among STEPS respondents in Lebanon, 13.8% reported a 
known high blood pressure or hypertension diagnosis; comparable figures were not provided in 
2003 Syria STEPS results.57,58 According to the 2016-2017 STEPS survey in Lebanon, 35.3% of 
Lebanese respondents had high blood pressure (systolic blood pressure ≥140 and/or diastolic 
blood pressure ≥90 mmHg).59 Mean systolic and diastolic blood pressure, respectively, were 
127.1 mmHg and 76.1 mmHg among Lebanese respondents, of whom 17.1% reported a previous 
high blood pressure or hypertension diagnosis.59  
In 2001, an estimated 115 deaths and 1,389 DALYs per 100,000 population per year 
were attributable to hypertensive disease in the Middle East and North Africa.68 In Lebanon 
specifically, the GBD estimated number of DALYs caused by hypertensive heart disease 
increased by 24% from 1990 to 2010 and just under 11% of the country’s 2010 estimated DALYs 
were attributable to high blood pressure, making it the fourth leading disease burden risk factor.69 
Hypertensive heart disease also accounted for 28% more YLL in Lebanon in 2010 as compared to 
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1990, rising from the country’s 16th leading cause of YLL in 1990 to the 14th in 2010.69 In Syria, 
the proportion of all YLL due to hypertensive heart disease rose 41% between 1990 and 2010 
from the 22nd to the 12th leading cause of YLLs; high blood pressure was the country’s second 
highest disease burden risk factor in 2010, attributed with 11% of the country’s estimated 
DALYs, largely for cardiovascular and circulatory diseases.70 
Syrian refugees are no exception to the Middle East’s high NCD burden. UNHCR 
estimates that 14.6% of adult Syrian refugees in Lebanon have a chronic disease and two similar 
surveys found that 39.8% and 43.4% of Syrian refugee households in Jordan had at least one 
household member with a chronic health condition (including hypertension, cardiovascular 
disease, diabetes, chronic respiratory disease, and arthritis).67,71,72 While estimates of chronic 
disease prevalence specifically among Syrian refugees in the region are sparse, the most recently 
published rates among adult Syrian refugees in Jordan (2015) estimated 9.7% prevalence for 
hypertension and 5.3% for diabetes. Comparable figures for Lebanon (published in 2016) are 
similar at 7.4% for hypertension and 3.3% for diabetes.67,73  
The STEPS survey conducted in 2016-2017 in Lebanon included Syrian refugees (both 
registered and non-registered), of whom 9.4% had raised fasting blood glucose or were currently 
on medication for raised blood glucose.59 The average fasting blood glucose among Syrian 
refugees was 97.5 mg/dl, and 4.8% reported diabetes diagnoses.59 High blood pressure prevalence 
reported among Syrian refugees in the 2016-2017 STEPS survey was 32.8%; mean systolic and 
diastolic blood pressure, respectively, were 127.4 mmHg and 76.8 mmHg, and 10.9% of refugees 
reported high blood pressure or hypertension diagnoses.59  
The demographic transition, longer life expectancies, and changes in lifestyle patterns 
portend an increasing burden of NCDs in the Middle East consistent with pre-crisis patterns.67,74 
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Previous studies in Syria found cigarette smoking was common across all age groups, and in 
particular among men age 18 – 35 years.75 Low levels of physical activity were common in urban 
populations, particularly in women, and body mass index (BMI) was shown to increase with 
age.76 Dietary risks ranked highest in the 2010 GBD ranking of DALYs attributable to primary 
risk factors in Lebanon, followed by high BMI, high blood pressure, smoking, high fasting 
plasma glucose, and physical inactivity, all of which are central risk factors for hypertension and 
diabetes.61 DALYs attributable to leading risk factors in Syria were similar as follows: dietary 
risks, high blood pressure, high BMI, smoking, high fasting plasma glucose, and physical 
inactivity.61 Consequently, both host and refugee populations in Lebanon suffer from a large 
burden of NCDs that are often difficult and expensive to manage and require continuous care and 
monitoring to mitigate long-term complications.4-6 The international community, as well as 
national actors, face immense challenges addressing the needs of affected populations in both 
refugee and host communities due to the high NCD burden, the complexity of managing these 
conditions, limited resources available for health care, and concerns about crowding Lebanese out 
of public services.6,44,77-79 
2.4. The Lebanese Health System 
The Lebanese health system, often described as “fragmented and pluralistic,” is marked 
by strong involvement of the private sector and outside actors, particularly for primary health care 
and pharmacy services.80 While the private sector is decentralized at the level of providers with 
little oversight, the public health system is centralized with links to health insurance 
organizations, though the state plays a large role in funding part of the care provided by the 
private sector. Health spending accounted for 5.9% of Lebanon’s gross domestic product in 2010, 
though health financing contributions varied widely with public sector contribution at 28.98%, 
 
 14  
 
private sector at 70.99%, and international donor contributions at 0.03% (which have since 
increased due to the refugee influx).80 Health financing in Lebanon is a complex assortment of 
public funding, private insurance, mutual funds, and the Ministry of Public Health (MoPH).81 
Less than half (44.9%) of Lebanon’s population benefits from some type of insurance.82 The 
National Social Security Fund (NSSF), a public insurance institution providing mandatory 
coverage for formal sector employees (excluding civil servants and uniformed forces) funded 
largely by employers and employee contributions, covers 23.4% of all residents in Lebanon, 
followed by the Army and Internal Security Forces schemes, which cover another 9.0% of 
residents.82 The remaining 53.3% of Lebanese reporting no formal health coverage are considered 
MoPH beneficiaries entitled to coverage of “what would be considered a catastrophic payment 
for households.”81 Though perhaps the most frequently cited and readily available, these figures 
on insured populations in Lebanon have been challenged as underestimates compared to MoPH 
records.81 Nevertheless, household spending on health (largely for insurance premiums, private 
clinic services, and medication) accounted for 44% of total health spending in Lebanon in 2009.80  
With 31.3 physicians per 10,000 population, Lebanon has the highest number of 
physicians per capita in the Eastern Mediterranean Region.83-86 The per capita density of nurses, 
previously among the lowest in the region, has increased in recent years substantially to 36.4 
nurses per 10,000 population in 2017.83,86,87 In 2010, 70% of physicians registered in the 
country’s two Orders of Physicians were specialists, and an estimated 10-15% of registered 
physicians did not practice in Lebanon.80 It must be noted that the cited average rates of health 
providers are potentially misleading as provider concentrations vary throughout the country and 
are predominantly focused in the capital of Beirut and specialist physicians are concentrated in 
private facilities or hospitals.80  
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Efforts were made to reform the health system in Lebanon’s 1990’s post-civil war period 
with a focus on primary health care and strengthening public hospitals. Of the more than 900 
health centers operated by both public and private bodies including the MoPH, the Ministry of 
Social Affairs (MoSA), local municipalities, non-governmental organizations (NGOs), civil 
society organizations, and religious/political groups, almost one-quarter are regulated and 
supported by the MoPH. MoPH network primary healthcare centers (PHCCs) receive financial 
and logistical support from the Ministry as well as frequent training activities and commodities.81 
An increasing number of PHCCs (nearly 200 as of August 2015 and 229 as of early 2019) are 
part of the country’s MoPH network, providing reduced cost care for vulnerable Lebanese 
nationals.88,89 In 2012, it was estimated that, at most, 20% of the population utilizes PHCCs in 
Lebanon, a figure that, though low, is more than twice that estimated in 2002.80 Through the joint 
Non-Communicable Disease Program (NCDP) with the WHO and the associated National 
Program on Controlling Diabetes, facilities in the MoPH network are also mandated to offer a 
spectrum of services for NCDs including, but not limited to prevention education/counseling, 
screening, regular follow-up monitoring care, and essential medicines. In addition to primary 
health care services, the NCDP “aims at establishing a link with the MoPH coverage of needed 
episodic hospitalization of the chronically ill that include diabetic complications, heart attacks, 
strokes, dialysis, and others, in order to ensure a continuum of care.”81 How this specifically 
translates to coverage of such hospital care or more complex secondary/tertiary care is less clearly 
outlined.  
In 2014, the MoPH published the most recent edition of Lebanon’s National List of 
Essential Medicines. An update from the 2002 version, this edition is similarly based upon the 
WHO’s Model List of Essential Medicines, outlining medicines believed to “satisfy the priority 
health care needs of the population.”90 The WHO’s definition of essential medicines explains that 
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they “are intended to be available within the context of functioning health systems at all times in 
adequate amounts, in the appropriate dosage forms, with assured quality, and at a price the 
individual and the community can afford.”90 The list of essential medicines is meant to be 
“flexible and adaptable” in implementation and is not innately a required formulary for individual 
dispensaries or health facilities. In Lebanon’s 2014 List of Essential Medicines, Dr. Walid 
Ammar, then Director General of the MoPH in Lebanon, expressed the intention for the list’s 
publication: “that all health providers would embrace this document as important tool for 
management of medicines and rationalizing prescription in the country.”91 
Chronic disease medications are available at a nominal fee to enrolled beneficiaries, 
including Syrian refugees and host Lebanese, in select dispensaries through a joint program 
between the MoPH and Young Men’s Christian Association (YMCA); however, the process 
necessary for receiving medicines through the YMCA program is illusively documented and 
lengthy. Based on information from key informants and health working group meeting notes, to 
receive YMCA medication for a nominal fee, patients are required to submit an application that 
includes legal identity documents and a copy of the relevant prescription(s) from a physician.92 
After applications are submitted, patients wait approximately three months before receiving 
approval for entry into the program. Once accepted to the program, patients generally receive the 
medication from a participating center every three months. Patients only receive medications 
included in their initial application and can only do so at the health facility listed on the 
application. Additional challenges are faced when facilities attempt to contact patients to pick up 
prescriptions once orders are received. Expiration of phone lines is frequent among all 
populations in Lebanon, and facilities are often unable to reach patients to inform them that their 
medications are available. For refugee patients experiencing frequent relocation, obtaining 
medication from the same facility every three months is extremely difficult, if not impossible. 
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2.5. Assistance for Syrian Refugees in Lebanon 
With refugees under the responsibility of UNHCR now accounting for one in six people 
in Lebanon, the country’s highly fragmented and privatized health system is immensely burdened 
by additional financial demands and increased infrastructure, capacity, and resource allocation 
needs.80,93,94 The Lebanese health system has incurred tremendous costs for delivering services, 
strengthening capacity, and maintaining infrastructure to meet the growing demand brought on by 
the influx of Syrian refugees.95 Unlike other countries hosting large numbers of Syrian refugees, 
Lebanon has not established formal camps for Syrian refugees nor health facilities dedicated to 
providing services only to refugees. In response to the Syrian crisis, UNHCR established an inter-
agency mechanism with the Lebanese government to coordinate the humanitarian response across 
all sectors. Delivery of health services for Syrian refugees in Lebanon is based on a primary 
health care strategy. As of mid-2015 when data for this study was collected, Syrian refugees 
could utilize primary healthcare services for subsidized rates at approximately 116 of more than 
1,200 existing PHCCs/dispensaries across the country, including existing MoPH PHCCs 
(Figure 2-3).13,79,88,96-99 
Subsidized care at participating primary level health facilities is offered to Syrian 
refugees for a fee of 3,000 to 5,000 LBP (approximately US$2 to US$3) per visit. Additional 
primary health facilities not supported by UNHCR or NGOs may also offer care at reduced rates, 
though these costs are not guaranteed, vary widely, and it is often difficult to identify PHCCs or 
private facilities providing reduced cost care.100 UNHCR covers 85% of diagnostic costs for 
select vulnerable refugee groups (children under five years, adults 60 years and older, the 
disabled, and pregnant or nursing women).37 Medication for chronic conditions are provided to 
refugees for a dispensing fee of 1,000 LBP (approximately US$0.66) through the ongoing 
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medication support program run by the YMCA; however, stocks are not always sufficient, and 
enrolling in the program can be a lengthy process requiring extensive formal documentation.96,101 
A third-party private administrator manages referrals for secondary and tertiary services 
for Syrian refugees.13,88,93,97,98 Though each case is evaluated individually, most coverage for 
secondary and tertiary care is provided for life-saving emergencies, deliveries, and care for 
newborns. Coverage for secondary or tertiary services for NCDs and associated complications are 
rarely referenced, suggesting that few if any of these cases are covered. Hospital care is provided 
to Syrian refugees in Lebanon by referral from a primary level health facility or self-presentation 
in the case of a life-threatening emergency. Eligibility is limited to cases fitting one of two 
categories: (1) emergencies (obstetric, medical, and surgical), and (2) elective cases for 
“complementary investigations” and/or specific treatment. Refugees not meeting eligibility 
criteria or otherwise seeking care at hospitals for non-life-threatening emergencies can be 
considered by the UNHCR Exceptional Care Committee to determine whether the case may be 
covered. If the Exceptional Care Committee does not approve the case, refugees must directly pay 
the full cost of care.37 Lebanon’s highly privatized health system often makes care for refugees 
similarly as expensive for vulnerable Lebanese.80,93 
Despite some subsidized primary care, many refugees are not able to access needed 
secondary and tertiary care because of resource and funding constraints; many cases that could 
have received early intervention do not receive care until their condition is advanced enough to be 
considered a health emergency if care is received at all. The cost of care and demand for 
secondary and tertiary services are notably high due to the sizable burden of NCDs among both 
Syrian refugees and Lebanese. The complexity of managing these conditions and the limited 
resources available for refugee health care are apparent given the current coverage gap for 
secondary and tertiary care. For both those that receive subsidized care and those where treatment 
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costs are not covered, the burden of even a small out-of-pocket payment can serve as a barrier to 
care, especially given the tenuous financial situation and increasing debt of many refugee 
households.102 Although health consultations are provided at participating primary level health 
facilities for a nominal fee, an estimated 39% of Syrian refugees in Lebanon are reportedly not 
receiving needed medical care because of the costs of treatment and medication, the long-term 
results of which are increased morbidity, mortality, and costs incurred for more specialized care 
for later complications.103 
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Figure 2-1. Lebanon’s Population Pyramid, 2016 
 
Central Intelligence Agency. The World Factbook: Lebanon. 2016. 
https://www.cia.gov/library/publications/the-world-factbook/geos/le.html (accessed October 29, 
2016). 
 
Figure 2-2. Syria’s Population Pyramid, 2016 
 
Central Intelligence Agency. The World Factbook: Syria. 2016. 
https://www.cia.gov/library/publications/the-world-factbook/geos/sy.html (accessed October 29, 
2016). 
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Data Source: United Nations High Commissioner for Refugees (UNHCR), Inter-Agency Coordination 
Lebanon. Lebanon information hub. 
https://www.dropbox.com/sh/4wqtdgihu566i9m/AABZcfPATVWNsmf6xMkLqUAWa?dl=0 (accessed 
January 8, 2016). 
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Chapter 3. Literature Review 
3.1. Hypertension and Type 2 Diabetes Treatment 
Treatment of both hypertension and type 2 diabetes require close, continued follow-up 
over time with standard treatments involving both pharmacological and lifestyle interventions.  
Hypertension 
Hypertension, also characterized as high blood pressure, is a major global health 
challenge. As outward symptoms are rare in early stages, patients are often not diagnosed until 
the condition has progressed, complicating treatment and management. As with many chronic 
NCDs, prevention strategies and screening to identify cases earlier in their progression can 
greatly improve health outcomes. Uncontrolled hypertension has been linked to heart disease, 
stroke, and kidney failure in addition to associated premature disability and mortality.41  
Standard treatment protocols for hypertension advise providers to begin treatment for 
elevated blood pressure by encouraging lifestyle modifications. If blood pressure levels cannot be 
controlled through lifestyle modifications alone, pharmacological treatment is advised in 
accordance with The Eighth Joint National Committee on the Prevention, Detection, Evaluation, 
and Treatment of High Blood Pressure’s 2014 Hypertension Guideline Management Algorithm 
and more recently revised 2017 American College of Cardiology/American Heart Association 
(ACC/AHA) Guideline for the Prevention, Detection, Evaluation, and Management of High 
Blood Pressure in Adults to achieve optimal blood pressure.104,105 Failure to intervene 
pharmacologically when systolic blood pressure is consistently above 130 mmHg or diastolic 
blood pressure is consistently above 80 mmHg, whether due to providers’ or patients’ decisions, 
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is often associated with greater risk of atherosclerotic cardiovascular disease and worse 
hypertensive health outcomes overall.104-106 
Type 2 Diabetes 
Type 2 diabetes is marked by insulin resistance and is often diagnosed at older ages. 
Uncontrolled long-term diabetes mellitus can result in retinopathy (with potential blindness), 
nephropathy (possibly leading to renal failure), and neuropathy (possibly leading to foot 
amputation), as well as increased risk of cardiovascular, peripheral vascular, and cerebrovascular 
diseases.107  
Type 2 diabetes treatment and management, much like hypertension, requires a 
combination of pharmacological intervention along with dietary and lifestyle modifications to 
maintain controlled blood glucose levels (defined as HbA1C* level of 7% or lower) and, in turn, 
prevent potentially severe cardiovascular, ocular, renal, and neurological complications.108,109  
3.2. Care Utilization for Hypertension and Type 2 Diabetes 
The Role of Care Utilization in Hypertension and Type 2 Diabetes Management 
Regular monitoring and continuous care visits are essential for controlling both 
hypertension and type 2 diabetes. Hypertensive patients not attending regular visits with health 
providers (specifically follow-up care received within a six-month period) have been found to 
have higher blood pressure. Early studies showed a higher prevalence of diastolic blood pressure 
above 90 mmHg among patients not seeing a physician for a period of more than six months 
(67%) compared to those who received physician care in the same period (30%).110 In addition to 
general hypertensive populations, this association between frequency of care and improved blood 
                                                     
* Glycated hemoglobin (HbA1C) is a standard test used to determine average blood sugar levels over extended periods 
(weeks or months) 
 
 24  
 
pressure has been reported in elderly sub-populations.111 Evidence also suggests a reduced risk of 
hospitalization among hypertensive patients with greater continuity of care, both in the United 
States and abroad.112,113 Similarly, regular care for type 2 diabetes has been shown to improve 
control of both blood glucose and blood pressure as well as lower the risk of hospitalization.114,115  
Estimates of Syrian Refugee and Lebanese Care Utilization 
Syrian Refugee Care Utilization 
A recent survey (2014) of Syrian refugees in Lebanon found that among households with 
at least one member with an NCD, 56.1% were unable to access necessary medicine or other 
health services.71 Results such as this suggest that condition management for Syrian refugees with 
NCDs may be more complicated, particularly with respect to medicines. For refugee populations 
living in non-camp settings, such as those in Lebanon, a high burden of NCDs translates to an 
immense burden on host countries’ health systems. Given the protracted nature of the crisis, the 
high costs of providing NCD care, and the large caseload of Syrian refugees with NCDs, 
implications for Lebanon’s health system are vast. The burden of out-of-pocket expenses on 
persons with NCDs is also substantial, especially given the tenuous economic status of many 
refugees. The extensive implications and unnecessary complications resulting from inadequate 
access to or use of health care by Syrian refugees in Lebanon has been reported previously, 
though no comprehensive quantitative assessments provide evidence of the extent of these 
impacts.100 
The Lebanese health system’s public sector is over-burdened, and its quality of care is 
perceived to be much lower than private sector care.80 This is particularly troublesome as cost 
was the primary barrier to care-seeking reported in numerous surveys, despite subsidized care 
provided by the MoPH and humanitarian organizations to Syrian refugees.71,116 In addition to 
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cost, inadequate equipment or medicines, long wait times, transportation difficulties, and absence 
of family permission have been commonly reported barriers to care-seeking in recent studies of 
Syrian refugees in Lebanon.71,117 Despite relatively high UNHCR registration figures,  average 
costs reported by refugees often indicate that the standard subsidized cost of US$2-US$3 for 
primary care at participating primary level health facilities is most often exceeded, likely an 
indication that refugees are receiving care at non-UNHCR or NGO supported centers.116 While 
the costs of clinical services for refugees carried by the MoPH, UNHCR, and NGOs is greater in 
Lebanon than in other settings where NCDs account for a smaller portion of the burden of disease 
among refugees, increased capacity and targeted services for refugees with chronic conditions 
including hypertension, diabetes, and cardiovascular disease have also helped improve disease 
control and health outcomes among Palestinian refugees in the region.118 
Lebanese Care Utilization 
Research on care utilization and treatment rates for NCDs among the Lebanese 
population shows varying results. A 2015 study of prevalence, awareness, treatment, and control 
of hypertension in Lebanon found that only 53.0% of study participants were aware of their 
condition and the overall treatment rate (defined as current use of antihypertensive medications) 
was 48.9%.50 These figures are higher than estimates from neighboring countries (namely Turkey, 
Egypt, and Palestine) where treatment rate estimates range from 23.9% to 40.0% and overall 
hypertension control rates range from 8.0% to 9.0%. Despite higher treatment rates in Lebanon 
than elsewhere in the region, that more than half of hypertensive patients remain untreated raises 
concern for the overall health of individuals and the costs incurred by governmental, non-
governmental, and international organizations subsidizing health care in Lebanon.119-121 
 
 26  
 
Differences in treatment and control rates favoring the Lebanese population may be 
attributable to their overall higher socioeconomic status and a higher ratio of physicians to the 
general population, among other factors. “Treatment and control” as typically defined miss an 
essential component of care for chronic conditions like hypertension and diabetes in that reported 
use of medication does not inherently indicate receipt of care from a health provider, nor does 
reported care-seeking speak to the quality of care received.122 Lebanese hypertension and diabetes 
patients report having medication prescribed largely by cardiologists and endocrinologists, with a 
minority prescribed medication for their condition from a general practitioner, likely a reflection 
of the Lebanese health system’s emphasis on specialist care.123 A small, though a noteworthy 
minority of these patients report multiple prescribers, most often two specialist prescribers. Such 
fragmentation has implications for continuity of care. Furthermore, the ability for patients in 
Lebanon to obtain medications directly from pharmacies without a proper prescription (whether 
new medication or refill of a previously prescribed medication) although illegal, has been 
previously observed and reported elsewhere.124-127 Owing to the illegal nature of the topic and 
political sensitivities, the extent and implications of this practice have been reported and 
interpreted various ways, though infrequently focused on medication for chronic diseases. A 2014 
study of completion of therapeutic and safety monitoring test among Lebanese outpatients on 
chronic disease medications found that only 3.0% of sampled patients had medication dispensed 
by pharmacists without physician consultation.123 Conversely, a qualitative study conducted by 
Integrity Research and Consultancy in 2014 reported the more frequent tendency for men to seek 
care directly at pharmacies, a finding supported by numerous studies and reports in other media 
of the practice of obtaining medication (particularly antibiotics) in Lebanon pharmacies without 
prescription.124,125,127-134  
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Numerous international guidelines reinforce the importance of safety monitoring tests for 
patients taking chronic medications; however, the extent of such monitoring varies widely. In the 
Lebanese population, previous studies reported nearly three-quarters of patients receiving 
incomplete therapeutic and safety monitoring tests recommended by standard treatment 
guidelines for patients on chronic medications.123 Specifically, only 27.0% of Lebanese 
community pharmacy outpatients screened in 2011 were considered completely monitored, 
65.0% partially monitored, and 8.0% unmonitored.123 The same study reported that only 35.0% of 
studied diabetic patients prescribed oral medications were receiving the frequency of HbA1C 
monitoring tests advised by the American Diabetes Association (at least two times per year for 
glycemically controlled patients and quarterly in patients for whom a treatment regimen has 
recently changed or who are not meeting targeted glycemic control).135 Among diabetic patients 
with incomplete monitoring (either partial or no monitoring tests), more than half (62.0%) of 
patients reported visiting a physician once per year or less. Similar results were observed for 
patients on statin therapy with 64.0% completing baseline liver function tests and 25.0% 
completing baseline creatine phosphokinase tests; in other words, 65.0% of patients on statin 
therapy had periodic liver function tests measured at least once during follow-up.123 
There is a noted gap between clinical practice in Lebanon and international guidelines.136 
While the MoPH has worked in recent years to train providers on standard treatment guidelines 
for several chronic NCDs (including hypertension and diabetes), results from the 2013 Initiative 
for Cardiovascular Service in the MoPH-PHCC network indicate persistent deficiencies in 
physician compliance with treatment protocols and an overarching culture of reliance on 
specialist, secondary, and tertiary care, even among general practitioners.137 A 2014 study of 
predictors of blood pressure control in the Lebanese population purported that poor provider 
adherence to guidelines may largely be attributed to lack of access to treatment guidelines, but 
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also noted the influence of physicians’ attitudes regarding existing practices.136,138 Limited 
flexibility in most guidelines is also a likely source of poor adherence as many guidelines cannot 
meet the complexity of the context in which they are practiced.136,138 Thorough adherence to 
guidelines in complex settings is particularly necessary for counseling patients about how to 
manage their conditions, possible complications, necessary lifestyle changes, and the importance 
of continuous monitoring and adherence to treatments.  
Facilitators and Barriers to Care Utilization for Hypertension and Type 2 Diabetes 
Numerous factors are associated with care-seeking and treatment of both hypertension 
and diabetes, though much of this research is from developed countries in relatively stable 
populations. Although extensive research on health behaviors, including care-seeking and health 
service utilization, exists for vulnerable populations and in low resource settings, there is limited 
evidence in contexts analogous to the protracted Syrian refugee response in Lebanon.139-148 Some 
factors associated with care utilization occur in multiple contexts, suggesting relevance regardless 
of the setting. These can broadly be categorized as patient characteristics, provider-related 
factors, and structural/environmental features.149-157 
Patient Characteristics 
Four types of patient-related factors are associated with health care-seeking behavior for 
hypertension and diabetes: (i) sociodemographic characteristics; (ii) condition-related factors; (iii) 
patient attitudes and beliefs; and (iv) psychosocial characteristics. Among the sociodemographic 
factors, care-seeking has mixed associations with marital status and general educational 
attainment; the evidence for age, sex, ethnicity, and minority status are more consistent.140,155,158-
161 A 1997 review of health care utilization predictors for individuals with chronic illness reported 
ambiguous results for the relationship between patient age and care utilization, but this 
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information is dated and the majority of more recent studies report increased utilization with older 
age, ostensibly reflecting an increased actual need for assorted health services with age.140,158,162-
164 Current studies also indicate that women utilize services more than men.140,152,158,159,161,164,165 
Cultural and religious norms in Arab countries strongly influence the function of sex in individual 
health behaviors, in some cases altering the magnitude of the association.159 Disparities exist in 
minority care-seeking, specifically ethnic and racial minorities, although higher use of care 
relative to non-minority populations has been consistently reported, particularly for diabetes.166-169 
In this case, increased minority utilization is postulated to result from increased disease severity 
and complications resulting from inadequate routine preventive care.  
The role of financial factors in care utilization is well-established. Financial resources can 
transform medical need into effective demand for care. Higher income and having health 
insurance are associated with increased health service utilization overall and for chronic health 
conditions such as hypertension and diabetes.140,159-162,170-174 Low socioeconomic status 
(education, employment, and income, among others) has also been assessed as a mediator on the 
causal pathway from socioeconomic position to care-seeking to health outcomes.155,172,175 
Competing demands for patients’ limited resources (primarily financial, but also time) also hinder 
health care utilization.142,146,161,172,174,176,177 In their 2014 study of barriers and enablers to health 
among homeless persons with diabetes in the U.S., Elder et al. noted that “urgent, daily needs 
have priority for time, money and emotional energy…” and that “chronic disease care, without 
acute symptoms, is low priority.”174  
Clinical or condition-related characteristics also influence individuals’ health behaviors, 
largely from the perspective of an individual’s need for care. Care for hypertension and diabetes 
increases with longer disease duration, greater disease and symptom severity, and the presence of 
complications and co- or multi-morbidities.77,140,155,158,162,164,167,177-182   
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In addition to sociodemographic and condition factors, individuals’ knowledge, 
perceptions, and beliefs about their condition and its management strongly influence care-seeking 
behaviors. While knowledge alone may not motivate seeking health services, increased 
knowledge and beliefs concerning the consequences of hypertension and diabetes, as well as 
individuals’ access to information about diagnosed conditions and available services are 
associated with increased care utilization.77,155,159,174,177 Beyond knowledge of the diagnosed 
condition for which care is needed, there is a relationship between overall health literacy and 
increased healthcare visits.159,172,183,184  
A patient’s first clinical encounter is motivated by their attitudes and beliefs, and 
continuity of care-seeking beyond the first visit is also influenced by their perception(s) about the 
quality of care they receive: did health providers devote sufficient time to consultations, were 
services culturally sensitive, and did patients trust their provider’s abilities.159,185-187 Moreover, 
self-efficacy, an individual’s confidence that they can perform necessary tasks, is associated with 
increased adherence to treatment and regular follow-up appointments.139,186,188 Additional 
psychosocial barriers and supports influence health care behaviors: psychological distress and 
fears, clinical depression and anxiety, and supportive factors such as social support and social 
networks.146,152,158,162,172,174,176,177,189,190 
Provider Characteristics 
Factors related to health providers also influence care-seeking and health service 
utilization: the patient-provider interaction/relationship, provider adherence to clinical guidelines, 
workload, provider type (i.e., generalist or specialist physician, nurse, pharmacist, etc.) and 
provider sex.144,146,147,149,151,156,185,191 Evidence supports increased care-seeking when there is a 
valued patient/provider relationship, but care-seeking delays and avoidance in the absence of such 
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relationships.146,155,165,173,177,186,188 In individuals with chronic conditions, patient trust in their 
health providers’ technical abilities facilitates increased follow-up care.144,146,178 Conversely, 
patients tend to have lower overall care utilization when their providers have high workloads and 
limited time available for them, and when their physicians have poor adherence to standard 
treatment guidelines.165,178,185,192 The type of health care provider also influences patients’ use of 
services, but the direction of association is inconsistent, depending upon the study 
context.149,151,172,191  
Structural and Environmental Factors 
Beyond individual patient and provider factors, the structure of the health system in 
which care for chronic conditions is sought has a role in care‐seeking. Structural factors that 
influence health care use include the acceptability, availability, accessibility, and affordability of 
available services.144-146,149,151,156,176,177,185,191,193 Availability of health care providers, services, 
medication, and testing equipment is central to initial care-seeking and continuity of follow-up 
care.146,149,165,176-178,194 Facility operating hours and appointment systems are core resources for 
accessible health services, and in some contexts, these can pose insurmountable barriers to 
accessing care.146,159,173,185,194,195 The provider network’s complexity can facilitate or hinder 
patients’ access to care.176,185,196 This is especially true in refugee and migrant populations where 
patients are new to a country, and lack a basic understanding of the health system, and may not 
know where and how to access available services.196 Research on the relationship between 
provider mix and care utilization is limited; however, a 2008 study indicated an inverse 
relationship between the ratio of primary care physicians to specialists within concentrated 
geographic areas and hospital admissions, emergency department visits, and surgeries.197 
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Other health system factors that decrease future care utilization beyond the first contact 
include long wait time and poor care quality during visits.159,165,177,178,185,194,195,198 There is an 
inverse relationship between cost and the use of health services both for care generally and for 
hypertension and diabetes.146,165,178,194  
Environmental factors, principally the distance to a health facility and transportation 
access and affordability are prominent determinants of individuals’ health care 
behaviors.146,165,172,177,178,194,195,199,200 Lower care utilization is associated with longer distances to 
health facilities, reflecting the burden on patients’ limited time and resources. There is substantial 
evidence that transportation access and its associated costs are critical but underappreciated 
components of care-seeking decisions.145,146,159,160,165,176,185,194-196,199,200 
Refugee-Specific Factors 
There is a growing body of research on refugees’ access to and use of healthcare, mainly 
in the U.S., Europe, and Australia and not focused on NCDs such as hypertension and 
diabetes.201-208 A 2001 Australian study on the effect of immigrant status on health insurance, 
health care access, and service utilization found decreased access to care among noncitizens and 
their children, regardless of health insurance coverage.209 Later research has tended to show 
higher rates of healthcare utilization among refugees relative to host country nationals, 
particularly in the first year of displacement.210,211 For example, in their 2015 study of health care 
utilization by Arab immigrants and Iraqi refugees in the U.S., Elsouhag et al. reported both 
increased refugee care utilization and health needs; however, unlike refugees, immigrants utilized 
care significantly less than the U.S. national rate.160 The comparison of refugees and immigrants 
in Elsouhag et al.’s research offers unique insight into the dissimilarities in health-seeking 
behaviors of refugees compared to immigrants and host country populations, each of whom is 
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afforded differential access to services in most countries. Refugees’ healthcare barriers include 
language impediments and navigating a healthcare system which likely has different policies, 
procedures, and norms from those of their country of origin. Specific reported challenges include 
not knowing where to seek care, accessing specialty care, unclear referral procedures. Health 
providers treating refugee patients also raise concerns about language barriers and ambiguity 
regarding available services and referrals for refugees requiring additional care.196,202-208,212 
3.3. Medication Adherence: Measurement, Role, and Determinants 
The WHO has identified medication nonadherence as one of the major causes of 
avoidable health care costs, morbidity, and mortality worldwide.213 It is estimated that between 30 
to 50% of all prescribed medication and 17 to 80% of prescribed long-term medication is not 
taken as directed.214-217 
A key challenge in studying medication adherence is the lack of agreement on 
terminology and how to define adherence. Various terms, such as adherence, compliance, 
persistence, and concordance, among others, have historically been applied to describe 
medication usage. These terms are used inconsistently across studies, hindering comparison of 
results, and potentially leading to misinterpretation in employing intervention strategies.218,219 
Medication compliance and adherence are frequently used interchangeably, though their 
technical distinction reflects the inherent complexity in medication usage itself.220 Medication 
compliance is traditionally understood to be “the extent to which the patient’s behavior matches 
the prescriber’s recommendations”; however, the term is now out of favor as it indicates an 
asymmetric power relationship rather than a therapeutic partnership.218,220,221 Definitions of 
medication adherence vary more widely. Historically, adherence concerned whether medication 
is filled, but over time it has come to include initiation, implementation, and discontinuation and 
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thus, may also include the extent to which medication is taken once it is filled.222-225 The term 
adherence often indicates a general adherence to overall treatment recommendations, as is the 
case in the WHO’s 2013 “Adherence to Long-Term Therapies: Evidence for Action” report in 
which adherence is defined as “the extent to which a person’s behavior—taking medication, 
following a diet, and/or executing lifestyle changes—corresponds with agreed recommendations 
from a health care provider.”225 While many studies define adherence broadly to include all 
aspects of treatment adherence (including diet, lifestyle, and care-seeking recommendations), the 
issues with medication use can be quite different from those concerning adherence to diet, 
lifestyle behaviors, or follow-up care and testing.226 For the purpose of this dissertation, the term 
adherence is used both because of the broader scope of its definition and its widespread use in the 
relevant literature.  
Medication adherence can broadly be organized into three components or types. The first 
type of nonadherence is nonfulfillment, or primary nonadherence, which occurs when patients do 
not fill prescriptions from health providers. This also includes patients who fill the prescription 
but never actually take the medication. Non-persistence, a second type of nonadherence, occurs 
when patients start a prescribed medication but choose to stop taking it without being instructed 
to do so by a medical professional. While non-persistence may be unintentional (i.e., when 
patients misunderstand or are not provided with proper instructions on how to take the 
medication), it is often intentional, and most patients who stop taking medication do so within six 
months of initiating.227 Medication persistence is often studied independently of adherence and is 
defined as “the duration of time from initiation to discontinuation of therapy.”218 A third type of 
nonadherence, nonconforming, occurs when medications are taken, but not according to the 
prescribed regimen. This may include timing, dosage, or skipping doses altogether. Patients are 
considered fully adherent to a medication regimen only when all three of these components are 
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achieved, meaning that to be fully adherent, pursuant to being prescribed a medication, patients 
must fill the medication, initiate taking it, and continue taking it as instructed. The varied 
consequences of nonadherence depend on the specific medication and the condition being treated. 
For example, an isolated incident of missing a cholesterol medication will not have substantial 
clinical significance in the way that occasionally missing a cardiac medication would. 
Measuring Medication Adherence  
One of the central challenges to researching medication adherence is the difficulty 
associated with reliably measuring it.228,229 Many methods have been tested and validated in 
various settings. Methods for measuring medication adherence fall into two categories: direct and 
indirect methods. Direct methods include testing blood samples and clinical observation (e.g., 
direct observed treatment or clinically observed therapy). Such methods are not as widely used 
outside of clinical settings as they provide data only on a limited period and are costly to 
implement and sustain. Conversely, indirect methods are more practical as they tend to be less 
labor and cost intensive than direct methods of measurement. The most commonly used indirect 
methods for measuring adherence include patient self-report, pill counts, prescription fill records, 
and, primarily in more developed settings, electronic medication monitors.  
Despite the advantages of indirect measurement methods, each method carries its own 
disadvantages as well. Patient self-report is arguably the least expensive and easiest method to 
implement, but results are often less reliable and tend to overestimate adherence, particularly 
when compared to alternative direct methods.228 Another commonly used method, pharmacy fill 
records, is also among the easiest ways of obtaining adherence information; however, the 
accuracy of the data included in databases varies and is often difficult to assess. This method is 
particularly troublesome in areas with inadequate record-keeping systems, as is often the case in 
 
 36  
 
many low- and middle-income countries. Moreover, the use of database information relies on 
several assumptions about adherence that may not hold and, in fact, may substantially bias 
analytic results. For example, adherence measures based on pharmacy records assume that 
patients take the filled prescription as advised. If this assumption does not hold, results may be 
highly inaccurate and may misinform recommendations or future interventions. Additionally, 
assuming that patients are not filling their prescriptions at a pharmacy other than that from which 
data are collected may be inaccurate, particularly in areas with a large number of dispensing 
outlets accessible to patients.230-239 Further along the spectrum of indirect measurement methods 
are electronic medication monitors. These monitors are built into the prescription bottle and track 
the time and date for each time a patient opens the bottle. Electronic medication monitors are 
widely considered to be the gold standard for measuring medication adherence and, although they 
can be beneficial for tracking how and when patients are taking prescribed medication, monitors 
are expensive and often impractical to implement, especially in less developed settings with 
limited resources.240 230 In the absence of a single “gold standard” method for measuring 
medication adherence, use of multiple adherence measures is considered one of the most accurate 
methods.241 
Given its superior feasibility, self-reported adherence measurement is often preferred 
over more direct measures of adherence in low resource settings where record keeping and the 
possibility of using electronic monitors are not feasible. Many validated tools for self-report of 
medication adherence are available and commonly used. While there is no firmly established gold 
standard for adherence measurement, the Morisky Medication Adherence Scale (MMAS) is 
perhaps the most widely validated and referenced self-reported measure. First published in 1986 
to assess adherence to antihypertensive medication, the MMAS-4 consists of four yes/no 
questions focused on forgetfulness, carelessness, stopping medication use because the patient 
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feels better, and stopping because the patient feels worse. Widely used for its length and relative 
ease of implementation, the MMAS-4 nonetheless initially showed fair psychometric properties 
with 81% sensitivity, 44% specificity, and a Cronbach’s alpha reliability of 0.61. An eight-item 
version of the MMAS, consists of a total of seven yes/no questions and a five-point Likert scale 
question. The MMAS-8 has improved psychometric properties as compared to the MMAS-4 
(93% sensitivity, 53% specificity, and a Cronbach’s alpha reliability of 0.83), has been found to 
maintain a high degree of concurrent and predictive validity with pharmacy fill rates in a number 
of studies, and has been adapted for use in a many countries and contexts.242,243 244-251 
In addition to the MMAS, the Hill-Bone Compliance to High Blood Pressure Therapy 
Scale (HB-HBP) and the Hill-Bone Medication Adherence Scale (HB-MAS), developed 
specifically for measuring compliance with hypertension treatment, are also frequently used and 
have been validated in numerous settings and populations.252-256 The 14-item HB-HBP assesses 
patient behaviors related to appointment keeping, diet, and medication adherence, while the 9-
item HB-MAS focuses exclusively on medication adherence and can also be applied to various 
chronic conditions aside from hypertension.  
Another commonly used adherence measure, The Brief Medication Questionnaire 
(BMQ), consists of nine main items with three additional subscales to be used based on the type 
of nonadherence identified.257 The three subscales (consisting of the regimen screen, belief 
screen, and recall screen) can be used to better adapt use of the tool to each patient; however, 
original validation of the BMQ did not include a sufficient sample to evaluate its psychometric 
properties, and limited evidence of the tool’s validity is available.252 
Numerous instruments developed to measure adherence to medication for psychiatric 
conditions have also been applied to other chronic conditions. The Drug Attitudes Inventory 
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(DAI) is widely used to evaluate adherence among psychiatric patients.258 This tool consists of 30 
questions covering seven factors: subjective positive attitudes, subjective negative attitudes, 
health/illness, physician, control, prevention, and harm, but has been found to correctly classify 
adherence in only 68% of patients.259 Criticized for limited construct validity, the DAI falls short 
in that it relies on clinicians’ judgment for assessment, arbitrarily classifies compliance versus 
non-compliance, and relies on patient’s attitudes towards the medication rather than inquiring 
directly about compliance.259 The Medication Adherence Rating Scale (MARS) is a ten-item 
yes/no instrument developed from the DAI and the MMAS-4 specifically intended to better 
assess medication adherence for psychosis medication. The MARS has shown improved 
reliability and validity as compared to these previous measures but has not been widely tested for 
non-psychiatric conditions.259  
An additional tool, the Brief Adherence Rating Scale (BARS), was designed to be 
administered by clinicians. The BARS consists of three questions about patients' knowledge of 
their medication regimen and missed medication in addition to an overall visual analog rating 
scale to assess the proportion of doses taken by the patient in the past month (0%–100%). The 
visual analog scale (VAS) rating determines the final adherence measure for this tool, which has 
shown good psychometric properties (73% sensitivity and 74% specificity in identifying non-
adherent outpatients with schizophrenia).260 The VAS alone, conducted by asking patients to 
estimate the percentage of medication doses that they took as prescribed over a determined period 
of time, has shown mixed results when applied to adherence to medication for HIV/AIDS. Some 
studies showed high correlation between the VAS and more objective, direct measures while 
others reported null associations between the VAS and objective adherence measures.261-264  
Another promising measure of medication adherence is the Adherence to Refills and 
Medications scale (ARMS).265 This scale contains the four items included in the abbreviated 
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MMAS-4, four additional items to evaluate how respondents take prescribed medication 
(including skipping and changing doses, among other common variants of non-adherence), and 
another four-item subscale assessing refill behaviors. Collectively, questions in the ARMS may 
also provide specific and actionable information on patient behaviors related to medication 
availability that are not included in many other adherence measures. A separate version of the 
ARMS, the ARMS-D, has been validated for use in diabetes research and is focused expressly on 
adherence to medication for diabetes, including questions about insulin therapy.266 
The Role of Medication Adherence in Hypertension and Type 2 Diabetes 
Hypertension 
Poor or non-adherence to prescribed antihypertensive medication(s) is strongly associated 
with reduced blood pressure control.225,227,267,268 While much evidence supports the relationship 
between lifestyle and nutrition in hypertension control independent from medication adherence, 
adherence to medication has long been posited as a principal factor on the causal pathway to 
improved disease control.269 Early evidence of this relationship showed that it is largely driven by 
a higher level of interaction with health care providers and, in turn, improved detection and 
diagnosis of hypertension. Though researchers suggest that increased interaction with health 
providers also improves hypertension control by improving access to medications, this direct 
relationship was not tested in early studies. More recent studies, however, provide stronger 
support for the relationship between poor or non-adherence to prescribed medication and poor 
health outcomes in patients with chronic diseases.269-273 
In addition to adverse health outcomes, inadequate adherence to prescribed medication 
has also been associated with increased health care costs in many studies in the United States and 
abroad.271,274-278 Increased health costs attributed to patients who discontinue or switch therapies 
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are clear, but the precise mechanism through which increased costs are incurred vary across 
studies. In addition to overall health costs, evidence supports the association between non-
adherence and increased costs related to hospitalizations and emergency room visits, suggesting 
an increase in complications or worsening health outcomes given relatively low all-cause 
hospitalization rates observed for patients with the highest levels of measured medication 
adherence as compared to those with lower adherence for diabetes, hypertension, 
hypercholesterolemia, and congestive heart failure.271,279  
Type 2 Diabetes 
Better medication adherence has also been associated with improved glycemic control, 
specifically, reductions in HbA1C levels, in several empirical studies.280-285 Existing literature 
also provides compelling evidence of an inverse relationship between medication adherence and 
hospitalizations or emergency department visits for patients prescribed medication for 
diabetes.271,286-292  
Reduction in diabetes complications have been associated with increased adherence; 
however, there is a relative dearth of literature available estimating the effect of adherence on 
such outcomes compared to studies exploring other aspects of adherence.293,294 Patients with 
worse intermediate health outcomes are more likely to increase adherence over time. Due to this 
and other factors contributing to the complex nature of the interaction between time-varying 
adherence and intermediate variables, conventional models are widely considered inappropriate 
and may explain the relative scarcity of evidence for these associations.294 A retrospective 
longitudinal cohort study of type 2 diabetes patients in the California Medicaid claims database 
examined the effect of adherence on the risk of complications of diabetes using longitudinal 
marginal structural models that accounted for time-varying confounding, the results of which 
 
 41  
 
found that hypoglycemic adherence significantly reduced the risk of microvascular complications 
among diabetic patients (hazard ratio=0.73).294 Adherent oral antidiabetic users have also shown a 
lower likelihood of developing ulcers, retinopathy, acute myocardial infarction, neuropathy, and 
amputations over shorter follow-up periods (18 months).293 Startling evidence also shows the 
effect of Medication Possession Ratio (MPR) on mortality across races/ethnicities.295  
As with hypertension, existing literature also establishes an association between 
medication adherence and overall medical costs for diabetes.225,280,292,296 By comparing health care 
costs across adherence quintiles, an observational retrospective cohort study in the United States 
in 2005 estimated net savings per patient for a 20% increase in drug utilization of $1,074, or an 
average return on investment of seven to one.271 This evidence is tied to the “offset” effect often 
cited as a rationale for higher drug costs, which posits that higher prescription drug costs will be 
offset by other costs ultimately being lower (e.g., crisis-oriented care such as emergency room 
visits and inpatient hospitalizations).271 
Prevalence of Medication Adherence in Hypertension and Type 2 Diabetes 
Current evidence suggests that as many as 50% of hypertension patients end treatment 
within the first year following diagnosis.297 Moreover, of the remaining patients who continue 
treatment, only 50% to 80% take their prescribed medication.298 General estimates of 
hypertension treatment adherence range similarly from 50% to 80%, depending upon the study 
design, sample population, and methods for measuring and determining adherence.299-304 While 
adherence rates differ for newly diagnosed patients versus those with longer hypertension 
durations, it is estimated that between 16% to 50% of all hypertensive patients stop taking their 
medication within the first year of diagnosis and missed doses are commonly reported among 
those who continue medication beyond the first year.305,306  
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Type 2 diabetes medication adherence rates are similarly estimated and range from 70% 
to 80%.225 A study of Medicaid-funded patients in the United States measured drug therapy 
adherence among patients with type 2 diabetes using pharmacy records and found that patients 
had an average of 130 days of continuous drug therapy per year. Additionally, after one year of 
study, only 15% of patients were persistent with filling prescribed single oral medication.307 
The extent of medication non-adherence in low- and middle-income countries is expected 
to be higher than in developed countries due to factors such as greater barriers to health care 
access and lack of health resources, which have both been found to increase the impact of non-
adherence and overall health outcomes.225 While not extensively reported on, medication 
adherence among hypertensive Lebanese patients has previously been identified as a challenge to 
adequate disease control.308,309 Medication adherence has not been widely studied among refugee 
populations, particularly adherence to chronic disease medications. While some studies have 
explored general medication adherence in refugee populations, the focus has largely been on 
antiretroviral therapy and tuberculosis medication in more traditional camp-based displacement 
settings.310-315 A limited number of published studies assessed access to medications in conflict-
affected, weak, and “disrupted” states; however, such studies examine only access and lack 
substantive evidence or discussion regarding the implications of access on medication 
adherence.316,317 Furthermore, most of the settings in which research has been conducted are not 
necessarily comparable to the Lebanese context. Lebanon is still recovering from the end of its 
own civil war in 1990, but the health care system and infrastructure are quite good compared to 
other studied “disrupted” states.  
Recent research on antihypertensive medication among Palestinian populations in the 
West Bank and Jordan may provide insight into utilization and adherence trends in populations 
facing circumstances similar to those of Syrian refugees in Lebanon. Hypertensive patients in the 
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West Bank showed overall poor adherence to antihypertensive medication in a 2014 cross-
sectional survey in which only 16.9% of sampled patients had high adherence, while 28.9% had 
medium adherence and 54.2% had poor adherence (according to MMAS scores).318 A study of 
antihypertensive medication utilization trends among Palestinians in Jordan from 2008 to 2012 
showed that hypertensive patients persistently used at least two antihypertensive medications 
daily with significant differences in utilization by type of antihypertensive drug.319 While not 
reported in the study, these differences may be reflective of variations in supply availability of 
certain drugs over others. 
Determinants of Medication Adherence 
Medication adherence is complex, and the outcome is affected by the patient, condition, 
and cost of care. Though little empirical evidence is available from middle-income countries and 
even less from low-income countries, determinants of medication adherence (or non-adherence) 
among hypertensive and diabetic patients are well-researched in the developed world. While 
many determinants are similar between hypertensive and diabetic patients, the complexity of 
these conditions leads to various condition-specific determinants of adherence. Broadly, 
medication adherence determinants can be organized into patient characteristics, condition and 
regimen factors, patient/provider interaction, and health system-related factors.  
Patient Characteristics 
The most prominent patient characteristic determinants of medication adherence in 
hypertensive and diabetic patients examined in existing literature include age, sex, social support, 
and race/ethnicity, as well as patient behaviors, health beliefs, and health literacy. Evidence for 
the relationship between age and adherence among diabetic and hypertensive patients has been 
mixed, though declining memory, often a key component of treatment adherence among older 
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populations, was found to be a key predictor of adherence in both diabetes and 
hypertension.289,293,309,320-326 Evidence of the association between sex and medication adherence 
among diabetic and hypertensive patients are similarly diverse, though the inconsistency of these 
associations may be due to several factors from potential confounders or effect modifiers to 
differences in context.321-323,325,327,328 Lower education levels were found to have a negative 
association with adherence to diabetes medications in numerous contexts.323,329 Social support, 
including family structures and community networks, is positively associated with medication 
adherence among patients with type 2 diabetes, particularly with regard to support of family 
members.330,331 While this relationship has not been assessed for the Lebanese or Syrian contexts, 
the strong, albeit complex, role of family in everyday life in these populations warrants 
exploration of the relationship.  
Unlike the conflicting associations observed between age/sex and adherence, research has 
consistently shown a relationship between race and/or ethnicity and adherence to medication, 
particularly so among diabetic patients.332-335 The effect of financial stress on adherence in 
previous studies reveals significant differences between racial and ethnic groups in patients taking 
less diabetes medication than prescribed because of cost.336 Interestingly, study findings show 
that despite similarly low annual incomes among Vietnamese and Mexican American patients, 
Mexican Americans reported not only more cost-related medication non-adherence, but also more 
financial barriers to medical care and more perceived burden of their diabetes when compared to 
both Vietnamese and white patients, indicating that changes to medication cost or insurance 
coverage may not mitigate adherence barriers related to patients’ perceptions and beliefs about 
financial burdens. Differences in associated adherence rates by ethnic minority groups, in 
addition to regional and urban/rural differences indicate a need to explore contextual factors 
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influencing adherence and to evaluate determinants of adherence specific to the context and 
population(s) in which intervention is intended.323,335,337-341  
Patient behaviors related to known risk factors for hypertension have been strongly 
associated with adherence to antihypertensive medication regimens in several studies. Smoking 
has shown a negative association with adherence to antihypertensive medications and a recent 
study of medication adherence in Lebanese hypertensive patients found that not only is smoking 
related to medication nonadherence, but the number of cigarettes per day and the duration of 
cigarette smoking were also negatively associated with medication adherence.308,321 The same 
study found a statistically significant association between adding salt to food and decreased 
adherence to antihypertensive medication and, as logically follows, a significant increase in 
adherence for patients following a recommended diet.308  
In addition to patient health behaviors, health beliefs held by patients also influence 
medication adherence for both hypertension and type 2 diabetes in many ways. Low perceived 
need for medication is strongly associated with low medication adherence in many chronic health 
conditions including hypertension and type 2 diabetes.214,280,342-345 In a cross-sectional study of 
patients with chronic diseases, beliefs about medications were found to be stronger predictors of 
adherence than sociodemographic characteristics and clinic factors.214 The beliefs in the 
aforementioned study included: disease belief (“I have diabetes only when the glucose is high”), 
necessity related medication belief (not taking medicines when sugar is normal), concerns related 
medication belief (worrying about side-effects), regimen complexity beliefs (reporting medicines 
were hard to take), and, self-efficacy (confidence in controlling their diabetes or more generally, 
confidence in controlling future health).344 Moreover, specific medication and condition-related 
beliefs were also predictive of poor adherence in the adjusted analysis of a cross-sectional study 
of patients with diabetes in the U.S.344 Diabetes fatalism, defined as “a complex psychological 
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cycle characterized by perceptions of despair, hopelessness, and powerlessness,” is also 
predictive of poor medication adherence.345-348 Early studies found a significant association 
between diabetes fatalism and patient self-care, poor glycemic control, and decreased quality of 
life; a direct association between increased diabetes fatalism and decreased medication adherence 
(as measured using the MMAS), after adjusting for diet, exercise, blood sugar testing, foot care, 
and diabetes knowledge has also been reported.346,347 
In the Lebanese context specifically, hypertensive patients’ health literacy was shown to 
influence adherence to antihypertensive medications. Specifically, patient knowledge in terms of 
understanding not only how to take prescribed medication, but also of their disease (measured as 
knowing the normal blood pressure range) were both significantly associated with higher 
medication adherence in bivariate analysis. In logistic regression analysis of the same study, 
patients who knew the normal blood pressure range were nearly five times more adherent than 
those who did not know the normal range (odds ratio=4.9).308 
Condition and Regimen Factors 
Beyond patient characteristics, factors related to the condition and medication regimens 
are also associated with medication adherence. Among diabetics, treatment intensification by 
adding another drug and/or with dose increases are predictive of decreased adherence.349 
Concurrent medication use has shown mixed results with both positive and negative association 
with medication adherence in a number of other studies of diabetic patients, though most often, 
the association has been negative.325,350-353 Lebanese hypertensive patients taking any over-the-
counter medication showed significantly lower adherence than those not taking over-the-counter 
medications, supporting some of the previously cited evidence on concurrent medication use.308 
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In addition to use of multiple medications, the complexity of medication regimens 
negatively impacts adherence to chronic disease medication. Overall, patients adhere better to 
once-daily medications, reportedly because they find it more convenient and easier to manage 
with daily activities.280,354 As such, simplified drug regimens in which unnecessary medication is 
omitted, whether by reducing the number of pills per day and/or dose frequency, has been found 
to improve adherence, often through use of fixed dose combinations.355-357  
Specific drug classes are related to adherence as well, though the results of these studies 
are mixed. With regard to hypertensive patients, Lebanese patients taking beta blockers as an 
antihypertensive medication were found to have reduced adherence rates compared to those 
taking combination drugs and those taking calcium channel blockers (CCB) were approximately 
three times more adherent than those taking other types of medication.308 The authors speculate 
that this association may be due to the fact that CCBs are generally prescribed for patients with 
higher blood pressure levels or those at higher risk of coronary disease, diabetes, indicating more 
advanced conditions or comorbidities that further the perceived importance of adhering to 
prescribed medication. 
Given the dearth of evidence in low- and middle-income countries and even greater 
absence of evidence from conflict settings results from studies in the United States provide some 
insight into potential determinants of medication adherence. For example, while a 1999 study of 
U.S. Medicare beneficiaries showed that the highest annual fill rates (the annual number of fills 
per drug class per year) were for metformin and sulfonylureas (annual fill rate=8.3) compared 
with newer drug classes (thiazolidinediones, meglitinides, and α-glucosidase inhibitors; annual 
fill rate=5.8), a 2008 study of Texas Medicaid recipients reported the lowest mean MPR (79.7%) 
to be for metformin when compared to other monotherapy drugs (84.4%).358,359  
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Adverse effects also strongly influence medication adherence. Studies in various contexts 
have shown lower adherence among both diabetic and hypertensive patients when medications 
were not tolerated or side effects were experienced.280,309,360,361 In addition to adverse events 
experienced for currently prescribed regimens, poor past medication experience can negatively 
influence adherence to currently prescribed regimens.362  
Several factors associated with patients’ conditions have been found to influence 
adherence. Shorter duration of diabetes and the presence of fewer diabetes complications are 
negatively associated with medication adherence; however, these associations may be more 
related to multicollinearity between higher numbers of complications, disease duration, and 
adherence than to the direct association between complications and medication adherence.324,363 
The association between comorbidities and adherence to hypertension or diabetes medications are 
widely studied, though results are inconsistent with regard to the nature of this association across 
comorbid conditions.280,325,351,364,365 
Patient/Provider Interaction 
It is commonly believed that patients who have an ongoing relationship with a provider 
will be more likely to understand their condition, the necessity and effectiveness of prescribed 
therapy(ies), and the importance of adherence to prescribed therapy. Lower continuity of care has 
been associated with poor adherence to medication among people with type 2 diabetes.366-368 
Evidence of this association is somewhat limited for hypertensive patients; however, qualitative 
research in Greece found that “good communication and a rewarding behavior of the physician” 
facilitated adherence.369 The association between patient-provider relationship and medication 
adherence has also been shown in a number of studies in a variety of countries and contexts 
including a 2015 cross-sectional study of hypertensive patients in Saudi Arabia that found more 
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than two times higher odds of antihypertensive medication adherence for patients reporting a 
good relationship with their provider after adjusting for demographic and disease characteristics 
such as gender, age, marital status, education and employment status, smoking, income, time 
since diagnosis, and comorbidities.370,371  
The patient-provider relationship is also important in treatment adherence even in the 
absence of continuity of provider care. Evidence supports the importance of providers engaging 
patients in their treatment plan and involving patients in the decision-making process rather than 
just counseling about selected medication. A 2002 study of patients seen at four U.S. Veterans’ 
Affairs outpatient clinics found that patients more actively involved in their treatment decisions 
reported significantly higher hypertension medication compliance.372 Such engagement not only 
gives patients a sense of ownership of their treatment but also further educates them beyond 
standard counseling often provided by physicians when prescribing medication, relating to the 
association between patient beliefs and medication adherence previously discussed.309,373-378  
Health System-Related Factors 
Economic factors have been strongly associated with adherence to prescribed medication 
among patients with diabetes in high-, middle-, and low-income countries alike. Many studies in 
the United States aiming to identify predictors of non-adherence report cost or other financial 
concerns as a factor, if not a central barrier, to non-adherence.293,324,379-381 For example, a 2012 
study of patients seen at community-based primary care practices in the U.S. showed a significant 
inverse relationship between antihypertensive medication adherence and cost-related adherence 
burden. In their 2004 study on cost-related medication underuse among chronically ill adults in 
the U.S., Piette et al. found that after adjusting for age, race, gender, education level, income, 
number of prescriptions, and prescription coverage, patients with monthly hypertension 
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prescription costs between US$51 and US$99 had 2.0 times higher odds of cost-related underuse 
compared to those with monthly out-of-pocket prescription cost of US$50 and under; monthly 
prescription costs of US$100 or more were associated with 4.6 times higher adjusted odds of 
cost-related underuse compared to monthly out-of-pocket prescription costs of US$50 and 
under.382 The association between monthly prescription costs and cost-related medication 
underuse were not statistically significant among diabetic patients in the same study; however, 
when adjusted for all covariates in the primary model except monthly out-of-pocket prescription 
costs, diabetes patients with no prescription coverage had statistically significantly higher odds 
(odds ratio = 2.3) of cost-related underuse than diabetic patients with prescription coverage.382  
Significant changes in adherence have previously been observed among type 2 diabetes 
patients with differing co-payment amounts.289,293,383-386 Colombi et al.’s 2008 study on the effect 
of copayments on adherence to oral diabetes medication found a statistically significant decrease 
in adherence prevalence with increased copayment amounts.289 Similar findings were supported 
by Gibson et al.’s 2010 study that found decreased adherence with increased levels of 
prescription drug cost sharing (measured using a cost-sharing index). Smaller, though still 
significant decreases in adherence were also associated with higher cost sharing for physician 
visits in this study.293 Countless studies of type 2 diabetics in low- and middle-income countries 
cite cost as the main factor related to non-adherence of prescribed medication; however, this 
presumption did not stand upon analysis in a study of Lebanese patients with chronic health 
conditions in which neither drug cost per patient, nor the presence of medical insurance were 
predictive of adherence.322,387,388 This null finding supports results from previous literature in 
which drug cost is less predictive of medication adherence than other criteria; however, 
conflicting results have been reported in previous studies of type 2 diabetes medication adherence 
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wherein increased medication costs were negatively associated with adherence, indicating a 
complex and likely context-specific relationship between costs and adherence.214,293,309,322,375,388,389 
In addition to cost factors, numerous other health system factors have previously shown 
association with adherence. Though not specific to diabetes or hypertension treatments, low 
accessibility of health services, long provider wait times, and difficulty obtaining prescriptions 
have previously shown association with poor medication adherence.390-396 Increased distance to 
the nearest pharmacy was inversely associated with compliance to therapy for type 2 diabetes and 
evidence in various settings indicates a similar relationship among patients with 
hypertension.362,371,397 Low patient satisfaction with the care they received or with past clinic visit 
experience(s) has also been associated with poor medication adherence, though not specific to 
diabetes or hypertension treatments.394,398-400 Individual clinic-level variation in adherence to oral 
hypoglycemic agents observed in a 2012 study of patients with diabetes treated in U.S. 
Department of Veterans Affairs primary health care clinics indicate the potential for an 
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Chapter 4. Methodology 
4.1. Conceptual Framework  
This study and its analytic strategy are guided by a conceptual framework of the 
association between patient, environment, and provider characteristics; individual health 
behaviors; and condition-related outcomes (Figure 4-1). The framework derives from Andersen 
and colleague’s behavioral model of health services utilization.402,403 That model has been 
elaborated since its conception in the 1960s. This study uses the fourth formal version of the 
behavioral model (1995), which combines individual level characteristics with health care system 
factors, personal health behaviors, health status outcomes, and, uniquely, the “dynamic and 
recursive nature” of the use of health services through various feedback loops.402,403 The 
behavioral model classifies individual and contextual determinants of health service utilization as 
predisposing, enabling, or need characteristics. Predisposing factors for care utilization include 
demographic/biological features, psychosocial elements, or health beliefs that incline an 
individual’s use of health services. Enabling characteristics such as income/socioeconomic status, 
competing demands, and access to information either facilitate or hinder a person’s ability to use 
services given their predisposition. Need-related characteristics indicate the level of either 
measured or perceived conditions requiring care. These factors are understood to influence 
individuals’ health behaviors (e.g., health service utilization and treatment adherence), which 
ultimately affect health-related outcomes (e.g., condition control, satisfaction with services, etc.). 
Upon the foundation of Andersen’s behavioral model, this study’s framework was 
adapted to reflect: (i) the Syrian refugee displacement context in Lebanon, (ii) the study’s specific 
focus on hypertension and type 2 diabetes, and (iii) medication adherence as an additional 
outcome of interest. Adaptations included the addition of specific determinants of care utilization 
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and medication adherence identified in Brown et al.’s 2004 framework on socioeconomic 
position and health among persons with diabetes mellitus, in addition to several other commonly 
cited models for health care utilization and literature referenced in the previous chapter.141,172,402-
405 These factors were then classified based upon Andersen’s model as predisposing, enabling, 
and need-focused. Additional variables are also included to account for environmental (including 
health system) and provider-related determinants based upon evidence identified in the literature 
review.  
The content of this research focuses on the relationship between selected predisposing 
and enabling factors in this framework (including structural, patient, and disease factors) and 
individual health behaviors, namely health care utilization and medication adherence. 
4.2. Overview 
As outlined in Chapter 1, the aims of this dissertation are to assess healthcare utilization 
and medication adherence for hypertension and type 2 diabetes among Syrian refugees and host 
communities in Lebanon, and to identify factors associated with care-seeking and medication 
adherence for these conditions among refugees. Two primary data sources were used for this 
research:  
1. A population level survey of health access and utilization conducted in Lebanon in 2015 
Survey data were used in Paper 1 to assess care-seeking and medication adherence 
at the population level among a representative sample of Syrian refugees and 
affected host communities in accessible areas throughout Lebanon.  
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2. Baseline data from a longitudinal cohort study 
Collected in 2015, these baseline data are used in Papers 2 and 3 to examine 
healthcare utilization and medication adherence in greater depth among care-
seekers at select primary level health facilities, excluding questions about initial 
contact with the health system.   
When combined, these data provide multifaceted information about healthcare utilization 
and medication adherence. A visual overview of the organization of the three papers’ data 
sources, sample populations, and outcomes of interest is provided in Figure 4-2.  
 
4.3. Paper 1 
Paper 1 characterizes care-seeking, health service utilization, and adherence to 
medication for hypertension and diabetes among Syrian refugees and host communities in 
Lebanon at the population level and explores household level determinants of care-seeking and 
medication adherence for these conditions among Syrian refugees.  
Data Source 
Paper 1 utilized data from the Household Survey of Syrian Refugee Health Status and 
Access to Care in Lebanon. This survey was conducted in March and April 2015 to characterize 
overall health-seeking behaviors and health service access. A total of 1,376 refugee and 686 host 
community households were surveyed using a cluster design with probability proportional to size 
sampling. Data are representative of Syrian refugees and affected host communities in accessible 
areas throughout Lebanon. Sampling, design, and implementation methods for this survey are 
published elsewhere and provided in Appendix A for ease of reference.73,116,406,407  
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Analytical Methods 
  Exploratory data analyses were conducted to investigate the extent of missingness and 
distribution of variables to be included in analyses, incorporating visual displays and diagnostic 
assessment to determine the appropriateness of analytical techniques. Care utilization, out-of-
pocket spending, and medication prescription and use were assessed using descriptive statistics 
and standard methods for comparison of means and proportions. Differences in household 
characteristics by population group, care-seeking, and interrupted medication adherence 
classification were examined using Pearson's chi-square and t-test methods. P-values and 95% 
confidence intervals were obtained from the data, accounting for survey cluster effects. Finally, 
logistic regression was performed to estimate the crude and adjusted odds of care-seeking and 
interrupted medication adherence among Syrian refugees and the nature of their relationship with 
relevant measured characteristics. 
4.4. Paper 2 
Paper 2 focuses on care utilization for hypertension and type 2 diabetes among Syrian 
refugees and host community members receiving care at select primary health facilities in 
Lebanon and investigates both clinical and demographic factors associated with utilization of 
health services. 
Data Source 
For this paper, baseline data from the Treatment Guidelines for Hypertension and Type 2 
Diabetes in Syrian Refugees and Host Communities in Lebanon study were utilized. Parent study 
interventions, objectives, and longitudinal methods are published elsewhere and provided in 
Appendix B for ease of reference.408,409  
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Participants and Sample Methods 
Study participants consisted of Syrian refugee, Lebanese, and in smaller number, Iraqi 
and Armenian care-seekers at ten primary health facilities in Lebanon supported by the 
International Organization for Migration (IOM) and International Medical Corps (IMC) in the 
South, Bekaa, Beirut, and Mount Lebanon governorates (Figure 4-3). Individuals without a 
hypertension or type 2 diabetes diagnosis, those less than 40 years of age, and adults lacking the 
capacity to independently participate in interviews were excluded from the study.  
The planned sample size for the parent study was based on the estimated existing 
caseload and projected newly diagnosed cases for each participating health facility. The total 
estimated caseload, anticipated proportions that could be reached by phone (estimated at 80%) 
and that would consent to participate (estimated at 80%), as well as the planned and maximum 
sample sizes to be enrolled from each health facility are presented in Table 4-1. The final enrolled 
sample size is presented by population group and diagnosed condition in Table 4-2.   
Potential participants were recruited using lists of diabetes and hypertension patients who 
visited each health facility within six months prior to the start of study enrollment. Study facilities 
submitted updated patient lists to IOM for study recruitment weekly through the end of the 
enrollment period, concluding after the first longitudinal study intervention was implemented in 
that facility. Interviewers called patients identified on these lists using the primary contact 
number provided and began by reading a brief script introducing the reason for the call and 
providing information about the study and the patient’s rights to decline participation. During this 
call, informed consent was obtained by interviewers trained in human subjects research and data 
collection practices, including the data collection tools to be used for the study. Of the 2,295 
individuals contacted to participate in the study, 21.6% (n=498) provided an incorrect phone 
number, 25.7% (n=592) were unavailable or unable to be reached by phone, 3.9% (n=89) did not 
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meet study criteria, 4.5% (n=104) refused to participate, and 0.1% (n=2) were deceased since the 
recorded care visit. A total of 1,010 patients (43.8%) were enrolled in the study, including 637 
Syrian refugees (63.1%), 330 Lebanese (32.6%), and 43 individuals of other nationalities (4.3%). 
Data Collection  
This study was designed using a mixed method approach utilizing both qualitative and 
quantitative data collection methods.  
Quantitative Data Collection 
Health facility assessments were performed at the start of the study to collect information 
about available equipment, drug supplies, and facility conditions. Facility assessments also 
included observation of the physical space, and documentation of the numbers of providers by 
type, facility operating hours, record-keeping practices, availability of equipment for diagnosis 
and management of hypertension and diabetes, as well as recent inventory and dispensing of 
medicines for these conditions.  
Enrollment interviews were conducted with every patient. In addition to providing 
consent for study participation, key indicators collected through these structured phone interviews 
included patient demographic and migration information; medical history and recent care seeking 
behaviors; and knowledge, attitudes, and practices related to diabetes and/or hypertension. 
Medical record reviews were conducted for each patient following enrollment. Key 
indicators included in record reviews related to provider compliance with guidelines and quality 
of care, frequency of patient visits, and both generic (death and loss to follow-up) and disease-
specific (complications and adverse events of hypertension and diabetes) patient outcomes. 
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All patient interviews were conducted by phone to ensure confidentiality and reduce the 
gratuity bias of interviews performed at health facilities. All data were collected on tablets using 
the Magpi mobile data platform by DataDyne LLC (Washington, DC). 
Qualitative Data Collection 
In addition to quantitative data collected via phone interviews, a total of 19 focus group 
discussions (FGDs) were conducted with Syrian refugees and Lebanese host community patients 
enrolled in the study, as well as health care providers working at study health facilities. Interview 
content focused on care-seeking and medication adherence, providing a more nuanced 
understanding of barriers to care, as well as treatment and medication adherence from both 
patient and provider perspectives. Two key informant interviews (KIIs) were also conducted with 
staff from humanitarian organizations providing services or programming for NCDs among 
Syrian refugees in Lebanon.  
Qualitative data collection was conducted by local IOM staff with one note-taker and one 
interviewer at each FGD. Oral informed consent was obtained from each participant before 
initiating the group discussion. FGDs were facilitated using semi-structured interview guides and 
lasted between 30 and 90 minutes, depending on time participants had available and interest in 
participation. 
Separate focus group discussions were conducted for Syrian refugees and Lebanese host 
community members in each geographic region. Groups were then further separated based upon 
whether care was sought for hypertension and/or type 2 diabetes in the six months prior to data 
collection. Table 4-3 presents the number of FGD participants by location and participant group. 
Focus groups were recorded to allow facilitators to more fully engage without 
compromising documentation. Following each discussion, the facilitator and note-taker discussed 
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participants’ contributions, interactions within the group, and how group composition or other 
factors may have influenced participants’ responses. Detailed notes were typed using recordings 
to expand upon notes taken during focus groups, then reviewed by data collection team members. 
FGD facilitators also debriefed with the Johns Hopkins Bloomberg School of Public Health 
(JHSPH) field coordinator throughout data collection to discuss questions, concerns, challenges 
faced, strengths, and weaknesses of each discussion.  
FGD summaries and field notes were analyzed using content analysis methods to identify 
key themes, consensus viewpoints, and viewpoints of a minority within groups, in addition to 
views that were unique to particular contexts or locations. FGD notes were analyzed separately 
for each participant group, after which findings were analyzed across groups to examine common 
themes further. 
Preliminary Data Cleaning 
A sequenced process-based classification used patient records, clinical data, and 
prescriptions to assign a uniform diagnosis category to patients in cases where reporting was 
inconsistent across data sources. Eight patients remained with an unclassified diagnosis and were 
subsequently dropped from analyses to ensure reliable reporting by condition. A similar process 
was used to classify population group (i.e., Syrian refugee, Lebanese host community, or other) 
among participants with conflicting reports across data sources; all participants were successfully 
classified.  
Limitations 
Restricting the study sample to individuals seeking care at study health facilities, while 
necessary for the main study objectives, is a limitation of this research in that it limits 
representativeness to a small subset of the population of Syrian refugees and host communities in 
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Lebanon who sought care in these locations. The prevalence of hypertension and type 2 diabetes 
is likely to be much higher in the community than only those recruited for the study without 
additional screening of the general population, and persons getting care from private clinics, 
pharmacies, or Syrian doctors practicing within the refugee community may well have different 
findings. As such, results are not necessarily applicable to all individuals with hypertension 
and/or diabetes who are not receiving care or who receive care at different types of health 
facilities or in other geographic areas of Lebanon. This is limiting because outcomes among 
patients not receiving care could be presumed to be far worse than in those receiving some level 
of care; however, results from this research can neither confirm nor preclude those assumptions. 
Analytical Methods 
For paper 2, data were first explored to characterize the degree and nature of missing 
observations, to examine frequencies and distributions, and to assess multicollinearity. 
Differences in health service utilization between Syrian refugees and Lebanese host community 
patients were examined using Pearson's chi-square and Wilcoxon-Mann-Whitney test methods. 
An alpha of 0.05 was used for all hypothesis testing. Equidispersion in utilization outcome 
variables was assessed using the Lagrange Multiplier test, which identified overdispersion both in 
the number of visits to a general practitioner (GP) and in visits to a relevant specialist 
(endocrinologist and/or cardiologist).410 To address the presence of excess zeros in the data, zero-
inflated and hurdle models were compared to determine the most appropriate regression model to 
employ in analyses. Akaike (AIC) and Bayesian Information Criterion (BIC) values indicated a 
preference for negative binomial hurdle models in all utilization outcome variables. The data is 
believed to contain only sampling excess zeros, further supporting the use of hurdle rather than 
zero-inflated models. Regression analyses included only Syrian refugees due to insufficient host 
community sample size. 
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4.5. Paper 3 
Paper 3 focuses on prescription and adherence to medication for hypertension and type 2 
diabetes among Syrian refugees and host community primary care patients and examines 
individual and household level determinants of interrupted medication use among Syrian 
refugees. 
Data Source 
As with Paper 2, analyses for Paper 3 utilized baseline data from the Treatment 
Guidelines for Hypertension and Type 2 Diabetes in Syrian Refugees and Host Communities in 
Lebanon study described in detail in the previous section.  
Analytical Methods 
Exploratory data analyses for paper 3 included visual displays of the distribution of 
variables of interest and diagnostic assessment of the suitability of planned analytical techniques. 
Differences in participant characteristics by population group and interrupted medication 
adherence classification were then examined using Pearson's chi-square tests. Finally, logistic 
regression was performed to determine the crude and adjusted odds of interrupted medication 
adherence among Syrian refugees and the association between interrupted adherence and 
measured demographic and clinical characteristics. Variables included in the base model were 
selected using evidence from the literature and the conceptual framework described previously. 
Given the relatively small host community sample size, insufficient number of host community 
participants reporting interrupted medication adherence, and the distribution of covariates of 
interest, regression analyses included only Syrian refugees.  
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4.6. Ethical Considerations 
The Syrian Refugee and Affected Host Community Health Access and Utilization Survey 
in Lebanon was approved by the Institutional Review Board at the American University of 
Beirut. The Johns Hopkins Bloomberg School of Public Health (JHSPH) Institutional Review 
Board also reviewed the protocol and determined that members of the JHSPH team were not 
involved in human subjects research because they did not have direct contact with participants or 
access to personal identifiers.  
All interviewers received training in basic principles of human subjects’ protection, as 
well as the informed consent processes and data collection practices for this study. To protect the 
anonymity of respondents, no information was recorded that could be used to identify the 
household or individual (including names, phone numbers, address, or other uniquely identifying 
characteristics). Interviewers obtained verbal informed consent from all participants by reading a 
consent form in Arabic outlining the purpose of the assessment, intended use of results, 
confidentiality, and the voluntary nature of participation. Potential respondents were informed 
that no identifying information would be recorded on the survey instrument or reported and that 
they had the right to decline to participate, stop the interview at any time, or to decline to answer 
any question. Potential respondents were also informed that the decision to take part or to refuse 
to take part would not influence their access to humanitarian assistance or protection. 
Interviewers were provided with information for participants on available services within the area 
and UNHCR registration in case this was requested. 
The Treatment Guidelines for Hypertension and Type 2 Diabetes in Syrian Refugees and 
Host Communities in Lebanon study was approved by the Ministry of Public Health in Lebanon 
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and Institutional Review Board at The Johns Hopkins Bloomberg School of Public Health. 
During the study, all interviews with patients were conducted over the phone.  
Eligible patients identified for enrollment were called by interviewers, who read a brief 
consent script providing information about the study, expectations for contact with enrolled 
participants, and the patient’s rights to decline participation. During this call, informed consent 
was obtained by interviewers (study staff) trained in human subjects research, informed consent 
processes, and data collection practices, including the data collection tools to be used for the 
study. Participants were also asked to go to a location where they are comfortable to complete 
each interview; participants were given the option of a call back at a later time if they were unable 
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Table 4-1. Treatment Guidelines Study Sample Size and Power Calculations 









IOM Supported Facilities 
Tyre 123 74 197 158 142 
Msayleh 193 116 309 247 223 
Nabatiyeh 140 84 224 179 161 
Bar Elias N/A N/A 125 100 90 
Taalabaya 16 18 34 27 25 




324 259 233 
Tayouneh 183 183 146 132 
Fanar 50 50 40 36 
Mrayje 72 72 58 52 
Karagheusian 715 715 572 515 
Maximum Planned Sample  1,609 
*estimated by taking 10% of the current caseload as newly identified cases monthly and extrapolating this out for a 6-













Type 2 Diabetes Total 
Syrian Refugees 325 85 227 637 
Lebanese 129 35 166 330 
Other Nationality 16 6 21 43 
Total  470 126 414 1,010 
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Table 4-3. Focus Group Discussion Participants by Location and Participant Group 
Participant Type Beirut/Mt. Lebanon Bekaa South Total 
Health Care Providers         
Physicians 2 3 6 11 
Nurses 3 4 4 11 
Pharmacists 0 0 2 2 
Total Provider FGD Sample 5 7 12 24 
Patients         
Syrian Refugees         
Recently sought care 11 9 3 23 
Did not recently seek care 12 8 8 28 
Lebanese Host Community         
Recently sought care 8 3 2 13 
Did not recently seek care 4 3 4 11 
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Figure 4-2. Organization of Dissertation Papers by Sample Population, Data Source, and 
Outcomes of Interest 
 
 




Care-Seeking & Medication Adherence 
Accessible  
Syrian Refugees &  
Affected Host Communities 
(Data Source: Health Access Survey) 
Paper 2 
Care Utilization 
Provider Type (GP/Specialist) 





at Select Primary  
Health Facilities
(Data Source: Treatment Guidelines 
Cohort Study Baseline Assessment) 
Recently received care in Lebanon 
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Chapter 5. Care-Seeking, Health Service Utilization, and Adherence to 
Medication for Hypertension and Diabetes Among Syrian Refugees and 
Affected Host Communities in Lebanon (Paper 1) 
5.1. Abstract 
Background. The inflow of Syrian refugees into Lebanon since 2011 has generated an 
immense demand on Lebanon’s health system. The burden of non-communicable diseases among 
both Syrian refugees and the Lebanese host community, the high cost of providing continuous 
care, and complex comingling of barriers to adequate monitoring and drug treatment adherence 
have implications for meeting both populations’ health needs.  
Methods. In consideration of these challenges, this study uses data from a survey of 
Syrian refugees and Lebanese host communities conducted in early 2015 to characterize care-
seeking, health service utilization and spending, and medication prescribing and adherence for 
hypertension and diabetes. A total of 1,376 refugee and 686 host community households were 
surveyed using cluster design with probability proportional to size sampling.  
Results. Results identified significant gaps between refugees and host community 
members in care-seeking, health facility utilization, out-of-pocket payments for care, and 
medication interruption. While host community cases had better access to care and fewer reports 
of medication interruption compared to refugees, out-of-pocket spending for the most recent care 
visit was significantly higher among host community care-seekers. Refugee care-seekers most 
frequently received care at primary health facilities, choosing to do so mainly for reasons related 
to cost, whereas host community care-seekers predominantly utilized private clinics with more 
concern for quality of care.  
Conclusions. Further efforts are needed to facilitate lower and more predictable health 
service costs for refugees and vulnerable host community members, as is continued 
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communication on how to access subsidized care. Expansion of new financing models, such as 
the flat fee model and incorporating facility-side support to meet demand may reduce the gaps 
between need and care-seeking practices in both refugees and host Lebanese and ensure 
sustainable, high-quality care for both populations.  
5.2. Introduction 
More than one million Syrian refugees have entered Lebanon since the start of the Syrian 
crisis, making it host to the highest number of refugees per capita worldwide.2,94 Contrary to the 
traditional model of providing refugee health care through a separate, parallel system, refugee 
care is instead integrated into the Lebanese health system through existing health 
facilities.88,97,411,412 The impact of this approach has been a considerable strain on the country’s 
health system, particularly given the high prevalence of chronic non-communicable diseases 
(NCDs) in both Lebanese and Syrian populations.93,413 
Through the joint Non-Communicable Disease Program (NCDP) with the World Health 
Organization (WHO) and the associated National Program on Controlling Diabetes, the network 
of health facilities regulated and supported by the Lebanese Ministry of Public Health (MoPH) 
are mandated to offer a range of services for NCDs. These services include education, screening, 
regular monitoring, and provision of essential medicines. The NCDP further aims to establish 
links for financial coverage of episodic hospitalization among those with chronic health 
conditions, including for complications of hypertension and diabetes.81 At the time in which this 
survey was conducted (2015), care was available for vulnerable Lebanese nationals for reduced 
costs at primary healthcare centers (PHCCs) in the MoPH National Network.88 As of August 
2015, Syrian refugees, including those registered with the United Nations High Commissioner for 
Refugees (UNHCR) and unregistered refugees, could utilize primary health services care at 
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approximately 116 of the more than 1,200 existing PHCCs/dispensaries across the country for a 
subsidized fee of approximately US$2 to US$3 per visit.13,79,88,96-99 Medication for chronic 
conditions is also provided to refugees at dispensaries throughout Lebanon for a handling fee of 
US$0.67, and for free at more than 400 facilities through the Young Men’s Christian Association 
(YMCA) chronic medications program, or, in some cases, through privately funded primary 
health care facilities.414,415  
Refugees meeting eligibility criteria and having an appropriate referral from a primary 
health care facility, or presenting with a life-threatening condition, are also entitled to UNHCR 
coverage of treatment costs for secondary and tertiary care. Since July 2018, UNHCR has 
supported referral care in accordance with standardized fees based upon MoPH fixed rates: 
refugees pay the first US$100, while UNHCR covers 75% of costs above US$100. Beneficiary 
cost shares are capped at US$800, with all excess costs covered by UNHCR. Prior to July 2018, 
in most eligible cases, UNHCR covered upwards of 75% of hospital costs dependent upon 
refugees’ vulnerability classification, though refugee shares were not capped.37,416,417 Hospital 
cases deemed ineligible for coverage are submitted to the Exceptional Care Committee for 
reconsideration based on financial need, necessity of care, and the cost of referred services. Even 
with this level of support, Lebanon’s highly privatized health system often makes care for 
refugees comparably as expensive as it is for vulnerable Lebanese.80,93 Alternative financing 
mechanisms such as a flat fee model, which would include bundled services for a nominal pre-
determined fee, are being explored, though they are in pilot or early phases of scale-up.418-420  
For refugees and vulnerable host populations, even those receiving subsidized care, the 
burden of out-of-pocket payments can be sufficient to prevent them from receiving care. This 
barrier is substantial considering the increasing debt and strained financial situation of many 
refugee households.102 Despite wide coverage of subsidized care, 39% of Syrian refugees in 
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Lebanon are reportedly not receiving needed medical care due to treatment and/or medication 
costs.103 Furthermore, a recent (2014) survey of Syrian refugees in Lebanon reported that 56.1% 
of households had a member with an NCD who was unable to access medicine or other health 
services, increasing the patient’s risk of complications in the long-term and the costs incurred for 
more specialized intervention.71  
There is a paucity of research exploring care-seeking rates in the Lebanese population; 
rather, previous studies focus primarily on treatment rates, often defined according to use of 
antihypertensive or antidiabetic medication(s). A 2015 study of prevalence, awareness, treatment, 
and control of hypertension in Lebanon reported the overall treatment rate to be 48.9%; however, 
this does not necessarily translate to the proportion of individuals with hypertension receiving 
regular monitoring and care from a health professional. Comparable estimates are scarce for 
Lebanese with diabetes, though it is estimated that almost three-quarters of patients on 
medications for chronic conditions receive incomplete therapeutic and safety monitoring tests 
recommended by standard treatment guidelines. In this same study, less than half of participants 
reported visiting a physician at least every six months, and three percent reported having 
medication dispensed by a pharmacist without physician consultation.123  
In addition to continuity of follow-up care, effective management of hypertension and 
type 2 diabetes most often require adherence to pharmacological intervention. Poor adherence to 
prescribed medication(s) is associated not only with poor health outcomes but also increased 
health costs long-term, predominantly for specialized care, hospitalization, and emergency room 
visits.225,227,267,268,280-285 An occasional missed dose is not uncommon for chronic medical 
conditions; reduced adherence beyond that, however, risks avoidable morbidity, complications, 
disability, and ultimately premature death.225,271,274-278,280,286-292,296  
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In the absence of a gold standard adherence measure, the diversity of measures applied 
across studies hinder comparison of reported adherence rates.421 Moreover, there is no established 
standard for ideal or acceptable population-level adherence prevalence that is empirically related 
to improved or worsened population health outcomes.421-424 Non-adherence to medication 
prescribed for chronic conditions was most recently (2017) estimated at 62% in a review of 
studies in the Middle East; however, estimates upon which this figure is based vary from 1.4% to 
83.3%, a range so wide that it demonstrates the limitation of cross-study applications of 
measurement methods and context-specific nuances.425 Equivalent estimates among Lebanese 
with chronic health conditions, including hypertension and diabetes, are also varied, with 22% to 
57% of participants reporting low/poor adherence.308,309 The only identified published estimate 
for Syrian refugees’ adherence to chronic disease medications reported that among beneficiaries 
in a 2018 evaluation of primary care NCD services offered by Médecins Sans Frontières (MSF) 
in Irbid, Jordan, 89% were classified as having high adherence (according to the Medication 
Adherence Report Scale).426 Qualitative results in the MSF evaluation differ from this estimate as 
non-adherence was reported by many more beneficiaries in focus group discussions and was 
noted by project staff.  
This paper describes and provides empiric evidence on care-seeking, health service 
utilization and spending, and medication prescribing and adherence for hypertension and diabetes 
by Syrian refugees and host communities in Lebanon. 
 




A national survey of Syrian refugees and affected host communities in Lebanon was 
conducted in March and April 2015 to characterize health-seeking behaviors and health service 
access. Detailed survey methods are provided in Appendix A for ease of reference.  
Sample size was determined for key objectives based on the most conservative 
prevalence estimate of 50%; calculations assumed 80% power and a design effect of 2.0. The 
planned sample was increased from the minimum identified size of 900 refugee households to 
1,400 refugee households and 700 Lebanese host community households to improve precision.  
Given the concentration of Syrian refugees and the low cost of visiting many locations 
due to the country’s small size, a 100 cluster x 21 household (14 Syrian refugee households and 
seven host community households) design was used. Clusters were assigned to cadastrals (low-
level administrative units) using probability proportional to size (PPS) sampling with UNHCR 
registration data, assuming that non-registered refugees had similar residence patterns. Permission 
to conduct the survey could not be obtained in 22 cadastrals, requiring reassignment of 28 clusters 
to accessible areas using PPS methods. The final sample distribution included 35 clusters (35%) 
in the North governorate, 34 clusters (34%) in Bekaa governorate, 25 clusters (25%) in Mount 
Lebanon governorate, four clusters (4%) in Beirut governorate, and 2 clusters (2%) in the South 
governorate (Figure 5-1). A representative sample from the South could not be obtained because 
only two cadastrals were accessible; due to violation of sampling assumptions, analyses exclude 
the South governorate. A total of 2,165 households were approached to participate. Of these, 
1.9% were not home, 0.2% were previously interviewed, 0.05% was ineligible, and 2.7% refused 
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to participate. The final sample included 2,062 households (1,376 Syrian refugee and 686 host 
Lebanese), equating to a response rate of 93.6%. 
ARC GIS software was used to allocate cluster start points within cadastrals randomly; 
only coordinates in populated areas were used. The nearest intersection to each start point, usually 
within a half kilometer, served as the starting location to which teams navigated using mapping 
software such as Google Maps. At the start location, interviewer pairs were sent in different 
directions to locate households; they approached the nearest business likely to be used by 
refugees (or community residents if there were no shops) and asked to be referred to nearby 
Syrian households. Upon interview completion, respondents were asked for a referral to the 
nearest Syrian household; this referral process was used until 14 Syrian refugee interviews were 
completed. Following every two interviews with Syrian households, the nearest Lebanese 
household was identified and interviewed. To improve the representativeness and coverage of the 
sample, no more than three households within an apartment building were included.  
When start points were in or near informal settlements, the settlement’s size was 
estimated by walking transects and/or the perimeter; larger settlements were sub-divided and 
assigned to different interviewers. Interviewers located the middle of the settlement/area and 
walked in a randomly selected direction, counting the number of shelters before reaching the edge 
of the settlement/area. A randomly selected number between one and the total number of shelters 
passed was used to identify the starting household. Interval sampling was then used in place of 
referrals in informal settlements to reduce the potential for bias. Only Syrian households arriving 
in Lebanon in 2011 or later were eligible to participate, as the aim was to capture the experiences 
of those displaced by the conflict. Families with both Lebanese and Syrian members were 
considered refugees if they came from Syria in or after 2011.  
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The questionnaire was initially developed for use in Jordan and subsequently adapted for 
the Lebanese context. The questionnaire focused on health service utilization, access and barriers 
to care, children’s health, and chronic medical conditions. Interviewers received two days of 
classroom training that focused on the questionnaire, e-data collection, interview techniques, 
basic principles of human subjects’ protections, and sampling followed by two additional days of 
field training. To protect the anonymity of respondents, no unique identifiers were recorded, and 
verbal consent was obtained. Interviews lasted between 30-60 minutes depending on the 
household size, number of children, and individuals with chronic medical conditions. Data was 
collected on tablets using the Magpi mobile data platform by DataDyne LLC (Washington, DC). 
The study was approved by the Institutional Review Board at the American University of 
Beirut. The Johns Hopkins Bloomberg School of Public Health (JHSPH) Institutional Review 
Board also reviewed the protocol and determined that members of the JHSPH team were not 
involved in human subjects research because they did not have direct contact with participants or 
access to personal identifiers. 
Variables 
The outcome variables of interested included care-seeking and medication adherence. 
Proper management of both hypertension and diabetes requires regular monitoring and health 
provider visits, which have been shown to have a positive association with health outcomes for 
both conditions (blood pressure and blood glucose), as well as secondary benefits including lower 
risk of hospitalization.110-115 Care-seeking was assessed for household index cases of hypertension 
and diabetes based on a series of questions about their most recent care visit for the condition. 
Care-seeking was classified as a binary outcome, according to whether or not the most recent visit 
was within the six months preceding interview. Care-seeking was modeled in the preceding six 
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months based upon the distribution of most recent care-seeking timing in the data and because it 
is the most conservative recommended follow-up interval for adults with elevated blood pressure 
according to the 2017 ACC/AHA guidelines for blood pressure management.105 Adherence was 
assessed as a binary variable for index cases based on whether or not respondents reported having 
stopped medication for two weeks or more in the preceding year. 
Explanatory variables included in analyses consisted primarily of household level 
characteristics and are detailed in Appendix C. 
Data Analysis  
Data were analyzed using Stata 13 (College Station, TX). Descriptive statistics and visual 
displays of explanatory and outcome variables were examined to identify the extent and patterns 
of missingness, distributions, and to determine the analytical strategy’s appropriateness.  
Differences in care utilization, out-of-pocket spending, and medication prescription and 
use by population group were examined using Pearson’s chi-square and t-test methods. P-values 
and 95% confidence intervals were obtained from the data, accounting for cluster effects using 
the Rao and Scott second-order corrected Pearson statistic for dichotomous variables and adjusted 
F-statistics for continuous variables. This procedure results in standard errors of point estimates 
and model coefficients that are adjusted for survey design effects.427 An alpha of 0.05 was used 
for all significance testing. 
Given the fundamental differences between hypertension and diabetes clinically and in 
the patient’s experience of the disease, as well as the effect that these differences may have on the 
outcomes of interest, care-seeking and adherence outcomes were modeled separately for each of 
the two conditions. 
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Differences between refugee and host community populations are explored through 
descriptive statistics and compared using Pearson's chi-square and t-test methods as described 
previously. Due to insufficient reports of interrupted medication adherence among Lebanese host 
community cases (8.6% for hypertension and 8.5% for diabetes) to support modeling, regression 
analyses included only Syrian refugees. This focus also allowed for the inclusion of refugee-
specific variables (e.g., receipt of cash assistance and time of arrival in Lebanon) that are likely to 
be useful for future program refinements.  
The crude and adjusted odds of care-seeking and interrupted medication adherence were 
estimated using similar logistic regression methods. Interaction terms for key explanatory 
variables were tested in toto, as well as with sequential addition of interaction terms. The Akaike 
(AIC) and Bayesian Information Criterion (BIC), which compare the quality of individual models 
relative to one another by giving preference to lower AIC/BIC values, indicated preference for 
the null model excluding all interaction terms.428 Wald and likelihood ratio tests, which assess 
variation in model fit when different variables are included, similarly indicated a preference for 
null models for all outcomes of interest, resulting in exclusion of interactions from final 
models.429 
5.4. Results 
Care-Seeking and Health Service Utilization 
Hypertension 
Care-seeking for hypertension was high among both Syrian refugees and Lebanese host 
community members. Of the 282 Syrian refugee hypertension index cases, most saw a doctor for 
hypertension in Lebanon (80.9%, CI: 75.2-85.5%) since arriving as early as 2011; 64.5% (CI: 
58.5-70.1%) reported seeking care in the preceding six months and 51.4% (CI: 45.2-57.6%) 
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within the past three months (Table 5-1). Lebanese host community members were significantly 
more likely to have sought care than refugees (P<0.001) with 98.3% (CI: 95.6-99.4%) of the 236 
cases reporting they had seen a health provider for hypertension in Lebanon. Although the timing 
of care-seeking for hypertension significantly differed between Syrian refugees and Lebanese 
host community cases, this is primarily driven by the 18.4% of refugees who never sought care in 
Lebanon as compared to only 0.4% of Lebanese (P<0.001). Similar to refugees, many host 
community index cases sought care for hypertension in the past six months (72.9%, CI: 66.1-
78.7%), and just over half reported receiving care within the past three months (55.1%, CI: 48.4-
61.6%).  
Significant differences between refugees and the host community were observed in the 
location in which care was sought (P<0.001). Of the 195 refugees receiving care for hypertension 
in the year preceding interview, most were treated in primary health facilities (54.9%, CI: 47.6-
61.9%), followed by private clinics (21.5%, CI: 16.6-27.5%), pharmacies (9.6%, CI: 5.6-14.8%), 
hospitals (8.2%, CI: 5.1-12.9%), and other facility types including mobile medical units (MMUs) 
and home-based providers (6.2%, CI: 3.0-12.3%).  
Of the 196 host community cases receiving care for hypertension in the prior year, over 
half were treated in private clinics (59.2%, CI: 51.0-69.9%), a significantly larger proportion as 
compared to Syrian refugees (P<0.001). Host community care-seekers were less likely to receive 
care at primary health facilities (19.4%, CI: 14.3-25.7%) and more likely to receive care at 
hospitals (15.8%, CI: 11.4-21.6%), though use of these locations was still less commonly 
reported. Other infrequently reported care-seeking locations among host community cases 
included pharmacies (2.6%, CI: 1.0-6.1%) and other facilities such as those mentioned above 
(3.1%, CI: 1.2-7.5%). No significant differences in care-seeker characteristics (household head 
education attainment, socioeconomic quartile, crowding, region of residence, and for refugees, 
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year of arrival in Lebanon and UNHCR registration status) were observed by facility type or 
sector where care was sought, either for refugees or host community members. 
The most frequently reported reasons for selecting the location where care was most 
recently sought for hypertension differed between refugee and host community care-seekers 
(Table 5-1 and Figure 5-2; P<0.001). Refugees most commonly selected facilities for cost-related 
reasons (65.6%, CI: 58.0-72.5%);  smaller proportions were motivated by quality of care† (13.8%, 
CI: 9.4-19.9%), geographic location (12.8%, CI: 8.5-18.8%), or other reasons, including 
availability of needed services or medical emergency (7.7%, CI: 4.3-13.4%). Conversely, only 
17.9% (CI: 12.7-24.5%) of host community care-seekers selected facilities for reasons associated 
with cost, as reflected by the high utilization of private clinics. Nearly half of host community 
care-seekers selected facilities based on perceived quality of care or continuity of care by their 
usual/family doctor (49%, CI: 40.8-57.2%), and less frequently by geographic location (15.3%, 
CI: 10.4-21.9%) or other reasons (17.9%, CI: 13.0-24.0%).  
The primary reason for selecting the facility type visited also significantly differed 
between Syrian refugees and Lebanese host community cases when stratified by type of facility 
(P<0.001 for both primary health facilities and private clinics) (Figure 5-2). This suggests that 
differences in reasons for selecting care locations between refugees and host community cases are 
not entirely driven by underlying differences in the distribution of facility types utilized by each 
population. The majority of refugees seeking hypertension care at primary health facilities 
(92.5%, CI: 85.6-96.3%) did so for reasons related to cost, with other motivations reported by 
only nominal proportions of refugees. Cost was also the most commonly reported motivation for 
host community primary health facility care-seekers (60.5%, CI: 43.0-75.7%), though perceived 
                                                     
† “Quality of care” also includes liking facility staff or family doctor practicing at the facility 
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quality of care/family doctor(s) practicing in the selected facility (15.8%, CI: 7.7-29.6%) and 
location (15.8%, CI: 6.7-32.8%) were reported more by host community cases than by refugees. 
Among those seeking hypertension care at private clinics, quality of care and continuity of care 
by their family doctor was the leading motivation both for refugee (47.6%, CI: 32.0-63.7%) and 
host community cases (69.0%, CI: 58.6-77.7%). Smaller proportions of refugees chose to visit 
private clinics because of location (26.2%, CI: 14.5-42.6%), and cost (19.1%, CI: 10.1-33.1%). 
Lebanese host community cases who sought care at private clinics also did so less frequently 
because of location (14.7%, CI: 9.3-22.4%), while only 1.7% (CI: 0.4-6.8%) cited cost as the 
reason for selecting to utilize a private clinic. 
Diabetes 
As with hypertension, care-seeking for diabetes was similarly high among both Syrian 
refugees and the Lebanese host community. Among the 136 diabetes index cases in refugee 
households, most received care for the condition in Lebanon (88.2%, CI: 81.8-92.6%). Many 
refugees sought care within the past six months (71.3%, CI: 63.6-78.0%) and more than half 
(61.8%, CI: 53.8-69.2%) sought care in the past three months. Care-seeking for diabetes was 
significantly higher among Lebanese host community members (97.2%, CI: 92.9-98.9%) 
compared to refugees (P=0.005). Most of the 144 host community diabetes index cases had 
received care in Lebanon (97.2%, CI: 92.9-98.9). The majority of host community cases sought 
care in the past six months (82.6%, CI: 75.9-87.8%), and more than half reported receiving care 
within the past three months (66.0%, CI: 58.3-72.9%). The timing of diabetes care-seeking for 
diabetes was not significantly different between Syrian refugees and Lebanese host community 
members (P=0.126) (Table 5-1).  
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Diabetes care-seeking location also significantly differed between refugees and the 
Lebanese host community (P<0.001). Of the 102 refugees receiving care for diabetes in the year 
preceding the interview, more than half received care in primary health facilities (60.8%, CI: 
50.7-70.1%). Primary health facilities were utilized by only 17.5% (CI: 12.1-24.5%) of the 126 
host community cases that sought care for diabetes in the preceding year. Among host community 
care-seekers, care was most commonly sought at private clinics (59.5%, CI: 51.2-67.3%), while a 
much smaller proportion of refugee care-seekers sought care at private clinics (20.6%, CI: 13.7-
29.7%). The remaining refugee care-seekers sought care at pharmacies (9.8%, CI: 5.5-16.8%), 
hospitals (3.9%, CI: 1.5-9.9%), and other facility types (4.9%, CI: 2.1-11.1%). Diabetes care was 
also less commonly sought by host community care-seekers at these locations (15.9%, CI:10.7-
22.8% at hospitals; 6.3%, CI:3.3-12.0% at pharmacies; and 0.8%, CI:0.1-5.6% at other types of 
facilities). As with hypertension care, no significant differences were observed in care-seeker 
characteristics by facility type or sector where care was sought for either population group. 
Reasons for selecting facilities for diabetes care were distributed similarly to those for 
hypertension with significant differences between refugee and host community care-seekers 
(Table 5-1 and Figure 5-2; P<0.001). Refugees most frequently sought care for reasons related to 
cost (78.4%, CI: 69.1-85.5%); geographic location (9.8%, CI: 5.4-17.1%), quality of care/family 
doctor(s) practicing in the selected facility (7.8%, CI: 4.1-14.6%), and other reasons (3.9%, CI: 
1.5-10.1%) were less commonly reported. Quality of care/preference for their family doctor was 
the leading reason for host community facility selection, reported by 50.8% (CI: 42.1-59.4%) of 
care-seekers. Host community members selected facilities for cost-related reasons far less 
frequently (20.6%, CI: 14.4-28.6%) than refugees, perhaps explaining higher utilization of private 
clinics among host community cases as compared to refugees. Host community care-seekers were 
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less frequently motivated by facility location (16.7%, CI: 10.8-24.8%) and other reasons (11.9%, 
CI: 6.8-20.0%).  
When stratified by the type of facility, Syrian refugees and Lebanese host community 
cases differed in the motivations that led them to seek diabetes care (P<0.001 for primary health 
facilities; P=0.009 for private clinics) (Figure 5-2). Refugee care-seekers’ motivation for visiting 
primary health facilities were focused primarily on cost (93.6%, CI: 83.7-97.6%) and varied less 
than the reasons reported by host community cases. Although 50.0% (CI: 29.9-70.1%) of host 
community cases utilized primary facilities mainly for cost-related reasons, perceived quality of 
care/preference for their family doctor (22.7%, CI: 9.6-44.8%) and location (27.3%, CI: 12.6-
49.4%) were also frequently reported reasons. Refugees seeking diabetes care at private clinics 
did so largely because of cost (47.6%, CI: 26.7-69.4%), with smaller proportions reporting 
reasons related to quality of care/family doctor(s) (23.8%, CI: 10.3-46.0%), location (19.1%, CI: 
7.9-39.3%), or other motivations (9.5%, CI: 2.3-32.2%). Lebanese host community cases who 
sought care at private clinics, however, did so largely because of perceived quality of care/family 
doctor(s) practicing in the selected facility (68.0%, CI: 55.1-78.6%), with smaller proportions 
motivated by cost, geographic location, or other reasons.  
Predictors of Care-Seeking 
Results of univariate and multivariate logistic regression analyses of predictors of care-
seeking for hypertension and diabetes in the six months before the interview among Syrian 
Refugees are presented in Table 5-2. There was no significant difference in the adjusted odds of 
care-seeking for hypertension or diabetes by household head sex, household head education level, 
monthly household expenditures, year of arrival in Lebanon, or receipt of cash and/or voucher 
assistance. Adjusted odds of care-seeking for hypertension in the prior six months were 
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significantly associated only with region of residence in univariate and multivariate regression 
analyses. Adjusting for other variables of interest, refugees in the North governorate had 1.94 
times higher odds of care-seeking (CI: 1.01-3.73) as compared to those in Beirut and Mount 
Lebanon governorates (P=0.046). The odds of care-seeking for diabetes in the six months prior to 
interview were significantly associated with region of residence in univariate analysis, though this 
relationship was only marginally statistically significant in the adjusted analysis. Refugees in 
Bekaa governorate had significantly lower odds of diabetes care-seeking (0.35, CI: 0.12-1.01) 
compared to refugees living in Beirut/Mount Lebanon governorates in multivariate regression 
analyses (P=0.053). While cases from households with above average monthly household 
expenditures had significantly higher odds of care-seeking as compared to those with below 
average monthly expenditures, this relationship was significant only in univariate analysis 
(P=0.040; adjusted P=0.119).  
Spending on Health Services 
For household index cases who reported seeking care for hypertension or diabetes in the 
year preceding the interview, self-reported cost of care-seeking for the most recent visit was 
collected. Care-seeking cost included out-of-pocket payment(s) made for the consultation, 
including any diagnostic and laboratory tests. Medication payments and payments made on the 
patient’s behalf by the United Nations, insurance, or another organization were excluded. Data on 
out-of-pocket expenditures are summarized in Figure 5-3 and presented in more detail in 
Appendix D. Out-of-pocket costs reported by respondents reflect reported expenditures at 
primary health care centers in public networks (MoPH and Ministry of Social Affairs (MoSA) 
facilities) as well as those operated privately and by non-governmental organizations (NGOs); 
further differentiation of costs at between facilities within and outside the MoPH-PHCC network 
was not possible.  
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Hypertension 
Overall, 66.7% (CI: 59.2-73.4%) of refugee hypertension cases and 77.0% (CI: 70.7-
82.3%) of host community hypertension cases reported an out-of-pocket consultation payment 
(Figure 5-3; P=0.017). The average out-of-pocket consultation payment was US$14.4 (CI: 9.8-
18.9; median US$3) for refugees and US$29.5 (CI: 24.8-34.2; median US$33) for host 
community members (P<0.001). Among only those who paid for care, the average out-of-pocket 
payment was US$21.7 (CI: 14.9-28.5; median US$10) for refugees and US$38.4 (CI: 33.3-43.5; 
median US$33) among the host community (P<0.001). 
Out-of-pocket expenditures for hypertension and diabetes care by facility type are 
presented in Figure 5-3. The highest proportion of Syrian refugee care-seekers incurring an out-
of-pocket cost was at private clinics (85.7%, CI: 71.8-93.4%) and the lowest in primary health 
facilities (73.8%, CI: 63.7-82.0%) (P=0.136). Significant differences in the cost of hypertension 
care by facility type were observed for Syrian refugee care-seekers (P=0.001). Not surprisingly, 
the highest average out-of-pocket cost (among care-seekers incurring any cost) was at hospitals 
US$81.4 (CI: 29.5-133.2; median=US$27) and the lowest at primary health facilities (average 
cost=US$10.0, CI: 4.6-15.4; median=US$5).  
Unlike among Syrian refugees, the highest proportion of host community care-seekers 
reporting out-of-pocket costs was among those who sought care at a primary health facility 
(86.6%, CI: 71.7-94.5%) and the lowest among those seeking care at hospitals (64.5%, CI: 45.6-
79.8%) (P=0.092). Despite this, the amount of out-of-pocket costs incurred by host community 
care-seekers reporting any payment was highest at hospitals (mean=US$69.8, CI: 47.1-92.4; 
median=US$50) and lowest at primary facilities (mean=US$21.7, CI: 12.1-31.2; median=US$10) 
(P<0.001).  
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Differences in the proportion of patients with any out-of-pocket payments between 
Lebanese and Syrian refugee care-seekers were not statistically significant within each facility 
type (primary level facility P=0.115, private clinic P=0.657, and hospital P=0.897). However, 
average out-of-pocket payment amounts at primary facilities were significantly lower for Syrian 
refugees (US$7.4, CI: 3.3-11.4; median=US$3) as compared to the Lebanese host community 
(US$18.8, CI: 10.1-27.5; median=US$10) (P=0.012).  
Diabetes 
Out-of-pocket consultation payments for diabetes were reported by 70.6% (CI: 62.3-
77.7%) of refugees and 82.5% (CI: 74.5-88.4%) of host community cases (P=0.025). The average 
out-of-pocket consultation payment among refugees was US$12.0 (CI: 8.2-15.7; median US$5) 
and US$31.6 (95% CI 26.7-36.5; median US$33) for host community members (P<0.001). 
Among those reporting any out-of-pocket payment for care, the average amount was US$17.1 
(CI: 12.0-22.2; median US$10) for refugees and US$38.7 (CI: 33.3-44.0; median US $33) among 
the host community (P<0.001). 
As with hypertension care, the highest proportion of Syrian refugees receiving care for 
diabetes who reported any out-of-pocket cost was at private clinics (90.5%, CI: 69.5-97.5%). 
Unlike hypertension care, however, the lowest proportion of refugees incurring out-of-pocket 
costs was among hospital care-seekers (50.0%, CI: 12.0-88.0%) (P=0.167). Accordingly, of 
refugee care-seekers incurring any out-of-pocket payment, the cost of diabetes care was highest at 
private clinics (US$26.9, CI: 19.7-34.1; median=US$23), which was significantly greater than at 
primary level facilities (US$13.5, CI: US$6.8-20.1; median=US$7) (P=0.010). Though the lowest 
cost among refugees with any payment was at hospitals, only two cases reported cost amounts for 
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hospital care (both of whom paid US$6.6, presumably reflecting financial support from UNHCR 
or another organization); thus, reliable hypothesis testing was not possible.  
The highest proportion of host community care-seekers reporting any out-of-pocket costs 
was at private clinics (94.7%, CI: 86.6-98.0%), but unlike refugees, the lowest proportion with 
payment was among primary level facility care-seekers (77.3%, CI: 55.2-90.4%) (P=0.029). 
Accordingly, the amount of out-of-pocket costs incurred by host community care-seekers 
reporting any payment was highest at private clinics (mean=US$44.2, CI: 38.2-50.2; 
median=US$33) and lowest at primary level health facilities (mean=US$16.5, CI: 9.0-24.0; 
median=US$10) ( P=0.015). No significant differences in the proportion of patients with out-of-
pocket payments were observed between Lebanese and Syrian refugee care-seekers within each 
facility type (primary level facility P=0.866, private clinic P=0.480, and hospital P=0.211). 
Statistically significant differences in out-of-pocket payments between Syrian refugees and host 
Lebanese were observed only at private clinics, where the average cost was US$26.9 (CI: 19.7-
34.1; median=US$23) among refugees and US$44.2 (CI: 38.2-50.2; median=US$33) among host 
community care-seekers (P=0.001). The number of hospital care-seekers reporting exact cost 
amounts was not sufficient to test population group differences.  
Medication Prescription and Current Use 
Summaries of medication prescription, current use, and interrupted use among household 
index cases of hypertension and diabetes are presented in Table 5-3. 
Hypertension 
Of the 282 Syrian refugee hypertension cases, medication for hypertension was 
prescribed for 97.2% (CI: 94.4-98.6); of these, 40.1% (CI: 33.0-47.7) were prescribed medication 
in Syria and 59.9% (CI: 52.3-67.0) in Lebanon. The country in which medication was prescribed 
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did not vary by length of time in Lebanon, however, and may be more a reflection of time since 
the initial diagnosis and/or prescription of the current medication. A high proportion of cases 
reported currently taking hypertension medication (79.4%, CI: 74.4-83.6); however, nearly one-
third (30.5%, CI: 24.8-36.9) reported having stopped their medication for two weeks or longer in 
the preceding year, mostly against medical advice (27.8% of all cases, CI: 22.3-34.1). Of those 
who stopped medication, 11.1% (CI: 5.0-23.0) did so in Syria and 88.9% (CI: 77.0-95.0) in 
Lebanon. The most common reason for refugees to stop taking hypertension medication was their 
inability to afford the medicine (77.8%, CI: 68.2-85.1).  
Of the 236 Lebanese host community hypertension cases, medication was prescribed for 
99.2% (CI: 96.6-99.8) and most cases reported currently taking medication (95.8%, CI: 91.9-
97.8). A small proportion (9.0%, CI: 6.0-13.3) of Lebanese hypertension cases reported having 
stopped their hypertension medication for two weeks or longer in the past year, and most stopped 
without instruction from a physician (8.6%, CI: 5.7-12.8). As with Syrian refugees, the most 
common reason members of the Lebanese host community reported for stopping hypertension 
medication was inability to afford the medicine (75.0%, CI: 51.3-89.5). Differences between 
Syrian refugees and Lebanese host community hypertension cases were significant concerning 
current medication use (P <0.001) and stopping medication, either with or without instructions 
from a physician (P <0.001) with Syrian refugees having lower adherence than the Lebanese host 
community. 
Diabetes 
Nearly all (98.5%, CI: 94.2-99.6) of the 136 Syrian refugee diabetes cases were 
prescribed medication either in Syria (33.6%, CI: 26.4-41.7) or Lebanon (66.4%, CI: 58.3-73.6) 
(Table 5-3). Many (89.7%, CI: 83.0-93.9) reported currently taking prescribed medication, 
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including oral hypoglycemic drugs as well as insulin. Of all refugee diabetes cases, 26.3% (CI: 
19.5-34.6) reported having stopped their medication for two weeks or longer in the prior year, 
mostly without a physician’s instruction to cease medication (25.0% of all cases, CI: 18.4-33.0). 
Of those who reported stopping medication, 11.8% (CI: 4.6-27.0) did so in Syria and 88.2% (CI: 
73.0-95.4) in Lebanon. Again, the most common primary reason for stopping diabetes medication 
was inability to afford the medicine (76.5%, CI: 57.8-88.5).  
Almost all (97.2%, CI: 92.9-98.9) of the 144 Lebanese host community diabetes cases 
were prescribed medication for the condition (Table 5-3) and most (95.1%, CI: 90.4-97.6) were 
currently taking diabetes medication. Of all host community diabetes cases, 11.4% (CI: 7.2-17.7) 
reported stopping medication for longer than two weeks in the past year; 8.5% (CI: 4.9-14.3) of 
all cases did so without instruction by a physician. Again, the most common reason for stopping 
medication for diabetes, excluding those who stopped per instruction by a physician, was cost 
(91.7%, CI: 57.8-98.9). Unlike in cases of hypertension, however, one-quarter (25.0%, CI: 9.5-
51.3) of diabetes cases that stopped taking medication did so per a doctor’s recommendation. 
Significant differences between Syrian refugees and Lebanese host community members with 
diabetes were observed in stopping medication (P=0.002 for any stopping; P <0.001 for 
medication stopped against medical advice), with Syrian refugees having lower adherence than 
the Lebanese host community. 
Predictors of Interrupted Medication Adherence 
Hypertension 
Results of univariate and multivariate logistic regression analyses for predictors of 
interrupted medication adherence among Syrian refugees are presented in Table 5-4. Adjusted 
odds of interrupted adherence to hypertension medication were significantly associated only with 
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having seen a health provider for hypertension in the preceding three months, which was 
protective (0.58, CI: 0.34-0.99) as compared to those who did not have a care visit in that period 
(P=0.046). There was no significant difference, either in univariate or multivariate analyses, in 
the odds of interrupted medication adherence by region, household head sex or education, 
monthly household expenditures, receipt of cash/voucher assistance, or year of arrival in 
Lebanon.  
Diabetes 
In multivariate regression analyses, odds of interrupted adherence to medication for 
diabetes were significantly associated only with monthly household expenditures. Being in a 
household with expenditures above the median was protective, showing reduced odds of 
medication interruption (OR= 0.35; CI: 0.14-0.91) as compared to index cases from households 
reporting below average monthly expenditures (P=0.031).  
There was no statistically significant difference in adjusted odds of interrupted 
medication adherence for diabetes by care-seeking in the preceding three months, region, 
household head sex or education, receipt of cash/voucher assistance, or year of arrival in 
Lebanon.  
5.5. Discussion 
The influx of Syrian refugees into Lebanon since 2011 has strained health system 
capacity to provide care, including medical services and essential medicines, to refugee and host 
Lebanese populations alike. This paper presents evidence of important differences in care-
seeking, health service utilization, and medication adherence for hypertension and diabetes 
between Syrian refugees and host communities in Lebanon. These activities are interconnected 
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and potentially influenced by care facility type and location, cost relative to a household’s ability 
to pay, perceived quality of care, and medical need.  
Care-Seeking and Utilization 
Continuous, quality care from a qualified healthcare provider is the essential foundation 
to effectively managing diabetes and hypertension. As patients experience the two conditions 
differently, their motivations can be influenced by the silent nature of hypertension versus 
symptomatic diabetes. However, differential prioritization of cost and perceived quality of 
care/family doctor(s) practicing in the selected facility by refugees and host community members 
suggest the further impact of contextual factors on care-seeking behavior.  
Care-seeking for hypertension and diabetes in Lebanon diverged between refugee and 
host community members. Host community cases were more likely to seek care than were 
refugees, and to have done so within the past six months. Although care-seeking is, on average, 
high in both populations, those who are not regularly seeking care for chronic conditions such as 
hypertension and diabetes can experience differences in adverse clinical events that more regular 
care might avoid.100  
Refugee hypertension care-seekers differ from host community care-seekers by the 
weight they give to the relative importance of facility type, cost, and quality/continuity. As 
refugees most often sought care in primary level health facilities, it is not surprising that cost was 
a priority motivation for treatment decisions, and that refugees were more cost-sensitive than host 
community cases. Similarly, host community cases’ predominant concern with quality of care is 
consistent with their greater use of private clinics. Unexpectedly, facility location was not a 
primary consideration either for refugees or host community individuals with hypertension. 
Prioritized reasons for seeking care for diabetes, such as cost or location, were similar to those for 
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hypertension overall; however, the reasons for selecting care locations for diabetes differed once 
responses were stratified by facility type. Host community members varied much more in their 
primary motivation for choosing a facility than refugees, the majority of whom were concerned 
with cost regardless of which facility type was used. Lebanese host community cases sought care 
at private clinics for their perceived quality, determined by prior care or family doctor(s) 
practicing in the selected facility. Refugees who sought care at private clinics, however, 
predominantly reported doing so for reasons related to [low] cost.  
At the time in which this study was conducted, primary health care was, and continues to 
be, provided to Syrian refugees for a consultation fee between US$2 to US$3 per visit in more 
than 100 primary level facilities (PHCCs and dispensaries) across the country. These include 
facilities both in and outside of the MoPH-PHCC Network.13,79,88,96-99 Care is likewise provided 
to vulnerable Lebanese at the same subsidized rates in these facilities, as is reduced cost care at 
all PHCCs in the MoPH network, where fees for Lebanese patients are capped at US$12.430 
Refugees seeking care at private clinics for reasons related to cost may reflect their 
misunderstanding about relative costs of care at primary facilities versus private clinics, which 
has been previously documented among Syrian refugees in Lebanon. Alternatively, care-seekers 
may believe that the specific clinics utilized were among those providing reduced-cost care for 
refugees.100,431  
During pilot testing and data collection, it was apparent that many refugees were unable 
to reliably classify the type of health facility they most recently visited. In particular, distinctions 
between PHCCs in the MoPH network and primary care facilities supported by UNHCR or 
NGOs were generally classified by refugees as one and the same, hence their inclusion as a single 
response option in the final questionnaire. This difficulty identifying facility types may also have 
extended to misclassification of private clinics, and in itself suggests telling evidence of many 
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refugees’ vague understanding of available support and where it can be accessed. This knowledge 
gap is consistent with refugee knowledge of available services reported in UNHCR’s annual 
Health Access and Utilization Survey (HAUS). According to the 2014 HAUS, which provides the 
most comparable findings to the time period in which data were collected, only 54% of Syrian 
refugees knew they should pay between 3,000 and 5,000 LBP (approximately US$2-US$3) for 
consultation at PHCCs.71 While there has been a slight improvement in knowledge of subsidized 
consultation fees, still only 60% of refugees reported knowledge of payment amounts in 2018, 
indication that the gap in awareness persists.432  
Refugee knowledge that chronic medication is available for a maximum of 1,000 LBP 
(US$0.66) was only reported in the 2013 and 2014 HAUS, and was much lower; only 1% of 
refugees reported knowing this in 2013 and 23.8% in 2014.71 In addition to distributing regularly 
updated health brochures with detailed information on how to access health care in Lebanon, 
UNHCR has also increased communication to refugees through various media such as (i) direct 
SMS messaging; (ii) a “health chatbot” on Facebook called Ask Noor where refugees can ask 
questions about health services and receive an immediate response; and (iii) Refugees Lebanon, a 
website created solely to provide information on a wide range of assistance for Syrian refugees in 
Lebanon including audio and video content.412,433,434 With continued communication efforts, 
UNHCR has reported marked improvement since 2013 in refugees’ knowledge of available 
health services and their cost. Despite improvements, a sizable proportion of Syrian refugees 
remain unaware of either the services available to them or the associated costs.  
The HAUS and numerous other studies of health care utilization by Syrian refugees in 
Lebanon have consistently shown cost to be the prime barrier to care-seeking generally and for 
chronic NCDs specifically.3,71,117,432,435-440 Limited awareness, confusion, or incorrect 
understanding about the cost of health care and subsidized services may contribute to the 
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influence that inability to afford care has on health behaviors, decreasing the likelihood of care-
seeking. This care-seeking decrement can apply both for refugees’ initial health care visit after 
arriving in Lebanon and subsequent visits where out-of-pocket payment was not as expected.  
Regression analyses were conducted only among Syrian refugees and among the 
variables in the conceptual model that guides analyses, the only statistically significant predictor 
in the adjusted analysis of the odds of care-seeking in the preceding six months was region of 
residence. Refugees living in the North governorate were significantly more likely than those 
living in Beirut/Mt. Lebanon to seek care for hypertension. This is aligned with regional trends in 
overall access to care in the most recent (2018) Vulnerability Assessment of Syrian Refugees in 
Lebanon, where access was reportedly lowest in Beirut and Mount Lebanon (70%) and highest in 
Akkar (98%; included in the North region in the present analyses;).3 Regional variations in 
healthcare access may be due to differences in the accessibility, number, and distribution of 
facilities providing subsidized care, sociodemographic characteristics, and refugees’ knowledge 
of available services.  For diabetes, average household monthly expenditure was statistically 
significantly predictive of care-seeking in univariate analysis – the higher the household’s 
expenditures, the more likely care was sought. Household expenditures in this context are used as 
a proxy for the household’s overall socioeconomic status, and thus, their ability to pay for health 
care. As such, it is inferred that this “ability to pay”, rather than only household spending, is 
associated with care-seeking. This is consistent with previous studies linking households with 
greater ability to pay and/or socioeconomic status with increased care-seeking generally, as well 
as for chronic and/or non-communicable conditions specifically. 
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Spending on Health Services 
Although the main aim of this work is to assess utilization, out-of-pocket consultation 
cost is also a central consideration for healthcare utilization, particularly as cost is a primary 
barrier to care-seeking for refugees. The proportion of refugees reporting out-of-pocket payments 
and refugee payment amounts were lower than those of host community members both for 
hypertension and for diabetes. This suggests that current humanitarian programming may be 
contributing to effectively maintaining refugee access to NCD care for those who are aware of 
where and how subsidized care is provided. The majority both of refugee and host community 
care-seekers reported some out-of-pocket payments, with an overall higher median cost for host 
community care-seekers (US$33 for both hypertension and diabetes) compared to Syrian refugees 
(US$3 for hypertension, US$5 for diabetes). This difference is likely due to subsidized care 
provided for refugees at many primary level facilities, which are far more commonly utilized by 
refugees. Payments were reported by a larger proportion of host community cases both for 
hypertension and for diabetes, consistent both with higher overall costs for host community care-
seekers and differential use of primary care facilities by refugees and private clinics by the host 
community. Host community care-seekers in this sample reflect households from communities 
among the most vulnerable and affected by the influx of Syrian refugees rather than the broader 
Lebanese population. Such disproportionally higher costs observed among the host community 
thus raises concerns about their continued ability to afford needed care.  
Among hypertension and diabetes refugee index case households, 74% and 72% 
respectively reported that all members were currently registered with UNHCR, and another 12% 
in both groups reported that some members were registered. Notwithstanding this, average 
reported consultation costs of US$10 for hypertension and US$14 for diabetes among refugees 
reporting any out-of-pocket payment at primary level health facilities exceed the standard 
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subsidized cost of US$2 – US$3 for such care. Median costs were lower (US$5 for hypertension 
and US$7 for diabetes), but only 47% of hypertension care-seekers and 42% of diabetes care-
seekers reported costs of US$3 or less at primary level facilities. The large proportion of primary 
level care-seekers reporting costs above the standard subsidized rate likely indicates care being 
sought at facilities outside the MoPH-PHCC network or not supported by UNHCR or NGOs.  
Another possible reason for costs reported above standard subsidized rates is that 
respondents included payment for medication and/or diagnostic testing when reporting 
consultation costs, resulting in a broader range of payment amounts. Although out-of-pocket costs 
for consultation and most medication for chronic conditions are offered for flat fees, cost-sharing 
for diagnostic testing is structured such that UNHCR covers 85% of tests, leaving the remaining 
15% for refugees to pay. Diagnostic and laboratory testing costs are unpredictable for care-
seekers and, especially in Lebanon’s highly privatized and specialist-centered health system, can 
reach unaffordable amounts. Moreover, subsidized diagnostic costs are provided only for specific 
“vulnerable” groups, such as children under five years, adults 60 years and older, those with 
disabilities, and pregnant or nursing women. Within the Lebanese health system’s pluralistic and 
fragmented structure, base costs for testing vary dramatically across facilities. This variability 
could be driving, or at least contributing to, individuals not seeking needed care. Instances of 
delaying or avoiding care-seeking may be prevented through bundled services provided at set 
costs communicated in advance of care.  
Two projects, the Emergency Primary Healthcare Restoration Project (EPHRP) and the 
Reducing Economic Barriers to Accessing Health Services (REBAHS) project, seek to address 
the inconsistency and unpredictability of overall healthcare spending as barriers to care among 
Syrian refugees and host communities in Lebanon. In an effort to meet the health needs of 
vulnerable Lebanese households, the World Bank, in partnership with the Lebanese MoPH, began 
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implementation of the EPHRP in 2016 with the objective of “restor[ing] access to essential 
healthcare services for poor Lebanese affected by the influx of Syrian refugees”.419 Through the 
end of 2019, the EPHRP will pilot provision of an essential health care package in the MoPH 
network of PHCCs and hospitals for 150,000 Lebanese with limited income. Specifically, the 
EPHRP provides an NCD service package free of charge to enrolled beneficiaries for case 
management of diabetes (consisting of five mandatory doctor’s visits per year, annual 
electrocardiogram (EKG), lab tests, foot exam, and medications) and hypertension (five 
mandatory doctor’s visits per year, annual EKG, lab tests, counseling, medications), as well as 
similar services for coronary artery disease.420 By December 2018, more than 120,000 individuals 
were enrolled in the project, with 101,454 users. Of these users, 14% received care through the 
diabetes package and 20% through the hypertension package.441  
Implementation of the REBAHS project began in January 2018 led by a consortium of 
international NGOs (INGOs) including Première Urgence Internationale, International Medical 
Corps, and the Foundation for the Social Promotion of Culture. The REBAHS project has similar 
objectives to reduce the burden of healthcare costs on “crisis-affected populations” in Lebanon 
and serves mostly Syrian refugees along with some vulnerable Lebanese.418 Much like the 
EPHRP, the REBAHS project provides support to select PHCCs through subsidized consultations 
and laboratory testing. Services are subsidized based on a flat fee model that requires a 3,000 
LBP (US$2) out-of-pocket payment for consultation, while the remaining visit costs, including 
those for laboratory and imaging tests, as well as medication, are covered by the supporting 
INGO. Both the EPHRP and REBAHS are still in the pilot phase, and evidence of their impact is 
not yet available. Early reports suggest that in this context, they are a promising model for 
reforming health financing to facilitate greater access for those most in need. The financial 
support provided through these projects enables regular, predictable costs to beneficiaries, 
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mitigating the fear of and potential for devastating expenditures on individuals requiring 
continuous care for conditions such as diabetes and hypertension. Both projects have already 
shown a substantial increase in demand at participating PHCCs. EPHRP monitoring indicated an 
increase in the utilization of PHCCs by Lebanese of 88% from 2015 to 2017, and a pilot project 
preceding REBAHS reported a 41% increase in the number of patients at participating PHCCs 
following implementation of a flat fee model.418,430,442 Subsidies such as these should continue to 
be explored, and evidence of their impact documented alongside plans to scale up both projects. 
Aside from subsidized costs, facility-level support interventions are an essential 
component for such projects’ sustainability. In addition to financial coverage for patient care, 
these projects also reinforce the Lebanese health system and facilitate improved quality of care 
through capacity building for enhanced service delivery quality and supply chain management, 
community outreach, and in-kind buffer stocks of essential medicines to prevent shortages and 
stock-outs.79,418-420 PHCCs’ ability to meet increased demands while maintaining sufficient quality 
of care relies on such complementary support, together with further financial support for 
increased staffing, facility maintenance, and operating costs.  
Improving refugee access to affordable health care cannot be considered without 
addressing existing barriers to care faced by many Lebanese. Doing so would risk furthering 
tensions between the two populations.443 Continuation of projects such as EPHRP and REBAHS 
has the potential to address both the immediate patient needs and development-centered goals of 
strengthening the health system. This presents an opportunity for equitable access to health care 
previously not realized for all Lebanese, irrespective of the additional challenges brought on by 
the Syrian crisis.430  The sustainability of the flat-fee model, similar subsidy approaches, and/or 
shifts towards universal health coverage depend upon continued external funding from the 
international community. Current funding shortfalls threaten the sustainability of assistance 
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approaches that are vital to improving the health of refugees and host Lebanese, and to sustaining 
improvements in the Lebanese health system.  
Medication Prescription and Adherence 
Nearly all hypertension and diabetes cases in this survey had been prescribed medication 
for their condition. Correspondingly large proportions of refugee and host community cases were 
currently taking prescribed medication for diabetes; however, a significantly smaller percentage 
of refugees reported currently taking prescribed medication for hypertension as compared to host 
community cases. Consequently, interrupted medication use (i.e., stopping for two weeks or 
longer) was significantly higher among refugees than among host community cases, though 
surprisingly similar between hypertension and diabetes. For both conditions, interrupted 
medication use was reported by more than one-quarter of refugees, which in both conditions is 
also more than three times as high as interruption reported by host community cases.  
Cost was the primary reason for medication interruption among both population groups 
and both conditions. More than three-quarters of cases that interrupted use of medication for 
hypertension and over half of those with interrupted use of medication for diabetes did so because 
of inability to afford the medication, which confirms the role of financial burden in health 
decision-making. As with care-seeking, gaps in knowledge about options for free or low-cost 
medication for hypertension and diabetes may be leading individuals to divert from prescribed 
treatment regimens, dosage, or even to forego medication use altogether when they may 
otherwise adhere to prescribed treatment if they were aware of the subsidized options. In 2014, 
only 23.8% of refugees were aware that chronic medication prescriptions could be filled for a 
maximum of 1,000 LBP/US$0.67; unfortunately, more recent data assessing refugee knowledge 
of medication assistance options are not available.71 Reported stock-outs or inconsistent 
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availability of medications can influence patients’ ability to afford medication and may also result 
in the need to obtain medication at private pharmacies where free or reduced-cost medication is 
provided. This suggests an opportunity for training and intervention to enhance inventory 
management and drug availability. 
Predictors of interrupted medication adherence were limited and differed between 
hypertension and diabetes. The relationship between care utilization and interrupted adherence 
was not significant for diabetes; however, receiving care for hypertension in the preceding three 
months was associated with lower odds of interrupted medication adherence. The discordance in 
this association for hypertension and diabetes could arise from the pathological differences of the 
two conditions. Diabetes most often presents symptoms that interfere with patients’ day-to-day 
lives, serving as both a reminder and possibly a motivator for more consistent care-seeking and 
compliance with treatment regimens. Conversely, hypertension is mostly asymptomatic. In the 
absence of daily “reminders” in the form of noticeable symptoms, health provider visits may 
serve as more of a reminder or motivation for treatment compliance. Better management of both 
conditions may be achieved by promoting more regular clinic visits, even if visits are just for a 
medication check-up rather than for a complete specialist examination. Among diabetics, higher 
socioeconomic status, characterized as households reporting monthly expenditures above the 
median for Syrian refugees, was protective against medication interruption, which is also 
consistent with cost being cited as the primary reason for interrupted adherence. 
Limitations 
As with all studies, it is necessary to consider the limitations when interpreting results. 
Concerning sampling, reliance on UNHCR registration data for sample design and cluster 
allocation may have resulted in sampling bias if the geographic distribution of registered and 
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unregistered refugees is different. Reallocation of clusters in areas controlled by military and 
political factions where permission to conduct the survey was not secured resulted in large areas 
of the country being excluded. The survey coverage area included only 53% of registered 
refugees and thus is not representative of the entire Syrian refugee population in Lebanon. 
Another sampling limitation was the 2:1 ratio of refugee to host community households. The 
primary aim of the assessment was to characterize health access for Syrian refugees; budget 
limitations precluded a larger sample size, and a decision was made to prioritize a larger refugee 
sample to enable regional comparisons. The smaller host community sample was a limitation in 
instances of rare occurrences (such as medication interruption or reasons for not seeking care). 
Larger sample size may have resulted in statistically significant differences for comparison across 
regions within Lebanon, as well as comparisons between refugees and the host community. 
The within cluster referral process also presents a potential for bias, as respondents may 
not have always referred the interview team to the nearest household. Referral procedures ensured 
that households were referred by different respondents and small clusters may have helped to 
attenuate within-cluster similarities and the associated design effect. Replacement sampling, 
which was done for logistical purposes, also could contribute to bias if there were systematic 
differences between households in which no one was home compared with those in which 
someone was present. Finally, the Lebanese host community sample was selected using a 
neighborhood approach and thus is reflective of those communities hosting the largest number of 
refugees. Findings on the Lebanese host community population should not be generalized to the 
Lebanese population at large. Host community respondents are representative of only a subset of 
the Lebanese population, which is likely to be of lower economic status and a different 
geographic distribution than the Lebanese population as a whole. 
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Interviews were conducted by Lebanese, which could have resulted in a higher refusal 
rate, hesitance or influence on Syrian refugees in responding to certain questions than if Syrians 
had conducted the interviews. As such, sensitive topics such as income or experiences in Syria 
may be susceptible to bias because of the interviewer nationalities. 
Respondents’ inadequate ability to accurately distinguish between different types of 
facilities that provide primary care in Lebanon is another limitation identified when pilot testing 
the survey questionnaire. The complex assortment of primary care facilities in Lebanon includes 
those in the MoPH network, a large number of centers operated by the MoSA and local 
organizations, public sector facilities supported by humanitarian NGOs, and a well-established 
number of private sector clinics. A single facility may fall into more than one of these categories, 
making classification for brief household surveys quite challenging. Despite extensive efforts by 
the study team to develop suitable response categories for the various types of primary care 
facilities, more specific classification of facilities lacked adequate reliability and validity and thus 
was excluded from the final version of the questionnaire. Regarding results disaggregated by 
types of health facilities, this survey is not able to differentiate between care-seeking and out-of-
pocket costs at PHCCs in the MoPH network and other primary level facilities. As such, results 
presented for primary level health facilities are not intended to indicate whether these facilities 
are in the MoPH network or operated/supported by NGOs, MoSA, or private entities.  
Additional limitations include the use of self-report for key outcome measures as over-
reporting care-seeking and medication adherence is likely increased due to social desirability and 
recall biases. Moreover, the single question medication adherence measure captures medication 
underuse; however, other manners of non-compliance are not explicitly measured (e.g., improper 
dosage, timing, and overuse). The cross-sectional study design prevents causal inference, limiting 
results to identifying associations instead of causality. Finally, the skewed distribution of key 
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variables and notably high overall reporting of medication adherence hinders detection of weaker 
associations. 
5.6. Conclusion 
This study provides empiric information regarding refugee and host community health 
care behaviors for managing hypertension and diabetes. Findings demonstrate significant 
disparities between the two populations in care-seeking, health facility utilization, out-of-pocket 
payments for care, and medication interruption. Results show greater access to care, preference 
for private clinics over primary level health facilities, and fewer reports of medication 
interruption in host community cases. Out-of-pocket spending, however, was significantly higher 
in host community cases than among refugees, reflecting differential financial support available 
to the two groups and, potentially, means for affording care. Results also show differences in 
motivation for treatment location selection, with host community cases demonstrating more 
concern for quality of care and continuity of care from their usual/family doctor(s) and refugees 
being more cost-sensitive, even when choosing to seek care at private sector facilities.  
The goal of sustainable, high-quality medical care is the same for refugees and the 
Lebanese host community. New models such as flat fee models being used in the EPHRP and 
REBAHS projects may be effective means for achieving this goal, and for closing gaps between 
need and care-seeking practices. Based on the present research, additional efforts are needed to 
facilitate minimal and predictable out-of-pocket payments for health services and to ensure that 
refugees and vulnerable Lebanese are aware that subsidized care is available to them and how it 
can be accessed. 
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Table 5-1. Care-Seeking for Hypertension and Diabetes  









  %  (95% CI) %  (95% CI) %  (95% CI) %  (95% CI) 
Last time care was 
sought* 
 n=282  n=236 n=136 n=144 
Less than one month 
ago 
26.2 (21.3-31.9) 25.0 (20.1-30.6) 33.1 (25.2-42.1) 25.7 (19.0-33.7) 
1 - 2 months ago 25.2 (20.4-30.7) 30.1 (24.8-35.9) 28.7 (21.7-36.9) 40.3 (32.7-48.4) 
3 - 6 months ago 13.1 (9.4-18.0) 17.8 (13.5-23.1) 9.6 (5.8-15.3) 16.7 (11.2-24.0) 
7 months - 1 year ago 4.6 (2.6-8.0) 10.2 (6.9-14.7) 3.7 (1.5-8.5) 4.9 (2.4-9.6) 
> 1 year ago 11.7 (8.1-16.6) 15.3 (10.9-20.9) 13.2 (8.7-19.6) 9.7 (5.7-16.0) 
Never sought in 
Lebanon  
18.4 (13.8-24.2) 0.4 (0.1-3.0) 10.3 (6.2-16.6) 0.7 (0.1-4.9) 
P-value† < 0.001 0.126 
Saw a doctor in 
Lebanon‡ 
80.9 (75.2-85.5) 98.3 (95.6-99.4) 88.2 (81.8-92.6) 97.2 (92.9-98.9) 
  P-value† < 0.001 0.005 
Most recent care 
location‡ 
 n=195  n=196 n=102 n=126 
Primary level facility 54.9 (47.6-61.9) 19.4 (14.3-25.7) 60.8 (50.7-70.1) 17.5 (12.1-24.5) 
Private clinic 21.5 (16.6-27.5) 59.2 (51.0-66.9) 20.6 (13.7-29.7) 59.5 (51.2-67.3) 
Hospital 8.2 (5.1-12.9) 15.8 (11.4-21.6) 3.9 (1.5-9.9) 15.9 (10.7-22.8) 
Pharmacy 9.2 (5.6-14.8) 2.6 (1.0-6.1) 9.8 (5.5-16.8) 6.3 (3.3-12.0) 
Other 6.2 (3.0-12.3) 3.1 (1.2-7.5) 4.9 (2.1-11.1) 0.8 (0.1-5.6) 
P-value† < 0.001 < 0.001 
Reason for selecting 
location‡ 
 n=195  n=196 n=102 n=126 
Low cost consultation  48.2 (40.5-56.0) 11.2 (7.6-16.3) 59.8 (50.0-68.9) 13.5 (8.1-21.5) 
Free consultation  17.4 (13.0-22.9) 6.6 (3.8-11.3) 18.6 (12.4-27.0) 7.1 (3.8-12.9) 
Like staff, quality, 
family doctor 
13.8 (9.4-19.9) 49.0 (40.8-57.2) 7.8 (4.1-14.6) 50.8 (42.1-59.4) 
Closest to residence 12.8 (8.5-18.8) 15.3 (10.4-21.9) 9.8 (5.4-17.1) 16.7 (10.8-24.8) 
Availability of needed 
services 
2.1 (0.8-5.3) 11.2 (7.1-17.3) 2.0 (0.5-7.6) 7.9 (4.0-15.2) 
Medical emergency 2.6 (1.1-6.1) 4.6 (2.3-9.1) 1.0 (0.1-6.8) 2.4 (0.8-7.2) 
Other 3.1 (1.0-9.2) 2.0 (0.8-5.3) 1.0 (0.1-6.9) 1.6 (0.4-6.3) 
P-value† < 0.001 < 0.001 
* As percent of household index cases reporting hypertension or diabetes diagnosis 
† Group comparison using Pearson's chi-square for proportions. Statistical significance indicated in bold (P<0.05) and bold 
italics (P<0.001). 
‡ As percent of household index cases receiving care in Lebanon for the condition in the year prior to interview 
 
 
 104  
 
 
Table 5-2. Estimated Odds of Hypertension and Diabetes Care-Seeking in the Preceding Six 
Months Among Syrian Refugees  
 
Crude OR  Adjusted OR 
  OR (95% CI) P-value  OR (95% CI) P-value 
HYPERTENSION 





Bekaa 1.34 (0.71-2.54) 0.368  1.44 (0.74-2.80) 0.283 
North 1.93 (1.01-3.68) 0.047  1.94 (1.01-3.73) 0.046 
Female-headed HH 1.86 (0.91-3.79) 0.088  1.82 (0.88-3.79) 0.105 
HH head completed ≥ primary education 0.81 (0.43-1.53) 0.512  1.03 (0.53-1.98) 0.935 
Above median monthly HH expenditures* 1.34 (0.78-2.29) 0.280  1.32 (0.74-2.35) 0.337 
Arrived in Lebanon 2013-2015 
(ref: 2011-2012) 
0.61 (0.37-1.02) 0.060  0.62 (0.37-1.04) 0.072 
Receipt of cash and/or voucher assistance† 1.16 (0.62-2.16) 0.642  1.12 (0.59-2.11) 0.735 
DIABETES 




   
 
Bekaa 0.31 (0.11-0.85) 0.023  0.35 (0.12-1.01) 0.053 
North 0.57 (0.20-1.58) 0.272  0.59 (0.20-1.74) 0.335 
Female-headed HH 2.13 (0.62-7.30) 0.224  2.16 (0.62-7.57) 0.224 
HH head completed ≥ primary education 0.86 (0.27-2.68) 0.786  0.90 (0.23-3.44) 0.873 
Above median monthly HH expenditures* 2.05 (1.03-4.06) 0.040  1.79 (0.86-3.74) 0.119 
Arrived in Lebanon 2013-2015 
(ref: 2011-2012) 
0.70 (0.34-1.42) 0.314  0.70 (0.34-1.46) 0.337 
Receipt of cash and/or voucher assistance† 1.42 (0.66-3.05) 0.362  1.58 (0.72-3.48) 0.254 
OR = odds ratio; HH= household. Statistical significance indicated in bold (P<0.05) and bold italics (P<0.001). 
* Relative to median monthly HH expenditures reported by Syrian refugees 
† Includes cash or voucher assistance received from a United Nations agency, NGO, or other religious or community 
group in the month preceding interview. Reference: no cash/voucher assistance received in previous month. 
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Table 5-3. Medication Use for Hypertension and Diabetes  









  % (95% CI) % (95% CI) % (95% CI) % (95% CI) 
Medication Prescription (n=282) (n=236) (n=136) (n=144) 
Ever prescribed medication for 
condition 
97.2 (94.4-98.6) 99.2 (96.6-99.8) 98.5 (94.2-99.6) 97.2 (92.9-98.9) 
P-value* 0.072 0.453 
Country where prescribed† (n=274)   (n=134)   
Syria 40.1 (33.0-47.7) --- 33.6 (26.4-41.7) --- 
Lebanon 59.9 (52.3-67.0) --- 66.4 (58.3-73.6) --- 
Currently taking medication† 79.4 (74.4-83.6) 95.8 (91.9-97.8) 89.7 (83.0-93.9) 95.1 (90.4-97.6) 
P-value* < 0.001 0.080 
Interrupted Medication 
Adherence (n=259) (n=233) (n=133) (n=140) 
Stopped medication for >2 
weeks in past year  
30.5 (24.8-36.9) 9.0 (6.0-13.3) 26.3 (19.5-34.6) 11.4 (7.2-17.7) 
P-value* < 0.001 0.002 
Stopped medication for >2 
weeks in past year against 
medical advice 
27.8 (22.3-34.1) 8.6 (5.7-12.8) 25.0 (18.4-33.0) 8.5 (4.9-14.3) 
P-value* < 0.001 < 0.001 
Where medication was stopped‡ (n=72)  (n=34)   
Syria 11.1 (5.0-23.0) --- 11.8 (4.6-27.0) --- 
Lebanon 88.9 (77.0-95.0) --- 88.2 (73.0-95.4) --- 
Reason for stopping 
medication§ 
(n=72) (n=20) (n=34) (n=12) 
Household could not afford the 
medication 
77.8 (68.2-85.1) 75.0 (51.3-89.5) 76.5 (57.8-88.5) 91.7 (57.8-98.9) 
Symptoms improved/felt better  6.9 (3.1-15.0) 10.0 (2.4-33.1) 8.8 (3.1-22.7) 8.3 (1.1-42.2) 
Did not know where to get the 
medication 
5.6 (2.1-13.9) 5.0 (0.7-29.1) 0.0 -- 0.0 -- 
Did not like available 
medications 
1.4 (0.2-9.4) 10.0 (2.4-33.1) 0.0 -- 0.0 -- 
Not available at 
pharmacy/health facility 
2.8 (0.7-9.9) 0.0 -- 5.9 (1.4-21.4) 0.0 -- 
Other 5.6 (2.1-13.9) 0.0 -- 8.8 (2.9-24.2) 0.0 -- 
P-value* 0.348 0.559 
* Group comparison using Pearson's chi-square for proportions. Statistical significance indicated in bold (P<0.05) and bold 
italics (P<0.001). 
† As percent of household index cases diagnosed with hypertension/diabetes  
‡ As percent of refugee index cases who stopped taking medication for >2 weeks in past year against medical advice 
§ As percent of all household index cases who stopped taking medication for >2 weeks in past year  
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Table 5-4. Estimated Odds of Interrupted Medication Adherence Among Syrian Refugees 
 
Crude OR Adjusted OR 
  OR (95% CI) P-value OR (95% CI) P-value 
HYPERTENSION 
Any hypertension care in past 3 months 0.59 (0.35-1.00) 0.052 0.58 (0.34-0.99) 0.046 




Bekaa 1.04 (0.50-2.15) 0.911 1.00 (0.45-2.20) 0.999 
North 1.03 (0.48-2.24) 0.931 1.06 (0.47-2.37) 0.888 
Female-headed HH 1.39 (0.67-2.88) 0.367 1.30 (0.58-2.89) 0.523 
HH head completed ≥ primary education 0.73 (0.38-1.40) 0.340 0.77 (0.38-1.56) 0.464 
Above median monthly HH expenditures* 0.86 (0.49-1.52) 0.610 0.94 (0.53-1.66) 0.816 
Arrived in Lebanon 2013-2015 (ref: 2011-2012) 1.11 (0.66-1.87) 0.682 1.09 (0.65-1.83) 0.738 
Receipt of cash and/or voucher assistance† 1.26 (0.61-2.59) 0.524 1.28 (0.61-2.71) 0.514 
DIABETES 
Any diabetes care in past 3 months 0.72 (0.30-1.74) 0.461 0.81 (0.32-2.07) 0.652 




Bekaa 0.62 (0.22-1.79) 0.374 0.46 (0.14-1.55) 0.209 
North 0.66 (0.27-1.59) 0.348 0.62 (0.25-1.56) 0.309 
Female-headed HH 0.58 (0.18-1.88) 0.361 0.71 (0.22-2.33) 0.566 
HH head completed ≥ primary education 2.52 (0.65-9.72) 0.177 2.29 (0.60-8.70) 0.219 
Above median monthly HH expenditures* 0.43 (0.17-1.10) 0.076 0.35 (0.14-0.91) 0.031 
Arrived in Lebanon 2013-2015 (ref: 2011-2012) 1.00 (0.41-2.44) 1.000 0.93 (0.36-2.35) 0.869 
Receipt of cash and/or voucher assistance† 1.60 (0.60-4.26) 0.345 1.85 (0.59-5.82) 0.287 
HH= household. Statistical significance indicated in bold (P<0.05) and bold italics (P<0.001). 
Interrupted medication adherence is defined as having stopped medication for hypertension/diabetes for two weeks or 
longer in the preceding year without instructions from a doctor to do so 
* Relative to median monthly household expenditures reported by Syrian refugees 
† Includes cash or voucher assistance received from a United Nations agency, NGO, or other religious or community group 
in the month preceding interview. Reference: no cash/voucher assistance received in previous month. 
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Figure 5-1. Health Access Survey Cluster Assignment by Governorate 
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Figure 5-2. Reason for Selecting Most Recent Hypertension and Diabetes Care Locations by 
Facility Type Utilized  
* Includes perceived quality of care, family doctor, or liking facility staff 
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Figure 5-3. Out-of-Pocket Payments for Hypertension and Diabetes Care in Lebanon by 
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Chapter 6. Care-Seeking and Health Service Utilization for Hypertension and 
Type 2 Diabetes Among Syrian Refugee and Host Community Care-Seekers 
at Select Primary-Level Health Facilities in Lebanon (Paper 2) 
6.1. Abstract 
 Background. The ongoing Syrian refugee crisis in Lebanon poses challenges to 
managing chronic medical conditions. Policies and practices to facilitate care without crowding 
out Lebanese patients have had some impact; however, the sustained high level of medical need 
requires evidence to adapt intervention to ongoing demand for quality care.  
Methods. This paper presents a baseline assessment of patients enrolled in 2015 in a 
longitudinal cohort study of care-seekers at ten primary health facilities in Lebanon. The primary 
objectives of this analysis are to assess the baseline frequency of general practitioner (GP) and 
specialist care visits among Syrian refugee and Lebanese patients, and identify factors associated 
with continued health care-seeking for hypertension and type 2 diabetes among Syrian refugees in 
Lebanon. Descriptive analyses were used to explore differences in care utilization between 
refugee and host community patients. Four negative binomial hurdle regression (NBH) models 
were used to evaluate the odds and frequency of care utilization for GP and specialist care 
utilization among Syrian refugees with separate models for hypertension and type 2 diabetes and 
for GP and specialist visits.  
Results. Utilization was consistently high for both populations. Refugees were more 
likely than Lebanese patients to seek care from GPs and to report higher GP visit frequency. 
Although Lebanese patients tended to rely on specialists’ care (cardiologist and/or 
endocrinologist), the difference from refugees was not significant. In multivariate NBH analyses 
for patients with hypertension, female sex, YMCA program enrollment and knowledge of stroke 
as a complication were associated with fewer GP visits and those with above median monthly 
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expenditures had fewer specialist visits. Age between 51-60 years (versus 40-50 years) was also 
associated with increased frequency of GP care but decreased odds of specialist care. Higher 
educational attainment had increased odds of GP care, while longer hypertension duration had 
increased odds of specialist care. Odds and frequency of specialist care decreased for housing 
instability, but frequency of specialist care increased for comorbid diabetes.  
For patients with diabetes, YMCA participants also had less frequent GP care, but 
increased odds of specialist care. Specialist odds also increased with above median household 
expenditures. Housing instability was associated with decreased odds and frequency of specialist 
care; however, the interaction between having above median household expenditures and housing 
instability had increased odds of GP care-seeking. Age was not significant for patients with 
diabetes, but the interaction of older age (over 60 years) and longer disease duration (longer than 
10 years) had increased GP care odds. 
Focus group discussions with patients and health providers identified factors motivating 
care utilization in both populations: cost, obtaining medication, and the tendency for Lebanese 
participants to delay care until an emergency required hospital care. They also revealed care 
system concerns including limited availability of specialists in study clinics and GP self-doubt 
about clinical knowledge to care for these conditions. 
Conclusions. Findings illustrate the overall high, but differential care-seeking behaviors 
of refugee and Lebanese patients and a complex interplay of factors influencing care utilization 
distinctly for GP and specialist care among refugees. Expanded training to increase GPs’ 
proficiency in managing hypertension and diabetes and improve all providers’ adherence to 
standard treatment guidelines, in addition to improving and scaling coverage of the YMCA 
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program could further support ongoing efforts to improve the quality of non-communicable 
disease management and health outcomes. 
6.2. Introduction 
As of June 2019, the Government of Lebanon estimates the country is hosting 1.5 million 
individuals fleeing the conflict in Syria.444 Lebanon’s health system is strained beyond capacity 
by the health needs of Syrian refugees and continued host community needs. This burden is 
exacerbated by the high prevalence of chronic non-communicable diseases (NCDs) in both 
Lebanese and Syrian populations, notably, type 2 diabetes (estimated prevalence of 8.8% in Syria 
and 14.9% in Lebanon) and hypertension (estimated prevalence of 24.9% in Syria and 28.8% in 
Lebanon).40,49-56,64-66 These conditions require lifelong management, including regular monitoring 
and follow-up by a health professional to reduce the risk of severe complications.268,445,446 The 
emergency response in Lebanon integrates humanitarian and stabilization efforts, seeking to meet 
refugees’ immediate needs while also supporting Lebanon’s national capacity, local institutions, 
and host communities.447 Healthcare for refugees is embedded in Lebanon’s existing health 
system. Primary healthcare for Syrian refugees is available at subsidized rates (US$2 to US$3 per 
consultation) through more than 100 existing primary health facilities across the country, 
including the Ministry of Public Health’s (MoPH) National Network of Primary Healthcare 
Centers (PHCCs).13,79,88,96-99 Lebanon’s health system is pluralistic, marked by high out-of-pocket 
expenditures, disjointed oversight, a dominant private sector, and a surplus of specialists, which 
account for 81% of providers in the MoPH-PHCC network.79,80,430 Medication for chronic health 
conditions are available for the cost of US$0.67 at more than 400 PHCCs and dispensaries 
through the Young Men’s Christian Association (YMCA) chronic medications program, and the 
United Nations High Commissioner for Refugees (UNHCR) covers 85% of diagnostic costs in 
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supported facilities.414,415 Hospital care for refugees meeting eligibility criteria (i.e., referred from 
a PHCC or presenting with a life-threatening condition) is subsidized, with UNHCR paying 75% 
of associated costs above US$100 and any remaining costs if beneficiary shares exceed 
US$800.37,416,417  
Despite the importance of consistent monitoring and professional care, little is known 
about NCD patients’ care-seeking behaviors in the Lebanese population, and even less so among 
Syrian refugees. According to a 2014 study of chronic pharmacologic treatment in Lebanon, only 
43% of Lebanese patients on antihypertension medication and 35% of those taking oral 
antidiabetic drugs had all recommended monitoring performed, while 15% of those on 
antihypertensives and 3% of those on oral antidiabetics did not complete any recommended 
monitoring tests.123 In the same study, half of all chronic health condition patients reported 
visiting a physician annually or less and three percent had medication dispensed by pharmacists 
with no physician consultation. Though care utilization was not analyzed separately by diagnosed 
condition(s), 63% of those with partial or no monitoring tests completed for diabetes treatment 
reported visiting a physician once per year or less (comparable data for patients on 
antihypertensives were not reported). A 2017 study of Lebanese hypertensive patients had similar 
results – 56% of hypertensive patients reported not regularly seeing a health provider.448 Other 
studies measure treatment rates overall or for select treatment components (e.g., medication 
prescription, adherence, or behavioral risk factors) rather than care utilization. No estimate of the 
frequency or regularity of care utilization among Syrian patients was identified either before the 
crisis or since; however, according to UNHCR’s 2018 Health Access and Utilization Survey, 
66% of Syrian refugee household members with a chronic condition reported accessing medical 
care and/or medicines for the condition in the preceding three months.432 
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Since the country’s civil war ended in 1990, the MoPH of Lebanon has enacted multiple 
health system reforms that have substantially improved service delivery, governance, and health 
outcomes for the Lebanese population. However, disparities in health outcomes and healthcare 
availability persist by geographic region, sex, and socioeconomic status.79,449 According to the 
MoPH, the number of Syrian refugees treated at PHCCs increased by 7.1% from 2013 to 2014 
while in the same period, the number of Lebanese patients decreased by 16.6%.79 Since the added 
needs of Syrian refugees are on a system not designed or adequately resourced to meet these 
additional demands, the system’s capacity and infrastructure leave both refugee and host 
communities with unmet health needs.450 The largest effect has been in the historically 
underserved and impoverished Lebanese communities, which also have the highest refugee 
concentrations. 
Health service utilization has been extensively researched, though the evidence of factors 
associated with chronic disease care-seeking primarily comes from stable and/or high-income 
settings. Common predictors of regular care utilization for chronic conditions across frameworks 
and models for understanding care-seeking behaviors are extensive and include patient-related 
factors, provider characteristics, and environmental (including health system) features.149-157 
Prevailing patient-related factors include: (i) demographic and socioeconomic characteristics 
(e.g., age, sex, education, income, competing resource demands); (ii) condition characteristics 
such as disease duration, comorbidities, and illness complexity; (iii) attitudes and beliefs 
including self-efficacy, perceived risks and benefits of care, perceived severity of the illness or 
need for care; and (iv) psychosocial characteristics such as support and social networks and 
personal stress.139-146,151,152,155,156,176,177,181,185,191,451,452 Some provider-related factors that influence 
care-seeking include the patient-provider interaction/relationship, adherence to clinical 
guidelines, and provider type (i.e. generalist versus specialist physician, nurse, pharmacist, 
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etc.).144,146,147,149,151,156,185,191 Environmental factors include distance to the health facility, health 
policies, and acceptability, availability, accessibility, and affordability of services.144-
146,149,151,156,176,177,185,191,193 
Despite a substantial body of research on care-seeking by different populations in varying 
contexts and, in particular, on care-seeking for hypertension and/or diabetes in stable, high-
income settings, there is a paucity of evidence identifying determinants of care utilization for 
chronic NCDs in contexts of protracted urban displacement such as Lebanon.139-147 According to 
the United Nations Interagency Task Force on NCDs, the risk of NCD-related complications is 
increased in emergency contexts, presumably from disrupted access to medication and/or health 
services and prolonged interruptions in treatment.453 Little is empirically known about care-
seeking behaviors in these contexts, and importantly about the factors associated with the nature 
and volume of chronic NCD care-seeking in populations affected by protracted displacement. To 
improve the humanitarian health response, better evidence is needed about what motivates and 
what inhibits care-seeking, and how refugees and host communities understand the healthcare and 
cost options available to them. 
The objectives of this analysis are to assess the baseline frequency of general practitioner 
(GP) and specialist care visits among Syrian refugee and Lebanese patients, and to build upon 
previous health service utilization models by characterizing factors associated with continued 
health care-seeking for hypertension and type 2 diabetes among Syrian refugees in Lebanon.  
6.3. Methods 
Data Source 
This paper presents a baseline assessment of health care utilization among Syrian refugee 
and Lebanese patients enrolled in the Treatment Guidelines for Hypertension and Type 2 
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Diabetes in Syrian Refugees and Host Communities in Lebanon study in early 2015. Detailed 
methods of the parent study are published elsewhere and provided in Chapter 4 and Appendix B 
for ease of reference.408,409 
Sample size calculations were based on the parent study’s objective of improved quality 
of care (adherence to guidelines) and reported clinic caseload. A total of 1,010 care-seekers at 10 
primary health facilities in the South (n=3), Bekaa (n=3), and Beirut/Mount Lebanon (n=4) 
governorates were enrolled in the parent study (Figure 6-1). Individuals of all nationalities were 
eligible to participate; however, those without a diagnosis of hypertension or type 2 diabetes, less 
than 40 years of age, and adults lacking the capacity to independently participate in interviews 
were excluded. This analysis presents results from 967 enrolled Syrian and Lebanese patients; 
other nationalities were excluded due to small sample size and the desired focus on refugees and 
host community patients.  
This study was designed using a mixed methods approach using both qualitative and 
quantitative data. Patients were recruited from study health facilities. If they indicated an interest 
in participation, a follow up phone call was made during which verbal consent was obtained and a 
baseline interview was conducted to collect information on demographic characteristics; medical 
history and recent care seeking behaviors; and knowledge, attitudes, and practices related to type 
2 diabetes and/or hypertension.  
In addition to quantitative data collected via phone interviews, 19 focus group 
discussions (FGDs) were conducted with enrolled Syrian refugee and Lebanese host community 
patients (75 patient FGD participants), as well as health care providers working at study health 
facilities (24 provider FGD participants). FGD content concentrated on understanding barriers to 
care-seeking, treatment, and medication adherence from both patient and provider perspectives.  
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The MoPH in Lebanon and the Institutional Review Board at the Johns Hopkins 
Bloomberg School of Public Health (JHSPH) approved this study. 
Data Analysis 
The care utilization variables analyzed as the outcome of interest were the number of 
visits to a GP and relevant specialist (endocrinologist, and/or cardiologist). These data were 
collected in a series of questions during the enrollment interview where each patient was asked 
how many times they had visited a GP, an endocrinologist, and a cardiologist in the last six 
months. Given the general and context-specific implications, both positive and negative, of 
seeking care from a GP versus a specialist, separate analyses were performed to explore 
utilization in terms of visits to a GP and a specialist. Two-stage models used these care-seeking 
dependent variables in separate sequential models: first, binarily classified as having had any visit 
to a GP/specialist, and second, continuously analyzed as the number of visits to a GP/specialist if 
at least one visit was reported in the first stage model. Explanatory analysis variables included 
individual and household characteristics and are detailed in Appendix C. 
Data were analyzed using Stata 13 (College Station, TX). Initial analyses were conducted 
to examine the extent of missingness and distribution of variables. Differences between refugee 
and host community patients were explored through basic descriptive statistics and visual 
displays of patient characteristics and health service utilization. The type of provider (GP, 
endocrinologist, cardiologist, etc.) visited was first examined for all patients combined, then 
separately for Syrian refugees and Lebanese host community patients using Pearson's chi-square 
and Wilcoxon-Mann-Whitney test methods to compare population groups.454 An alpha of 0.05 
was used for all hypothesis testing.  
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Syrian refugees and host communities differ substantially. Additionally, financial support 
for health services can also vary materially between populations, potentially influencing care-
seeking and the frequency of health care. These differences argue against a single model for both 
populations, while the small sample of Lebanese patients led to conducting multivariate 
regression analyses only among Syrian refugees. Care utilization for hypertension and diabetes 
were analyzed using separate models since each condition has unique characteristics and distinct 
associations with barriers to and facilitators of care utilization.  
Utilization was modeled using negative binomial hurdle (NBH) models, which assume 
separate decision-making processes for choosing to seek care and for the frequency with which 
care is sought. In count data such as these, the assumption of equidispersion (i.e., the variance is 
greater than the mean) necessary for general Poisson models is often violated.455 Lagrange 
Multiplier tests identified overdispersion both in the number of visits to a GP and in visits to a 
relevant specialist for both hypertension and type 2 diabetes patients.410 As such, six models 
including Poisson, negative binomial, zero-inflated, and hurdle models were tested for each of the 
utilization outcome variables included in this analysis. Methods for model testing and selection, 
as well as goodness-of-fit statistics are provided in detail in Appendix E. Based on quantitative 
model comparison and consideration of the analysis objectives, final analyses employed four 
distinct NBH models: (i) GP care utilization among patients with hypertension, (ii) specialist care 
utilization among patients with hypertension, (iii) GP care utilization among patients with type 2 
diabetes, and (iv) specialist care utilization among patients with type 2 diabetes.  
Variable selection for empirical analyses aimed to build uniform models for each 
outcome variable (i.e., visits to a GP and to a specialist for hypertension and for diabetes) while 
balancing sufficient parsimony to accommodate statistical modeling assumptions with 
preservation of the integrity of results. Regression models for both clinical conditions and both 
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GP and specialist care visits without interaction terms were compared to more complex models 
that incorporated the following interaction terms: (i) time since diagnosis and age, (ii) time since 
diagnosis and hypertension/diabetes comorbidity, (iii) time since diagnosis and knowledge of 
condition complication(s), (iv) time since diagnosis and sex, (v) comorbidity and age, and (vi) 
time in current residence and household expenditure level. To determine whether to include the 
identified interactions in each of the final models, Akaike (AIC) and Bayesian information 
criterion (BIC) values were compared following sequential and joint addition of interaction terms 
to the base model. Interaction terms producing models with a difference of AIC greater than four 
from the base model were retained.456 Because hypertension and diabetes manifest differently and 
in ways that can influence care-seeking behavior, and since utilization of generalist and 
specialists care vary, this group of interaction terms did not uniformly meet criteria for inclusion 
in all final models. In the logit model for care received from a GP by patients with diabetes, 
interaction terms between time since diagnosis and patient age, and between time in current 
residence and household expenditure level met this criterion and thus were included in the final 
model. These interactions failed to materially improve the other three outcome models, as did all 
other interaction terms tested, so were excluded from final models. All models were adjusted with 
robust estimators of the standard errors to account for heterogeneity between participants 
recruited from the ten different health facilities.  
6.4. Results 
Health Service Utilization: Descriptive Overview 
Summaries of patient-reported care utilization in the preceding six months are presented 
for hypertension (Table 6-1) and type 2 diabetes (Table 6-2). Results are also presented in 
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Figure 6-2 with further disaggregation by condition diagnosis, including comorbid hypertension 
and diabetes, within each population group. 
Hypertension 
Enrollment interview results indicated that nearly all study participants diagnosed with 
hypertension (97.7%, CI: 96.4-98.6%) had one or more visits with a health provider in the six-
months prior to interview, both among Syrian refugees and host Lebanese. Care utilization was 
highest for visits with GPs, who were seen by 66.1% (CI: 62.8-69.3%) of patients with 
hypertension. A significantly higher proportion of refugees (69.0%, CI: 65.0-72.9%) saw a GP 
than did host community patients (60.7%, CI: 54.8-66.3%; P=0.015). Among those reporting any 
visit to a GP, refugees also reported a significantly higher mean number of visits (2.9, CI: 2.6- 
3.2) as compared to host community patients (2.0, CI: 1.8- 2.2) (P<0.001).  
Cardiologists were the second most commonly utilized provider type among hypertension 
patients overall (62.8%, CI: 59.5-66.1%) and the most common provider utilized by host 
community patients (69.2%, CI: 63.5-74.4%). Lebanese cardiologist care-seeking was 
significantly higher than refugees (59.4%, CI: 55.2-63.5%; P=0.005); however, among patients 
reporting any care received from a cardiologist, both refugee and host community patients 
reported a mean of 2.2 visits in the preceding six months (P=0.751).  
Fewer than half of patients with hypertension (44.0%, CI: 40.7-47.5%) reported seeing an 
endocrinologist and an average of 2.3 (CI: 2.1-2.5) endocrinologist visits was reported by all 
patients with at least one visit. A much smaller proportion of refugee patients (39.1%, CI: 35.0-
43.3%) received care from an endocrinologist as compared to host community patients (53.2%, 
CI: 47.3-59.0%) (P<0.001), though the number of visits was similar in both populations 
(P=0.513). The high proportion of hypertension patients receiving care from an endocrinologist is 
 
 121  
 
partially due to the relatively high number of hypertension patients with comorbid diabetes 
(Figure 6-2), indicating more rational utilization than presumed when viewed solely by the 
presence of hypertension diagnosis. Of all refugee hypertension patients, 18.9% saw only a GP, 
25.7% saw only an endocrinologist and/or cardiologist, and 55.4% reported visits to GPs and 
specialists. Lebanese utilization was similar with 6.1% having seen only a GP, 33.6% only a 
specialist, and 60.3% both GPs and specialists. 
Other providers were utilized less commonly by patients with hypertension than were 
GPs, cardiologists, and endocrinologists. Ophthalmologist visits were reported by 19.7% (CI: 
17.1-22.6%) of patients overall, and were less common among refugees (15.8%, CI: 12.8-19.1%) 
than Lebanese patients (27.1%, CI: 22.1-32.6%) (P<0.001). Ophthalmologist care was received a 
similar number of times by refugee and host community patients with an average of 1.4 (CI: 1.3-
1.6) visits among all patients visiting at least once (P=0.067).  
Visits to a nutritionist were reported by only 2.2% (CI: 1.4-3.5%) of patients, among 
whom there was an average of 2.2 visits (CI: 1.0-3.3). Relatively few patients (16.3%, CI: 13.9-
19.0%) reported seeing other specialists in the preceding six-month period, with an average of 1.7 
visits (CI: 1.5-1.9). 
Hospitalizations in the same six-month period were reported by 11.8% (CI: 9.5-14.4%) of 
patients with hypertension. Patients who reported at least one hospitalization had an average of 
2.1 (CI: 1.8-2.4) hospitalizations. Refugee and host community patients were similar both in the 
proportion with any hospitalization and in the average number of hospitalizations (P=0.881 and 
0.078, respectively). 
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Type 2 Diabetes 
As with hypertension, care utilization was high among patients diagnosed with type 2 
diabetes, of whom 97.6% (CI: 95.8-98.7%) reported at least one health provider visit within the 
preceding six months (Table 6-2). Unlike among patients with hypertension, endocrinologists 
were the most commonly utilized provider type among patients with type 2 diabetes (74.9%, CI: 
70.9-78.6%). On average, patients reported 2.6 (CI: 2.3-2.8) endocrinologist visits in this period. 
GPs were the second most frequently utilized provider by diabetes patients, of whom 62.6% (CI: 
58.2-66.8%) reported at least one visit, with an average of 2.5 (CI: 2.2-2.7) visits by GP care-
seekers. Similar to hypertension, refugee patients with type 2 diabetes reported a significantly 
higher number of GP visits (2.8, CI: 2.54-3.2) as compared to Lebanese patients (1.9, CI: 1.7- 
2.1) (P=0.001). Cardiologists were seen by nearly half (48.9%, CI: 44.5-53.3%) of all patients 
with type 2 diabetes, with an average of 2.2 visits (CI: 1.9-2.4). Of all refugee diabetes patients, 
12.8% saw only a GP, 30.5% saw only an endocrinologist and/or cardiologist, and 56.7% 
reported visits to GPs and specialists; 4.5% of Lebanese diabetes patients saw only a GP, 35.3% 
only a specialist, and 60.2% had GP and specialist visits. 
Ophthalmologists were utilized by a smaller proportion of patients overall (21.2%, CI: 
17.8-25.0%), though more commonly by Lebanese patients (28.9%, CI: 22.7-35.6%) as compared 
to refugees (16.3%, CI: 12.4-20.9 %) (P=0.001). Similar numbers of visits were reported by 
refugee and Lebanese patients, averaging 1.5 (CI: 1.3-1.7) overall (P=0.135). Similar to 
hypertension patients, few patients with diabetes (3.1%, CI: 1.8-5.0%) saw a nutritionist in the 
preceding six months, with an average of 2.1 visits (CI: 1.1-3.2) or other specialist (17.0%, CI: 
13.8-20.5%) with an average of 1.6 visits (CI: 1.4-1.8).  
Compared to patients with hypertension, hospitalization was less common among those 
with type 2 diabetes, of whom 6.2% (CI: 4.2-8.8%) reported an average of 1.9 (CI:1.3-2.5) 
 
 123  
 
hospitalizations in the preceding six months. Hospitalizations were similar between refugees and 
Lebanese, both in the proportion of patients reporting a hospitalization and in the number of 
hospitalizations (P=0.597 and 0.962, respectively). 
Predictors of Refugee GP and Specialist Care Utilization 
Results from the NBH models for GP and/or specialist care-seeking and utilization for 
hypertension and type 2 diabetes are presented in Table 6-3. 
Hypertension 
Probability of care utilization (first stage) 
Among patients with hypertension, the odds of having seen a GP were significantly 
associated only with patient education levels wherein care-seeking odds were 1.47 (CI: 1.01-2.13) 
times greater for patients who completed primary level education or higher compared to those 
that did not complete at least primary schooling (P=0.044).  
Relative to patients 40 to 50 years old, the odds of specialist care for hypertension were 
reduced in patients between 51 and 60 years old (OR=0.72, CI: 0.56-0.93) (P=0.011); specialist 
care-seeking odds were similarly reduced for patients over 60 years in terms of magnitude, but 
this difference was not statistically significant (P=0.435). Patients who reported having lived in 
their current residence for one year or less also had significantly lower odds (OR=0.63, CI: 0.47-
0.85) of specialist care for hypertension as compared to those who have been in their current 
residence more than one year (P=0.003). In terms of clinical characteristics, patients initially 
diagnosed with hypertension more than 10 years prior had odds of specialist care 1.38 (CI: 1.10-
1.73) times higher than patients diagnosed within the past 10 years (P=0.005).  
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Neither GP nor specialist care-seeking by patients with hypertension was significantly 
associated with patient sex, household expenditures, diabetes diagnosis, enrollment in the YMCA 
chronic medications program, or knowledge of stroke as a complication of hypertension.  
Frequency of care utilization (second stage) 
Conditioned on reporting at least one visit to a GP within the preceding six months, 
hypertension patients between 51 and 60 years old had 28% (IRR=1.28, CI: 1.04-1.56) more GP 
visits than patients between 40 and 50 years old (P=0.018). As with the odds of GP care, the 
association between age and GP care utilization was not significant for patients over 60 years 
(P=0.699). Conversely, female patients had 20% (IRR=0.80, CI: 0.67 -0.94) fewer GP visits than 
men (P=0.008). The number of GP visits was also significantly lower in patients enrolled in the 
YMCA chronic medications program (IRR=0.43, CI: 0.33-0.56; P<0.001) and marginally lower 
in patients who were able to identify stroke as a complication of hypertension (IRR=0.77, CI: 
0.60-0.99; P=0.042).  
Conditioned on having at least one visit to a specialist in the preceding six months, 
patients with household expenditures above the median amount reported by all Syrian refugee 
patients had 17% (IRR=0.83, CI: 0.77-0.90) fewer specialist visits for hypertension as compared 
to those with below median (P<0.001). Housing instability was also associated with fewer 
specialist visits; patients living in their current residence for one year or less had 25% fewer visits 
than those in their current residence more than one year (IRR=0.75, CI: 0.57-0.99; P=0.042). In 
contrast, patients diagnosed with both hypertension and diabetes had 59% more specialist visits 
compared to patients without diabetes comorbidity (IRR=1.59, CI: 1.32-1.91; P<0.001). The 
number of GP and specialist hypertension care visits were not significantly associated with 
education attainment and time since initial hypertension diagnosis.  
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Type 2 Diabetes 
Probability of care utilization (first stage) 
For patients with diabetes, housing instability (i.e., having lived in their current residence 
for one year or less) alone was associated with significantly reduced odds of seeking care from a 
GP (OR=0.48, CI: 0.23-1.00; P=0.049). Although having above median monthly expenditures is 
not significant on its own, the interaction between the length of time in current residence and 
monthly expenditures reveals the effect of shorter time in current residence on reduced GP care-
seeking odds is overcome in patients reporting above median household expenditures. The main 
effects of age and time since diagnosis on the odds of GP diabetes care visits were not statistically 
significant; however, the presence of a significant interaction between these two variables 
indicates that patients between 51 and 60 years old who were diagnosed more than ten years 
previously were more likely to have received GP care than would be expected by reporting the 
main effects of age or time since diagnosis alone, even after adjusting for potential confounders.  
As with GP care-seeking, the odds of specialist care-seeking for diabetes were 
significantly lower (OR=0.56, CI: 0.38-0.82) among those who lived in their current residence for 
one year or less (P=0.003). Patients reporting monthly household expenditures above the median 
amount for all refugees had 1.46 (CI: 1.10-1.93) times higher odds of seeking specialist care 
compared to those with below median household expenditures (P=0.008). Likewise, patients in 
the YMCA chronic medications program had more than four times higher odds of seeing a 
specialist (OR=4.23, CI: 1.49-11.95) than patients not enrolled in the program (P=0.007).  
Neither GP nor specialist care-seeking for diabetes was significantly associated with sex, 
education attainment, hypertension comorbidity, knowledge of at least one complication of 
diabetes, patient age alone [i.e. main effect], and time since diagnosis alone [i.e. main effect]. 
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Frequency of care utilization (second stage) 
Among patients with diabetes who saw a GP in the preceding six months, those in the 
YMCA chronic medications program had fewer than half as many GP visits as patients not 
enrolled in the program (IRR=0.47, CI: 0.31-0.73; P=0.001). Patients living in their current 
residence for one year or less had 34% fewer visits relative to those with residence durations 
longer than one year (IRR=0.66, CI: 0.46-0.95; P=0.025).  
Neither the frequency of visits to a GP nor to a specialist were significantly associated 
with patient age, sex, or education attainment, household expenditures, hypertension comorbidity, 
time since initial diabetes diagnosis, or knowledge of at least one complication of diabetes.  
Qualitative Findings 
FGDs conducted with patients and health care providers supply additional insights into 
factors motivating care utilization for hypertension and diabetes in the Lebanese context. When 
prompted to discuss reasons why patients may not regularly visit health providers for 
hypertension/diabetes care in Lebanon, nearly all patient FGD participants cited financial reasons 
first despite existing policies that attempt to reduce financial barriers. At all study facilities, 
consultations were provided to patients for a nominal fee (approximately US$2-3 for refugees and 
comparable, though variable amounts for Lebanese). Although many participants recognized that 
this subsidized fee schedule is potentially helpful in making care more accessible, they 
emphasized that even relatively small fees are still not affordable for many people. This 
affordability barrier was reported both in FGDs with Syrian refugees and in those with Lebanese. 
As one Lebanese participant summarized, “All is due to poverty. When you don’t have money, you 
can’t seek care.”  
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Furthermore, when asked how often they visit a health worker for their condition in 
Lebanon as compared to in Syria prior to displacement, most refugee participants reported 
seeking care for these conditions at least twice as often before coming to Lebanon. Although not 
all participants elaborated on why there is reduced care-seeking in Lebanon, all who did so 
attributed it to the high costs associated with care in Lebanon relative to Syria where they 
normally received free care. Cost concerns mainly focused on fees for consultation, diagnostic 
testing, and medications, but several refugee FGD participants in the Bekaa governorate 
identified transportation constraints, explaining that when they did go to the doctor, they only 
visit the clinic closest to their home because they cannot afford transportation elsewhere.  
In all FGDs with patients and providers, there was a consensus that many, if not most, 
patients make health facility follow-up visits only to obtain prescribed medication refills. Many 
study facilities are partnered with the YMCA chronic medications program offering chronic 
disease medication for approximately US$0.67; those not included in the YMCA program 
provide other, comparable assistance either through the supporting international non-
governmental organizations or subsidizing costs directly. Patients almost universally cited health 
facility provision of free or extremely low-cost medication as their primary incentive for regularly 
seeking care. Nurses and physicians also agreed that free or reduced-cost medication was the 
leading reason for patient follow-up visits. Nurses in one Beirut FGD offered a similar scenario 
based on the requirement for patients enrolled in the YMCA program to regularly see a physician 
to receive their medication:  
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“Since it is chronic disease, they say we need to keep taking the same 
medication for the rest of our lives, so they don’t come back for check-up. But 
they are stuck when they come to take their meds from the pharmacy, and they 
present a prescription which is one year old. At the pharmacy, they are 
informed that they need to be examined by the doctor. So, they do that not 
because they are convinced but because they know this is the only way for them 
to keep getting their meds.” – Nurse, Beirut governorate 
Similarly, medication stock-outs and unavailability were raised by Syrian and Lebanese 
patients in Beirut as their reason for not regularly visiting health providers. Participants did not 
see the value in visiting a doctor if their prescribed medication is not available at the health 
facility. Lebanese patients raised further concerns that led them to avoid seeking care including 
the disparity in subsidized costs for refugees relative to Lebanese, and the impact that the large 
number of Syrian patients has had on health facility conditions. According to many Lebanese 
patients and nurses in the Bekaa, there are long wait times, loud and uncomfortable waiting areas, 
and insufficient seating in waiting areas due to over-crowding from additional Syrian refugee 
patients. Collectively, these are reported to have driven many Lebanese patients to avoid follow-
up visits entirely.  
FGDs revealed a tendency for Lebanese patients to avoid care visits entirely unless it is 
for an emergency or they are symptomatic/acutely ill. Physicians and nurses all described 
instances of patients not receiving routine care until complications were present or comparable 
crises occurred. In all FGDs with Lebanese patients, at least one patient, and in some groups more 
than one patient, disclosed personally having not gone to the doctor for extended periods, only to 
experience an emergency related to their hypertension/diabetes that required them to go directly 
to the hospital for care. This was far less common with refugees, wherein only one participant 
claimed not to seek care unless “the case was severe.” 
Though FGD participants did not generally discuss utilization of GP versus specialist 
care, several described challenges with the overall availability of specialists in the facilities in 
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which they received care. In many facilities, specialists are only present on select days and during 
a set time, which limits their capacity to treat all patients seeking specialist care. GPs see patients 
in these facilities many more hours per week but are not necessarily more accessible for consult 
as they too have high patient loads. Though it did not emerge as a theme across FGDs with all 
providers, several GPs, notably those in the South governorate, recognized the limits of their 
capacities to treat patients with hypertension and/or diabetes and the needs for referral to a 
relevant specialist. One GP specifically did not prescribe medication for these conditions, 
explaining: “I can’t go into treatment 100%... Personally, I don’t know which meds are available 
for chronic [conditions], I refer to [a] cardiologist.”  
Most of the study health facilities attempt to implement standards of referral for new 
hypertension and/or diabetes patients, giving preference to specialist care for patients with 
confirmed hypertension/diabetes diagnoses. This referral practice has care quality and cost 
implications depending on facility staffing patterns. For new cases, patients are first seen by a GP 
for diagnosis and then referred to a cardiologist (for hypertension care) and/or an endocrinologist 
(for diabetes care). This is minimally problematic in health facilities that have specialists on staff 
available to see these patients for the same consultation fee as a GP; however, not all facilities 
have the appropriate specialists working within their clinic, and even those that have specialists 
only have them on site for limited periods on certain days. When the initial care facility does not 
have a specialist, patients must pay for two separate visits, in addition to any testing ordered 
during each of the visits. Moreover, costs for specialist care at another facility may not be 
subsidized to the same extent as at the initial point of care, potentially involving catastrophically 
high out-of-pocket fees. Costs at health centers outside the MoPH-PHCC network and/or not 
supported by outside organizations can vary dramatically, particularly for specialist care, in many 
cases far exceeding patients’ ability to pay. This is notably the case in private clinics, which are 
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frequently utilized by Lebanese patients, operating with limited, if any, oversight of fee schedules 
and provision of care. 
6.5. Discussion 
This study provides evidence on care-seeking and health service utilization at primary 
level health facilities in Lebanon by Syrian refugee and host community patients diagnosed with 
hypertension and type 2 diabetes. These conditions pose the risk of severe, life-threatening 
consequences if not properly managed. Both are ambulatory care sensitive conditions, meaning 
that appropriate intervention at the primary care level can reduce the risk of complications and 
their accompanying long-term requirements for secondary and tertiary care.457 Managing these 
conditions is complex, and requires initiating and maintaining diet and lifestyle changes and, 
most often, daily pharmacotherapy. Regular monitoring and quality follow-up care by 
appropriately trained health providers are essential.  
Except for hospitalization, which was uncommon for either condition, care utilization 
was consistently high. However, Syrian refugees and host Lebanese patients showed differing 
care-seeking behaviors. For each condition, refugees were more likely to seek care from GPs, and 
to report more frequent GP visits. Lebanese patients, by contrast, tended to rely more on 
specialists’ care (cardiologist for both hypertension and diabetes, and endocrinologist for 
diabetes), though the difference was not statistically significant. Comorbid hypertension and type 
2 diabetes was more common among Lebanese host community patients (50%) than in Syrian 
refugees (36%). Overall, this suggests that although comorbidity was high in both groups, 
Lebanese patients were comparatively more clinically complex, possibly contributing to their 
higher use of specialists. Coupled with Lebanese FGD participants’ reported tendency to avoid 
care-seeking unless conditions require emergency care, and to use private clinics rather than 
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primary level facilities, the long-term cost and clinical consequences of unmanaged comorbidity 
are potentially quite substantial.  
For patients with hypertension, education attainment was the only characteristic 
associated with odds of seeking GP care – those with more formal education had increased odds 
of having received GP care in the preceding six months. Previous studies, mainly in higher 
income countries and not focused on displaced populations, have reported mixed results on the 
relationship between educational attainment and health utilization.458-461 While knowledge of their 
disease (specifically, of stroke as a complication of hypertension) was associated with reduced 
GP use, the relationship was marginally significant and may be a data artifact. Alternatively, 
condition knowledge alone is insufficient to lead to the initiation and daily maintenance of the 
changes required to actively manage a chronic disease. The Transtheoretical or Stages of Change 
Model, which identifies five stages in the process of moving from initial diagnosis to action and 
maintenance, posits that each stage requires resources and information tailored to meet a patient’s 
needs at that particular stage. 462,463 Knowledge of stroke as a potential outcome of unmanaged 
hypertension may not have aligned with the stages that many individual patients in our sample 
occupied, leading it alone to be insufficient motivation to drive behavior for regular care-
seeking.464 In the process of change, in addition to “having the right tools at the right time”, 
principally in terms of disease knowledge, other components of the Transtheoretical Model, such 
as patient self-efficacy to maintain care and treatment adherence, are critical to designing 
effective interventions.465,466  
Overall high care-seeking rates in this context are likely due in part to subsidized services 
at study health facilities for both refugees and vulnerable Lebanese patients, and refugee patterns 
of care-seeking are influenced by numerous governmental, United Nations, and non-
governmental organizations’ policies and programs. For example, enrollment in the YMCA 
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chronic medications program was associated with reduced frequency of GP visits for both 
conditions, yet higher odds of specialist care-seeking for type 2 diabetes. Enrolling in the YMCA 
program requires extensive documentation, a recorded formal diagnosis with accompanying 
prescription, and a participating health facility through which patients are required to receive 
routine follow-up care. Once these have been accomplished, patients can receive medication from 
the health facility through which they were enrolled, provided that they also receive regular 
physician consultations, most often with a specialist. The inverse relationship between frequency 
of GP care with YMCA program enrollment and increased odds of specialist care for diabetes 
presumably reflect a medical history in Lebanon long enough to have identified and successfully 
enrolled in the YMCA program and thus established a care history sufficient to directly receive 
specialist care at the facility through which they are enrolled without triage by a GP. Expanding 
and improving the YMCA program, specifically in terms of ease of enrollment and 
implementation of follow-up care requirements, could reinforce access to specialist care in this 
context. 
Beyond programs and policies, medical complexity can modify care-seeking. For 
example, specialist care for hypertension was understandably higher for those with comorbid 
diabetes, both in the odds of any care-seeking and in the frequency of visits, suggesting rational 
use of specialist care by patients with more complex conditions. In addition, the odds of specialist 
care-seeking for hypertension increased in patients who were diagnosed more than 10 years 
previously. Although the duration of diabetes alone was not related to odds of GP care-seeking, 
among patients over 60 years old, a longer duration of diagnosed diabetes was associated with 
significantly increased odds of GP care-seeking. This is an important interaction given continued 
efforts by humanitarian organizations and the MoPH to improve care for NCDs and differential 
targeting of assistance and vulnerability classifications tied to beneficiary age, specifically those 
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65 years and older. For example, the ongoing World Bank/MoPH Emergency Primary Healthcare 
Restoration Project (EPHRP) and similar projects include, or are planning to include, an essential 
care package for individuals 65 and older.418,419  
For those diagnosed with diabetes more than ten years ago, recent care utilization 
suggests that a longstanding diagnosis may also be a proxy for established habits of care-seeking 
that preceded displacement. The elevated odds of GP care-seeking associated with being in the 
oldest patient age group (over 60 years) and having a diabetes diagnosis for at least 10 years 
needs to be distinguished from age alone and diabetes duration alone. Neither factor in itself was 
associated with care-seeking; however, together they identify a group that may be more adaptive 
or resilient to displacement changes based on experience or long-established routines for 
managing their condition(s).  
Housing instability alone had reduced odds of GP care-seeking. For some, the time in 
their current residence may reflect an intentional move that would not otherwise indicate 
vulnerability or instability; however, compared to the 70% of refugees in this study who had been 
in their current residence for longer than one year, those who had lived in their current residence 
for less than one year also reported a significantly higher number of total relocations since 
arriving in Lebanon. This suggests that for many, residence duration may be a valid proxy for 
household stability, which in turn can influence health service utilization through various 
mediating factors. Though recent relocation may not innately signify household instability, it 
warrants further research, including exploration of other types of household instabilities and 
competing demands on financial resources.  
Although the 2018 Vulnerability Assessment of Syrian Refugees in Lebanon (VASyR) 
found that most refugees had been living in the same accommodation for more than one year, 
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security of tenure and both individual and collective evictions pose continued concerns.3 
According to the 2018 VASyR, 10% of Syrian refugee households in Lebanon changed 
accommodation in the prior six months, of whom 36% moved due to eviction and 25% because 
they were unable to afford rent. More than 6% of households had been evicted at least once since 
arriving in Lebanon. Housing instability in this context is primarily linked to economic 
vulnerabilities such as adoption of emergency coping mechanisms, increasing rent costs, and 
accumulating debt.3,447 Refugees are not a homogeneous group in terms of socioeconomic 
standing; consequently, instability in housing may be offset somewhat by higher socioeconomic 
status and resources. The interaction of having housing instability with above median monthly 
household expenditures in this study was associated with increased odds of GP care, suggesting 
that the ability to make greater expenditures may overcome the depression of care-seeking 
associated with housing instability alone. Alternatively, this and similar counter-intuitive results 
may reflect unobserved heterogeneity in the sample.  
Patient relocation implies abandoning previously utilized facilities near their former 
residence and finding new providers/facilities in proximity to their new residence.432 This would 
be especially difficult for patients enrolled in the YMCA program through a specific health 
facility/dispensary from which they receive care and medication(s).467 If a refugee’s relocation is 
not in proximity to their prior residence, identifying a new health facility participating in the 
YMCA program and reestablishing YMCA enrollment may deter some from continued routine 
care visits. FGDs in this study and reports from other surveys among Syrian refugees in Lebanon 
identified transportation costs, in addition to provider or facility costs, as a barrier to care-
seeking, suggesting that patients may be unlikely to travel longer distances to see the same 
provider or obtain YMCA medication from a facility after relocating. The relationship between 
residence duration and odds of care-seeking, whether for GP or for specialist care, may also be 
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related to knowledge of subsidized services available in close proximity to their new residence. 
Despite improvements in recent years, Syrian refugees’ knowledge of subsidized health care and 
services available to them, and where these services can be accessed continues to be cited as a 
fundamental impediment to care-seeking.71,432  
Specialist care-seeking, unlike GP care, had no significant interactions. Several 
individual characteristics did, however, operate in contrasting directions for GP and specialist 
care-seeking: housing instability was associated with reduced odds of use, while being enrolled in 
the YMCA program and having above median monthly household expenditures were each 
associated with elevated odds of seeking specialist care.  
Health service utilization is nuanced, and patient decisions reflect considerations based 
on the context in which care is sought. Syrian refugees in Lebanon are navigating a fragmented 
health system with a large private sector presence and an excess of specialists, which account for 
over 80% of physicians in the MoPH-PHCC network.80,430 Generalist care is often a component of 
managing NCD patients, though previous evidence indicates benefits from disease control in 
patients who regularly receive specialist care. Some generalists (in FGDs for this research and in 
previous studies) report diabetes as being particularly complex to manage, and as having less 
clear guidance compared to other medical conditions on the steps to achieving treatment 
targets.191 In Lebanon, GPs have graduated from medical school but do not complete a residency 
program, thus, the self-doubt in treating diabetes communicated by GPs during FGDs may not be 
unfounded.468  
Though the number of individual specialists working in primary level health facilities 
often exceeds the number of GPs, specialists’ working hours limit the functional supply. 
Specialists are often inadequately available in primary health facilities to meet the level of patient 
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demand for their services, posing an additional hurdle for refugees seeking subsidized specialist 
care at supported health facilities. Despite receiving advanced training following medical school, 
there is little evidence establishing specialists’ adherence to treatment guidelines in this context. 
Findings from the MoPH’s initiative for cardiovascular services in the national PHCC network 
corroborate shortcomings in the quality of care provided for chronic conditions throughout 
Lebanon’s primary healthcare network, noting physicians’ overall “deliberate negligence in 
abiding by guidelines” and generalist physicians’ continued tendency to refer patients with 
chronic NCDs for specialist treatment.137  
An alternative means for bettering NCD care quality is to improve the care provided by 
GPs to treat common chronic conditions. Training and capacity building for GPs to treat diabetes 
and hypertension with a higher degree of both clinical knowledge and self-efficacy could more 
effectively utilize the existing workforce patterns and physician mix in Lebanon while supporting 
provision of quality care to all patients in accordance with international treatment guidelines and 
standards. Building upon the experience of the MoPH’s cardiovascular service initiative and 
expanding health worker training on guidelines and standards of care incorporated into more 
recent projects such as the EPHRP, Reducing Economic Barriers to Accessing Health Services in 
Lebanon (REBAHS), and numerous small-scale projects have the potential to improve patient 
care quality and, in turn, health outcomes for Lebanese and refugee patients alike.79,137,418,469 
Although past care-seeking behaviors, including preference for 
specialist/secondary/tertiary care among both Lebanese and Syrian populations do not appear to 
be prominent in this study, patient preferences, prior beliefs, and expectations of care providers 
may constrain increased reliance on GPs. Targeted research is needed to assess both Syrian and 
Lebanese patients’ perceptions and beliefs regarding generalist versus specialist care for these 
conditions and, in turn, whether GP capacity building could be a viable near-term improvement. 
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Previous research, including a 2005 study of collaborative practice in treating chronic 
illness in a primary health care center in Lebanon, provides evidence of the benefits of GP and 
specialist interactions and cooperation within health facilities on care quality, cost, and health 
outcomes.470,471 Collaborative care models vary, but efficient coordination broadly relies on GPs 
to provide continuity of care, with limited specialist consultation for complex cases. While 
collaborative care models show promise, their implementation process, organization, and 
effectiveness can be condition- and setting-specific.472 The feasibility of collaborative models 
requires further exploration at scale in the current Lebanese context. 
Syrian refugees bring with them learned behaviors and expectations based on their 
previous health experiences. In Syria, prior to the current crisis, specialist care could be sought 
directly, without requiring a GP referral.473 While this is generally the case in Lebanon, FGDs 
with health care providers distinguished that in practice many facilities still triage patients 
through a GP, requiring another visit to see the appropriate specialist, adding cost and likely 
delaying care. Lebanon does not have a formal referral system, but the ongoing National 
Accreditation Programme for PHCCs requires referral between primary and secondary care for all 
accredited facilities. In conjunction with ongoing accreditation efforts, the MoPH is currently 
piloting a referral system to link facilities in the MoPH-PHCC network with public hospitals in a 
limited number of municipalities; however, even when implemented at scale, the referral system 
would not likely include many private sector facilities.430 Consequently, the public-private, 
specialist-generalist divide and reliance on insufficiently trained GPs in primary level facilities 
may persist. Inconsistent oversight within the plurality of Lebanon’s health system hinders patient 
information sharing and inter-facility referrals, threatening the continuity of care essential to 
effective long-term management of chronic conditions. The scarcity of fully trained primary 
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care/family physicians and the high cost of specialist care concentrated in privately funded 
facilities jeopardize the quality, affordability, and long-term accessibility of NCD care. 
Limitations 
As with all studies, interpretation of these findings should consider the limitations of the 
parent study (Appendix B) and present analysis. Use of cross-sectional enrollment data in this 
analysis prevents causal inference; findings indicate associations, but not necessarily directional 
causality. Furthermore, the use of self-report to measure multiple variables is a potential 
limitation of this analysis. Self-reported utilization may provide information not available in 
medical records; however, utilization is often underreported, especially among patients with 
higher frequency care-seeking. Additionally, patient knowledge of their exact age and recall of 
the duration since initial hypertension or diabetes diagnosis may also be inaccurate. Other 
variables previously demonstrated to be associated with care-seeking and care utilization, such as 
specific additional comorbidities, disease severity, perceptions and beliefs relating to the 
conditions studied, and other psychosocial factors were not included in data collection 
instruments and as such, are not available for this analysis.  
6.6. Conclusion 
These results present both success and areas of focus for improved refugee and Lebanese 
host community health service utilization for hypertension and type 2 diabetes. Overall GP and 
specialist care are more accessible than in most humanitarian settings. Findings show greater use 
of GPs by refugee patients while Lebanese patients rely more on specialist care. Distinct patterns 
in care-seeking and the factors associated with the odds and frequency of GP and specialist care-
seeking for both conditions make evident the complex interplay of care utilization determinants 
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among refugees. The nature of Lebanon’s health system adds further complexity to patient 
decisions regarding GP versus specialist care-seeking. Findings from the present study also 
demonstrate the widespread impact of enduring housing insecurity among Syrian refugees, 
underscoring the importance of continued advocacy, integrated response, and programs centered 
on rent support, income-generation, and poverty alleviation for outcomes across sectors. 
Limited availability of specialists in primary health facilities despite their 
overrepresentation across the health system, inadequate GP capacity to treat complex conditions 
such as hypertension and diabetes, questions about all physicians’ adherence to treatment 
guidelines, and inconsistent referral mechanisms all hinder consistent access to quality care. 
Expanded training to increase GPs’ hypertension and diabetes management expertise and 
improve all providers’ adherence to standard treatment guidelines can further support ongoing 
efforts to improve NCD management and health outcomes, while improving and scaling coverage 
of the YMCA program could reinforce access to specialist care. 
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Table 6-1. Hypertension Care Utilization in the Preceding Six Months  
  Overall Syrian Refugees Host Community 
P-value  (N=847) (N=552) (N=295) 
  Point (95% CI) Point (95% CI) Point (95% CI) 
% with ≥1 visit to any 
health provider 97.7% (96.4-98.6%) 98.0% (96.4-99.0%) 97.2% (94.6-98.8%) 0.506 
Number of Health Provider Visits 
General Practitioner     
% with ≥1 visit 66.1% (62.8-69.3%) 69.0% (65.0-72.9%) 60.7% (54.8-66.3%) 0.015 
Median* 2   2   2   < 0.001 Mean* 2.6 (2.4- 2.8) 2.9 (2.6- 3.2) 2.0 (1.8- 2.2) 
Endocrinologist     
% with ≥1 visit 44.0% (40.7-47.5%) 39.1% (35.0-43.3%) 53.2% (47.3-59.0%) < 0.001 
Median* 2   2   2   0.513 Mean* 2.3 (2.1- 2.5) 2.3 (2.0- 2.5) 2.4 (2.1- 2.6) 
Cardiologist     
% with ≥1 visit 62.8% (59.5-66.1%) 59.4% (55.2-63.5%) 69.2% (63.5-74.4%) 0.005 
Median* 2   2   2   0.751 Mean* 2.2 (2.0- 2.3) 2.2 (2.0- 2.4) 2.2 (2.0- 2.5) 
Ophthalmologist     
% with ≥1 visit 19.7% (17.1-22.6%) 15.8% (12.8-19.1%) 27.1% (22.1-32.6%) < 0.001 
Median* 1   1   1   0.067 Mean* 1.4 (1.3- 1.6) 1.6 (1.3- 1.8) 1.3 (1.1- 1.5) 
Nutritionist     
% with ≥1 visit 2.2% (1.4-3.5%) 1.6% (0.7-3.1%) 3.4% (1.6-6.1%) 0.099 
Median* 1   1   1   0.502 Mean* 2.2 (1.0- 3.3) 2.6 (0.6- 4.6) 1.8 (0.2- 3.4) 
Other Specialist(s)     
% with ≥1 visit 16.3% (13.9-19.0%) 16.3% (13.3-19.7%) 16.3% (12.2-21.0%) 0.990 
Median* 1   1   1   0.217 Mean* 1.7 (1.5- 1.9) 1.8 (1.4- 2.1) 1.5 (1.3- 1.7) 
Hospitalizations n=710 n=463 n=247   
% w/ any hospitalization 11.8% (9.5-14.4%) 11.9% (9.1-15.2%) 11.5% (7.8-16.2%) 0.881 
Median† 2   2   2   
0.708 Mean† 2.1 (1.8- 2.4) 2.1 (1.8- 2.5) 2.0 (1.5- 2.5) 
P-value for group comparisons using Pearson's chi-square for proportions and Wilcoxon-Mann-Whitney test methods for 
continuous variables. Statistical significance indicated in bold (P<0.05) and bold italics (P<0.001). 
* Median and mean number of visits for all hypertension patients with at least one visit to respective provider type 
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Table 6-2. Type 2 Diabetes Care Utilization in the Preceding Six Months  
  Overall Syrian Refugees Host Community 
P-value 
 
(N=513) (N=312) (N=201) 
  Point (95% CI) Point (95% CI) Point (95% CI) 
% with ≥1 visit to any 
health provider 97.6% (95.8-98.7%) 98.0% (95.7-99.3%) 96.9% (93.4-98.9%) 0.436 
Number of Health Provider Visits 
General Practitioner 
    
% with ≥1 visit 62.6% (58.2-66.8%) 64.7% (59.2-70.0%) 59.2% (52.1-66.1%) 0.206 
Median* 2   2   2   0.001 Mean* 2.5 (2.2- 2.7) 2.8 (2.4- 3.2) 1.9 (1.7- 2.1) 
Endocrinologist 
    
% with ≥1 visit 74.9% (70.9-78.6%) 71.8% (66.5-76.7%) 79.6% (73.4-84.9%) 0.047 
Median* 2   2   2   0.872 Mean* 2.6 (2.3- 2.8) 2.6 (2.3- 2.9) 2.6 (2.3- 2.9) 
Cardiologist 
    
% with ≥1 visit 48.9% (44.5-53.3%) 44.2% (38.6-49.9%) 56.2% (49.1-63.2%) 0.008 
Median* 2   2   2   0.288 Mean* 2.2 (1.9- 2.4) 2.1 (1.8- 2.3) 2.3 (1.9- 2.7) 
Ophthalmologist 
    
% with ≥1 visit 21.2% (17.8-25.0%) 16.3% (12.4-20.9%) 28.9% (22.7-35.6%) 0.001 
Median* 1   1   1   0.135 Mean* 1.5 (1.3- 1.7) 1.7 (1.4- 2.1) 1.4 (1.2- 1.6) 
Nutritionist 
    
% with ≥1 visit 3.1% (1.8-5.0%) 2.9% (1.3-5.4%) 3.5% (1.4-7.0%) 0.704 
Median* 2   2   1   0.143 Mean* 2.1 (1.1- 3.2) 2.8 (0.9- 4.7) 1.3 (0.8- 1.7) 
Other Specialist(s) 
    
% with ≥1 visit 17.0% (13.8-20.5%) 17.9% (13.9-22.7%) 15.4% (10.7-21.2%) 0.457 
Median* 1   1   1   0.690 Mean* 1.6 (1.4- 1.8) 1.6 (1.3- 2.0) 1.5 (1.3- 1.8) 
Hospitalizations n=465 n=280 n=185   
% w/ any hospitalization 6.2% (4.2-8.8%) 5.7% (3.3-9.1%) 6.9% (3.7-11.5%) 0.597 
Median† 1   1   1   
0.962 Mean† 1.9 (1.3- 2.5) 1.9 (1.1- 2.7) 1.9 (0.8- 2.9) 
P-value for group comparisons using Pearson's chi-square for proportions and Wilcoxon-Mann-Whitney test methods for 
continuous variables. Statistical significance indicated in bold (P<0.05) and bold italics (P<0.001). 
* Median and mean number of visits for all type 2 diabetes patients with at least one visit to respective provider type 
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Table 6-3. Odds and Frequency of Care Visits to General Practitioners and Specialists for 
Hypertension and Type 2 Diabetes in the Preceding Six Months Among Syrian Refugees 
  General Practitioner Specialist  
Logit ZTNB Logit ZTNB  
OR (95 % CI) IRR (95 % CI) OR (95 % CI) IRR (95 % CI) 
HYPERTENSION 
Patient Characteristics 
    
Age (ref: 40 – 50 years) 
    
51 - 60 years 1.19 (0.61-2.34) 1.28 (1.04-1.56) 0.72 (0.56-0.93) 1.16 (0.96-1.40) 
> 60 years 2.01 (0.91-4.43) 1.04 (0.85-1.28) 0.71 (0.30-1.68) 1.32 (0.85-2.06) 
Female 1.34 (0.93-1.94) 0.80 (0.67-0.94) 0.72 (0.41-1.27) 0.96 (0.74-1.25) 
Completed ≥ primary 
education  1.47 (1.01-2.13) 0.81 (0.48-1.37) 0.69 (0.43-1.13) 1.08 (0.91-1.29) 
Above median monthly HH 
expenditures* 1.19 (0.99-1.43) 1.01 (0.68-1.49) 1.07 (0.50-2.28) 0.83 (0.77-0.90) 
In current residence ≤ 1 year 1.36 (0.78-2.37) 1.02 (0.75-1.40) 0.63 (0.47-0.85) 0.75 (0.57-0.99) 
Clinical Characteristics     
Diabetes Comorbidity 0.86 (0.63-1.16) 0.99 (0.82-1.20) 2.31 (0.99-5.40) 1.59 (1.32-1.91) 
>10 years since diagnosis 0.89 (0.65-1.22) 1.06 (0.75-1.50) 1.38 (1.10-1.73) 0.88 (0.73-1.07) 
Enrolled in YMCA Program 0.74 (0.55-1.00) 0.43 (0.33-0.56) 1.12 (0.44-2.89) 0.81 (0.60-1.10) 
Knowledge of stroke as a 
complication of HT 1.16 (0.83-1.61) 0.77 (0.60-0.99) 0.87 (0.61-1.24) 1.04 (0.75-1.45) 
TYPE 2 DIABETES 
Patient Characteristics     
Age (ref: 40 – 50 years)     
51 - 60 years 1.11 (0.61-2.04) 1.36 (0.85-2.18) 0.84 (0.53-1.33) 1.15 (0.85-1.57) 
> 60 years 1.12 (0.74-1.69) 1.33 (0.77-2.31) 1.09 (0.57-2.08) 1.01 (0.82-1.25) 
Female 0.96 (0.75-1.24) 1.01 (0.77-1.31) 0.85 (0.42-1.70) 1.00 (0.82-1.20) 
Completed ≥ primary 
education  1.07 (0.64-1.78) 0.68 (0.39-1.20) 0.68 (0.35-1.31) 1.17 (0.73-1.89) 
Above median monthly HH 
expenditures* 0.49 (0.23-1.02) 0.94 (0.60-1.46) 1.46 (1.10-1.93) 0.84 (0.61-1.16) 
In current residence ≤ 1 year 0.48 (0.23-1.00) 0.95 (0.78-1.17) 0.56 (0.38-0.82) 0.66 (0.46-0.95) 
Clinical Characteristics     
HT Comorbidity 1.14 (0.59-2.17) 1.01 (0.74-1.37) 0.87 (0.56-1.36) 1.11 (0.66-1.85) 
>10 years since diagnosis 0.30 (0.08-1.06) 0.89 (0.55-1.45) 1.18 (0.66-2.10) 0.86 (0.63-1.17) 
Enrolled in YMCA Program 0.65 (0.34-1.24) 0.47 (0.31-0.73) 4.23 (1.49-11.95) 0.78 (0.55-1.12) 
Knowledge of ≥1 complication 
of diabetes† 1.20 (0.86-1.66) 1.18 (0.88-1.57) 0.93 (0.42-2.08) 1.02 (0.81-1.27) 
Interactions     
>10 years since diagnosis * 
age 51 – 60 years 4.31 (0.89-20.77) --- --- --- 
>10 years since diagnosis * 
age > 60 years 6.83 (1.32-35.46) --- --- --- 
Current residence ≤ 1 year *     
> median expenditures* 5.26 (1.43-19.31) --- --- --- 
ZTNB = zero-truncated negative binomial regression; OR = odds ratio; IRR = incidence rate ratio; HH = household; HT = 
hypertension. Statistical significance indicated in bold (P<0.05) and bold italics (P<0.001). 
* Relative to median monthly household expenditures reported by Syrian refugees 
† Defined as identifying at least one complication of diabetes, including eye problems, kidney problems, foot ulcers, and heart 
problems. Reference: not able to identify any complication of diabetes 
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Figure 6-2. Hypertension and Type 2 Diabetes Care Utilization in the Preceding Six Months 
by Provider Type and Diagnosed Condition(s)  
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Chapter 7. Prescription and Adherence to Medication for Hypertension and 
Type 2 Diabetes Among Syrian Refugee and Host Community Care-Seekers 
at Select Primary Level Health Facilities in Lebanon (Paper 3) 
7.1. Abstract 
Background. Since 2011, the conflict in Syria has displaced more than one million 
refugees into Lebanon. The high prevalence of non-communicable diseases (NCDs) among both 
Syrian refugees and the host communities within which they are settled places an immense 
burden on Lebanon’s health system for medicines and medical services. Adherence to prescribed 
medication is strongly tied to health outcomes for many chronic NCDs, particularly for 
hypertension and diabetes.  
Methods. This paper presents a baseline assessment of patients from ten primary level 
health facilities in Lebanon enrolled in a longitudinal cohort study in 2015. This analysis sought 
to characterize medication prescription and adherence among Syrian refugee and host community 
patients, and to identify factors associated with interrupted adherence among Syrian refugees. 
Differences in household characteristics by population group and interrupted adherence to 
medication for hypertension and diabetes were examined using Pearson's chi-square and t-test 
methods. Logistic regression was performed to assess determinants of interrupted medication 
adherence only among Syrian refugees given insufficient sample size and reports of medication 
interruption by host community patients.  
Results. Interrupted medication adherence was low among Syrian refugee and host 
community patients for both hypertension (12.8% and 1.6%, respectively) and type 2 diabetes 
(10.0% and 1.6%, respectively). Conversely, qualitative findings from focus group discussions 
indicate that non-adherence was most often reported for individual doses or a few days at a time, 
far shorter durations than two weeks or longer specified in the question used to measure 
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adherence quantitatively. This highlights a crucial shortcoming of quantitative analysis based on 
measurement of adherence interruption for longer periods of time in this context. For both 
hypertension and type 2 diabetes, older age and housing stability were protective against 
interrupted adherence to prescribed medication. Patient enrollment in the joint Ministry of Public 
Health/Young Men’s Christian Association chronic medications program was also protective 
against interrupted adherence for hypertension, but not for diabetes. Longer time since initial 
diagnosis was associated with increased odds of medication interruption for diabetes, though not 
for hypertension. Findings also indicate a potential association between knowledge of the 
pathological condition, particularly knowledge of possible complications and medication 
adherence.  
Conclusions. Continued efforts to scale-up employment of community health workers 
and/or refugee outreach volunteers to provide health education, monitoring, care, and referral 
services to vulnerable populations in Lebanon; consideration of diabetes distress in ongoing 
programming; enhanced pharmaceutical inventory management; and physician training and 
support for prescribing practices that consider drug availability and cost may support improved 
medication adherence in this population. This study further suggests that many methods for 
capturing adherence/non-adherence may lack sufficient reliability in this context given the range 
of influencing factors and types of non-adherence. As such, caution should be taken in 
interpreting adherence reports in previous studies, and further efforts made to utilize measures 
with increased sensitivity to the relevant type(s) of non-adherence in this context moving forward.  
7.2. Introduction 
Since the start of conflict in March 2011, an estimated 7.2 million Syrians have fled to 
neighboring countries across the region, approximately 1.5 million of whom are currently settled 
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in Lebanon.2 The impact of this influx of refugees on the Lebanon’s economy, demographics, and 
stability is pervasive as, with one in six people in the country considered a refugee under the 
United Nations High Commissioner for Refugees’ (UNHCR) responsibility, Lebanon continues 
to host the world’s highest number of refugees relative to its host population.94 Unlike other 
countries hosting large numbers of Syrian refugees, Lebanon has not established formal camps 
for Syrian refugees and there are no health facilities dedicated to providing services only to 
Syrian refugees (as of the time of writing). UNHCR established an inter-agency mechanism with 
the Lebanese Government to coordinate the humanitarian response to the Syrian crisis across all 
sectors. Health assistance for Syrian refugees is based on a primary health care strategy, wherein 
primary health services for refugees are subsidized in existing primary level health facilities 
throughout the country and referrals for secondary and tertiary services managed by a private 
sector third-party administrator.88,97,98,411  
Like many countries in the region, Lebanese and Syrian populations are in the late stages 
of the epidemiologic transition from communicable, maternal, neonatal, and nutritional 
conditions to non-communicable diseases (NCDs).44-48 Diabetes prevalence has been estimated at 
7.4% in Syria and 14.4% in Lebanon.40,49-54 Though evidence of the burden of hypertension in 
Syria and Lebanon is not as widely available as diabetes estimates, previous literature has 
estimated regional prevalence of hypertension at 29.5%, with prevalence in Syria at 24.9%, and 
28.8% in Lebanon.64-67 While estimates of chronic disease prevalence specific to Syrian refugees 
in the region are limited, the most recently published rates among adult Syrian refugees in 
Lebanon (2016) estimated 7.4% prevalence for hypertension and 3.3% for diabetes.67,73 
Effective treatment of hypertension and type 2 diabetes require continued follow-up and 
monitoring with recommended treatments involving both pharmacological and lifestyle 
interventions. Failure to intervene pharmacologically when systolic blood pressure is consistently 
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above 130 mmHg or diastolic blood pressure is consistently above 80 mmHg is often associated 
with worse clinical outcomes including heart disease, stroke, loss of ophthalmic acuity, and 
kidney failure, resulting in premature disability and mortality.41,104-106 Much like hypertension, 
type 2 diabetes management requires a combination of pharmacological, dietary, and lifestyle 
interventions to sustain “controlled” blood glucose levels (defined as HbA1C* level of 7% or 
lower) and prevent potentially severe cardiovascular, ocular, renal, and neurological 
complications.108,109 
Low or non-adherence to prescribed antihypertensive and antidiabetic medication(s) is 
strongly associated with poor blood pressure and glycemic control.225,227,267,268,280-285 Existing 
evidence has also established an association between medication adherence and quality of life, as 
well as subsequent medical costs for patients with hypertension and diabetes. Though the specific 
mechanism through which increased costs are incurred varies, it is primarily related to increased 
costs related to hospitalizations, emergency room visits, and pathological sequalae associated 
with inadequate adherence.225,271,274-278,280,286-292,296  
Comparison of medication adherence rates across studies is limited by the lack of 
uniform adherence definitions and measurements.421 Furthermore, though prevailing patient 
adherence thresholds to meet therapeutic goals have been investigated based upon clinical 
implications, explicit standards against which to assess population level adherence rates have yet 
to be established.421-424 Worldwide, as many as 50% of hypertension patients are estimated to end 
treatment within the first year following diagnosis; of those who continue treatment, between 
50% and 80% consistently take medication(s) as prescribed.225,297,298 Adherence rates for patients 
with type 2 diabetes trend similarly, with the bulk of evidence coming from developed countries 
                                                     
* Glycated hemoglobin (HbA1C) is a standard test used to determine average blood sugar levels over extended periods 
of time (weeks or months) 
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reporting adherence prevalence ranging from 70% to 80%.225 Though measurement methods and 
definitions of adherence vary across studies, a 2011 systematic review of medication adherence 
among patients with chronic conditions in the Middle East region reported estimated rates of non-
adherence ranging from 1.4% to 88% for all chronic conditions; rates for patients with 
hypertension ranged from 23% to 49.5% and from 1.4% to 27.1% among patients with 
diabetes.474 A more recent review of medication adherence in the region reported an overall 
average non-adherence prevalence of 61.7%, although individual study estimates ranged from 
1.4% to 83.3%, further demonstrating the variability resulting from different contexts and 
measures.425 
Though not extensively studied or reported, medication adherence among Lebanese with 
hypertension has previously been recognized as a challenge to disease management.308,309 “High” 
medication adherence, as measured and classified by the Morisky Medication Adherence Scale 
(MMAS), was reported for half (50.5%) of respondents in a 2016 evaluation of medication 
adherence among Lebanese patients with hypertension, while 27.1% were classified with 
“medium” adherence, and the remaining 22.4% with “poor” adherence.308 Another cross-sectional 
study of Lebanese patients in 2015 revealed far worse adherence for chronic diseases generally: 
57.4% of patients were classified with low adherence, 25.7% with medium adherence, and only 
16.9% highly adherent, also according to MMAS classifications.309 Similarly poor adherence has 
been reported elsewhere in the region, most notably among Palestinian patients with hypertension 
in the West Bank, among whom the prevalence of “high” adherence was only 16.9%.318 
Comparable adherence estimates for hypertension, diabetes, or chronic conditions broadly among 
the Syrian population are sparse, both prior to and since the start of the current conflict.  
Study of medication adherence among refugee populations is limited, particularly 
adherence to chronic disease medications. The only such adherence estimate published for Syrian 
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refugees is a 2018 evaluation of primary care NCD services offered by Médecins Sans Frontières 
(MSF) in Irbid, Jordan. MSF reported that in a convenience sample of 300 Syrian refugee 
beneficiaries, 89% were classified as having high adherence according to the Medication 
Adherence Report Scale (MARS-5)426. In addition to limitations due to small sample size and 
selection bias in convenience sampling, this estimate was noted to have been contradicted by non-
adherence reported in focus group discussions (FGDs) with sampled beneficiaries and staff 
accounts, implying potential social desirability bias in adherence reporting. Qualitative findings 
and ongoing program monitoring from MSF’s evaluation found that many more patients reported 
skipping or reducing doses, temporarily stopping prescribed medication, and sharing medications 
with others in their families and communities. Comparable adherence estimates are not available 
for Syrian refugees in Lebanon; however, medication shortages, limited availability, and 
increasingly prohibitive costs have been reported since the start of the crisis with broad 
presumption that these and other challenges translate to reduced medication adherence among 
Syrian refugee populations throughout the country and the region.93,475,476  
Subsidized consultations and provider services are afforded to Syrian refugees and many 
host Lebanese at a number of primary health facilities throughout the country. Chronic disease 
medications are also available at a nominal fee to those enrolled in the joint program between the 
Ministry of Public Health (MoPH) of Lebanon and the Young Men’s Christian Association 
(YMCA). These medications can be obtained in select dispensaries across Lebanon; however, the 
process for receiving medicines through the program is extensive and sparsely documented. For 
refugees and vulnerable host populations, even those receiving subsidized care, the burden of 
even a small out-of-pocket payment can prevent receiving needed care given the increasing debt 
and strained financial situation of many households.102 Despite wide coverage of subsidized care 
and medications, 39% of Syrian refugees in Lebanon are reportedly not receiving needed medical 
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care due to treatment and/or medication costs. The long-term consequences of this are increased 
morbidity, mortality, and costs incurred for specialized care for later complications.103  
The primary objective of this paper is to explore the relationship between predisposing 
factors and adherence to medication prescribed for hypertension and type 2 diabetes among 
Syrian refugees in Lebanon. Examining factors associated with reduced or non-adherence to 
medications for these conditions can inform programming and focus interventions to improve 
adherence and ultimately, clinical outcomes. Secondarily, this paper also characterizes 
differences in medication prescription and use between Syrian refugees and host communities to 
understand whether and to what extent disparities are present. 
7.3. Methods 
Data Source 
The present analysis utilizes baseline data from a larger study, Treatment Guidelines for 
Hypertension and Type 2 Diabetes in Syrian Refugees and Host Communities in Lebanon, 
implemented in ten primary health facilities in Lebanon from 2014 through 2016. Detailed 
methods of the parent study are provided in Chapter 4 and Appendix B.408,409  
Participants consisted of patients at 10 study health facilities supported by the 
International Organization for Migration (IOM) or International Medical Corps (IMC). in 
Lebanon’s South (n=3), Bekaa (n=3), and Beirut/Mount Lebanon (n=4) governorates. Individuals 
of all nationalities, including both Syrian and Iraqi refugees, in addition to Lebanese and 
Armenian patients, were enrolled; however, those without a diagnosis of hypertension or type 2 
diabetes, less than 40 years of age, and adults lacking capacity to independently participate in 
interviews were deemed ineligible for participation.  
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Sample size for the parent study was informed by clinic caseloads, and the proportions of 
patients expected to be reachable by phone (80%) and willing to participate (80%). Calculations 
assumed the most conservative baseline rate of 50% for provider adherence to guidelines, α = 
0.05, β = 0.20 (power = 0.80), and were one-sided based on the assumption that provider 
compliance would not decrease. A maximum sample size of 1,609 participants was projected; 
however, fewer participants were successfully enrolled due to over-estimation of clinic caseloads. 
The final study sample included 1,010 patients and is presented by population group and 
diagnosed condition in Table 7-1.  
Patients at study health facilities with hypertension and/or type 2 diabetes diagnoses were 
identified by facility staff and asked if they were willing to participate in the parent study, A 
follow up phone call to patients interested in participation was made by study staff during which 
verbal informed consent was obtained and documented in survey forms. Verbal informed consent 
was obtained with approval of the Institutional Review Board at the Johns Hopkins Bloomberg 
School of Public Health (JHSPH) because interviews were conducted over the phone, and thus, 
did not involve in-person contact between the study team and patients. After consent, a baseline 
interview was conducted to collect patient demographic characteristics; medical history and 
recent care seeking behaviors; and knowledge, attitudes, and practices related to type 2 diabetes 
and/or hypertension. Medical record reviews were also conducted following enrollment, 
collecting data related to each patient’s clinical history and provider compliance with guidelines.  
In addition to quantitative data, 19 focus group discussions were conducted with enrolled 
Syrian refugee and Lebanese host community patients, in addition to health care providers 
working at study health facilities. FGD content centered on more detailed information about 
barriers to care-seeking, treatment, and medication adherence from both patient and provider 
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perspectives. Detailed methods for qualitative data collection and analysis are provided with 
parent study methods in Chapter 4 and Appendix B.  
This study was approved by the MoPH in Lebanon and the Institutional Review Board at 
the Johns Hopkins Bloomberg School of Public Health. 
Variables 
A wide body of evidence supports the role of medication adherence as a principal factor 
on the causal pathway to improved disease control in patients with hypertension and type 2 
diabetes.269 Interrupted medication adherence was assessed as a binary variable based on whether 
or not patients reported having stopped medication for two weeks or more in the six months prior 
to study enrollment. Adherence was measured separately for medications to treat hypertension 
and those for diabetes. An analysis of the validation of this question for capturing adherence 
compared to the four-item Morisky Medication Adherence Scale (MMAS-4) is provided in 
Appendix F. 
Explanatory variables included in analyses consisted of patient demographic and clinical 
characteristics and are provided in detail in Appendix C. 
Data Analysis 
Results from the Treatment Guidelines for Hypertension and Type 2 Diabetes in Syrian 
Refugees and Host Communities in Lebanon study previously published elsewhere suggest a 
relatively minimal difference in key outcomes across study periods following longitudinal study 
intervention.408,477 Additionally, considering the relatively rare reporting of interrupted medication 
adherence in patients with hypertension (8.9%) and type 2 diabetes (6.7%) alike, baseline data 
provides the largest available sample without the influence of loss to follow-up or parent study 
 
 154  
 
interventions. As such, this paper presents a baseline assessment of study participants, providing 
evidence of patients’ behaviors and characteristics without additional intervention to most 
effectively inform recommendations for the Syrian refugee response in Lebanon.  
Data were analyzed using Stata 13 (College Station, TX). Exploratory data analyses were 
conducted to investigate the extent of missingness and distribution of variables to be included in 
analyses. Basic descriptive statistics and visual displays of household characteristics and 
medication use were examined for the salient comparison groups: population group (Syrian 
refugee versus Lebanese host community), and interrupted medication adherence (stopped for 
two weeks or longer vs did not stop). Differences in participant characteristics by population 
group and interrupted medication adherence classification were examined using Pearson's chi-
square and t-test methods. An alpha of 0.05 was used for all hypothesis testing.  
Given the relatively small host community sample size, insufficient number of Lebanese 
host community participants reporting interrupted medication adherence, and the distribution of 
covariates of interest, multivariate logistic regression analysis was conducted only among Syrian 
refugees. Assessment of medication prescription and use in the host community was a secondary 
objective, thus, differences between refugee and host community populations are explored 
through descriptive statistics and compared using Pearson's chi-square and t-test methods but 
excluded from regression analyses.  
Diagnostic assessments were performed to determine the appropriateness of analytical 
techniques. Taking into consideration the constraints of sample size that could be realized in this 
setting, variable selection for adjusted analyses sought parsimonious final models accommodating 
sufficient variance to meet model assumptions. Because the conditions themselves are in many 
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ways so different and the nature of illness can influence conditional or non-adherence, data for 
hypertension and diabetes were analyzed using separate models. 
Logistic regression was performed to determine the crude and adjusted odds of 
interrupted medication adherence among Syrian refugees. Interaction terms for patient 
characteristics (e.g. age, sex, education, household expenditure level, time since diagnosis etc.) 
with key explanatory variables were tested using both joint and sequential additions to the base 
model. None of the tested interactions significantly improved the model fit for either hypertension 
or diabetes adherence models when assessed using the Akaike (AIC) and Bayesian information 
criterion (BIC) values as well as both Wald and likelihood ratio tests; thus, interaction terms are 
omitted from the final models. 
7.4. Results 
Medication Prescription and Current Use 
A summary of prescription and adherence to medication for hypertension and type 2 
diabetes as reported by enrolled patients is presented in Table 7-2. An overview of specific 
medication prescribed to patients based on facility health records is presented in Appendix G. 
Hypertension 
Medication prescription for hypertension was consistently high in the study sample, with 
all patients self-reporting ever having been prescribed medication for hypertension and nearly all 
(98.1%, CI: 96.3-99.1%) reporting current medication use for hypertension (Table 7-2). 
Prescriptions were reported less frequently in the health records available for these patients 
wherein 69.9% (CI: 66.4-73.3%) of all patients with hypertension had documentation of 
prescribed medication. Sparse record keeping, coupled with varied incentives across the ten study 
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facilities and overall absence of consequences for not recording dispensing in many cases may 
mean that there were an unknown number of medicines prescribed or dispensed but not recorded. 
Prescription reporting in health records was statistically significantly lower among Syrian refugee 
patients with hypertension (66.5%, CI: 62.1-70.6%) as compared to Lebanese host community 
patients (77.3%, CI: 71.3-82.6%) (P=0.003). Among all patients with hypertension, an average of 
1.79 (CI: 1.71-1.86) medications for the condition were reported in health facility records at 
enrollment; this figure was similar for Syrian refugees and host community patients. Of the 502 
patients with medication for hypertension reported in health facility records at enrollment, 30.3% 
(CI: 26.3-34.5%) had at least one medication newly prescribed at the most recent visit. Newly 
prescribed medication was significantly more common among Syrian refugee patients, of whom 
38.8% (CI: 33.4-44.3%) reported at least one newly prescribed medication as compared to only 
14.7% (CI: 9.8-20.8%) of Lebanese host community patients (P<0.001).  
Type 2 Diabetes 
As with hypertension, all patients with type 2 diabetes self-reported medication 
prescription for the condition during study enrollment (Table 7-2). Prescriptions recorded in 
patient health records for those with type 2 diabetes were also similar to those with hypertension; 
72.4% (67.1-77.2%) of all patients with type 2 diabetes had documentation of medication 
prescribed for the condition. As with prescriptions for hypertension however, limited record 
keeping in study health facilities may have resulted in additional medication prescribed or 
dispensed to participants but not documented in patient records. 
Among patients with type 2 diabetes, an average of 1.43 (CI: 1.37-1.49) medications for 
the condition were reported in facility records at baseline; this was similar for Syrian refugees and 
Lebanese host community patients (P=0.659). At least one medication was newly prescribed at 
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the most recent visit for 26.4% (CI: 21.5-31.7%) of the 307 patients with type 2 diabetes 
medication prescription(s) reported in facility records at enrollment. As with prescribing for 
patients with hypertension, the proportion of patients with diabetes with at least one newly 
prescribed medication was significantly higher among Syrian refugees (32.5%, CI: 26.0-39.5%) 
as compared to the Lebanese host community (15.5%, CI: 9.3-23.6%) (P=0.001).  
Interrupted Medication Adherence: Descriptive Overview 
Patients who reported having stopped medication prescribed for hypertension or type 2 
diabetes against medical advice for two weeks or longer in the six months preceding interview 
were classified as having “interrupted medication adherence”. Self-reported medication 
adherence was high among patients with hypertension and type 2 diabetes throughout follow-up 
(Table 7-2). At enrollment, 9.3% (CI: 7.3-11.7%) of all patients with hypertension reported 
having stopped prescribed medication for the period of time in question, while 8.9% (CI: 6.9-
11.2%) of patients were classified as having interrupted medication adherence (i.e., having 
stopped without instruction from a health provider to do so). Among patients with type 2 
diabetes, 7.1% (CI: 4.9-9.8%) reported having stopped prescribed medication and 6.7% (CI: 4.6-
9.3%) were classified as having interrupted adherence. Observed differences in interruption of 
medication adherence for hypertension and diabetes without instruction from a physician were 
statistically significant between Syrian refugee and Lebanese host community patients. Among 
Syrian refugee patients with hypertension, 12.8% (CI: 9.9-16.2%) had interrupted medication 
adherence at enrollment compared to only 1.6% (CI: 0.4-4.1%) of host community patients 
(P<0.001). Interrupted adherence to medication for type 2 diabetes was observed in 10.0% (CI: 
6.7-14.1%) of Syrian refugee patients as compared to only 1.6% (CI: 0.3-4.6%) of host 
community patients (P<0.001).  
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Reasons for medication interruption were similar by condition and primarily concentrated 
on cost, as was reported by 71% of patients with interrupted adherence to medication for 
hypertension and 77% of patients with type 2 diabetes. The other most frequently cited reasons 
for interruption were not knowing where to obtain the medication, inability to locate a pharmacy 
with the medication in stock, and patients’ perceptions that their condition had improved. 
Interruption motivated by patients’ perceived condition improvement is particularly challenging 
as, given that hypertension in particular is largely asymptomatic, patients may ascribe symptoms 
to their disease that may not be related.  
Predictors of Interrupted Medication Adherence 
Results of univariate and multivariate logistic regression analyses for predictors of 
interrupted medication adherence for hypertension and type 2 diabetes among Syrian refugee 
patients are presented in Table 7-3.  
Hypertension 
Odds of interrupted adherence to medication for hypertension were significantly 
associated with the number of years since diagnosis (-) and knowledge of stroke as a 
complication of hypertension (-) in univariate analysis but not in adjusted analysis. The crude 
odds of interrupted medication adherence were 0.48 (CI: 0.27-0.84) times lower for patients able 
to identify stroke as a possible complication of hypertension as compared to those unable to 
identify this complication (P = 0.010). The number of years since initial hypertension diagnosis 
was also protective, showing reduced odds of interrupted adherence in those diagnosed 10 or 
more years ago as compared to those diagnosed fewer than five years ago (OR=0.26, CI: 0.11-
0.9765 P=0.004).  
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After adjusting for other covariates of interest, the odds of interrupted medication 
adherence were significantly associated with enrollment in the YMCA chronic medications 
program (-), patient age (-), education level completed (primary or higher) (+), and having lived 
in current residence location for one year or less (+). Patient enrollment in the YMCA chronic 
medications program was associated with decreased odds of interrupted medication adherence for 
hypertension (OR= 0.35, CI: 0.14-0.86, P = 0.023), as was older age (OR=0.96, CI: 0.93-0.99; 
P=0.025). Conversely, completion of primary education or higher was associated with 
significantly higher odds of medication interruption (OR= 2.48; CI: 1.26-4.88) compared to those 
who completed no formal or less than primary education, after adjusting for other variables of 
interest (P=0.008). Housing insecurity, measured as having lived in the current residence for one 
year or less, was also associated with significantly higher odds of medication interruption (OR= 
2.70, CI: 1.46-4.99) as compared to patients who have lived in their current residence for longer 
than one year (P = 0.001).  
There was no statistically significant relationship between the adjusted odds of 
interrupted medication adherence for hypertension and diabetes comorbidity, time since 
diagnosis, knowledge of stroke as a complication of hypertension, patient sex, or monthly 
household expenditures.  
Type 2 Diabetes 
The adjusted odds of interrupted adherence to medication for type 2 diabetes were 
significantly associated with time since diagnosis (+), patient age (-), and having lived in current 
residence for one year or less (+). Longer duration of time since diagnosis was associated with 
increased odds of interrupted adherence. Compared to patients initially diagnosed with diabetes 
less than five years ago, those diagnosed between five and nine years ago were 3.03 (CI: 1.03-
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8.87) times more likely to report interrupted medication use (P=0.043). Patients diagnosed ten or 
more years ago had 3.59 (CI: 1.14-11.35) times higher odds of interruption compared to those 
diagnosed less than five years prior to the interview (P=0.030). Conversely, older age was 
associated with lower odds of interrupted adherence (OR: 0.92, CI: 0.87-0.98; P=0.011). Housing 
insecurity, defined as having lived in the current residence for one year or less, was also 
associated with higher odds of medication interruption (OR= 3.46, CI: 1.44-8.34, P=0.006).  
There was no statistically significant difference in adjusted odds of interrupted adherence 
to medication for type 2 diabetes by hypertension comorbidity, patient enrollment in the YMCA 
chronic medications program, knowledge of at least one complication of diabetes, sex, education 
level completed, or monthly household expenditures. 
Additional Contextual Factors and Considerations  
Quantitative results from this study indicate high levels of adherence in both Syrian 
refugee and Lebanese host populations, aligned with estimates from a 2018 evaluation of MSF’s 
NCD care program for Syrian refugees in Jordan.426 Qualitative evidence from the 
aforementioned evaluation however, in addition to program staff reports and documentation of 
medication shortages, availability concerns, and prohibitively high costs suggest that medication 
adherence is a particular challenge for Syrian refugee populations throughout the region with 
chronic health conditions managed with pharmacotherapy.93,475,476 
Through FGDs conducted with individuals and health care providers participating in the 
Treatment Guidelines study and anecdotal feedback, insights were obtained that in some areas 
reconcile prior reports of medication accessibility, availability, and affordability challenges in this 
context with the current study’s quantitative study findings. Many FGD participants, both Syrian 
and Lebanese, reported less than perfect adherence to medication prescribed for hypertension and 
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type 2 diabetes; however, the key insight from the qualitative data was that most often non-
adherence was reported for durations of less than two weeks at a time. A few participants 
discussed stopping medication for one week at a time and a small number acknowledged simply 
forgetting to take the medication from time-to-time. Most patients, however, described 
intentionally skipping or reducing individual doses to make filled prescriptions last longer, albeit 
potentially at sub-therapeutic levels, rather than stopping medication for more extended periods 
of time. This would not be detected in the single-question measure of adherence used in 
quantitative tools for this study, which classified adherence based on stopping medication for a 
period of two weeks or longer. These observations suggest specific refinements to enhance the 
utility of quantitative adherence measures for future research. 
Both Syrian refugees and Lebanese host community participants explained that they try 
to extend the time before refills in an effort to save on the cost of medication and also out of fear 
they would not be able to locate a pharmacy or health facility with medication in stock. When 
asked about the availability of medications prescribed for their conditions, participants’ responses 
varied by the specific medication they sought. For example, one Lebanese participant in the 
Bekaa reported that Insulin had not been available for the preceding four months, and that other 
medications had been unavailable for varying periods ranging from one month to one year. 
Across geographic locations and participant nationalities, even if some medication is available at 
times, the sporadic and unpredictable nature of availability was a prominent concern and a clear 
driver of taking medication less frequently than instructed. As one Lebanese participant in the 
Bekaa claimed, “90% of people would take meds if they were provided.” 
The trend of patients’ self-initiating modification of medication dosing was also raised by 
health care providers during FGDs, particularly in the South governorate. Physicians seemed 
aware of many patients skipping doses or otherwise not following instructions on how and when 
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to take prescribed medications, and of the challenge of inconsistent availability of multiple 
classes of drugs. Many, though not all, providers described efforts to prescribe medication, or a 
medication class, that would be available at the health center.  
In-house dispensaries at the ten health facilities included in this study varied in their size, 
capacity, staffing, sourcing, and reporting systems. Nonetheless, dispensing and stock-out reports 
from facility assessments conducted at the start of the study in late 2014 corroborate many of the 
medication availability challenges raised in FGDs with patients and providers. While some 
facilities maintain stock of all, or most, of the medications for hypertension and type 2 diabetes 
listed on Lebanon’s 2014 Essential Medicines List, many include only some of these medications 
on their formularies. For example, one of the smaller study facilities located in the Greater 
Beirut/Mount Lebanon region reported only carrying Metformin (Glucophage) and Amlodipine 
(Amlor). Other essential medications for these and co-occurring conditions include Gliclazide 
(Diamicron), Acenocoumarol (Sintrom), Amiodarone (Cordarone), Digoxin (Lanoxin), 
Hydrochlorothiazide (Esidrex), Molsidomine (Corvasal), and Valsartan (Diovan). These 
medicines either have never been procured or were not procured in the year preceding facility 
assessment at all three facilities in the South governorate. This may support the reported limited 
medication availability raised in FGDs, particularly in the South governorate. For example, 
patient health records indicated that 52.6% of enrolled patients with type 2 diabetes were 
prescribed Gliclazide (Diamicron) during the study period, despite the facility assessments’ 
indication this medication had never been purchased. At two larger health facilities in the Bekaa, 
Metformin (Glucophage) was prescribed for more than 65% of study patients with type 2 
diabetes; however, that medicine was reportedly out of stock for 15 and 35 days, respectively, in 
the three months prior to baseline facility assessments. In one of these facilities, Amlodipine 
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(Amlor), prescribed for nearly 30% of patients with hypertension was also reportedly out of stock 
for 15 days in the same three-month period.  
In FGDs, some physicians attributed skipped doses or interrupted medication adherence 
not only to financial reasons or medication availability, but also, or instead, to patients feeling 
well or “think[ing] they aren’t really sick.” In contrast to patient FGDs, much of the discussions 
with health providers focused on patients’ ability to understand instructions on how and when to 
take prescribed medication and patient knowledge of complications that may present if they do 
not correctly take medication. Patient illiteracy was reported by many physicians as a barrier to 
medication adherence. While some described approaches for mitigating the issue, including 
giving oral instructions and drawing symbols on medication packaging to demonstrate when it 
should be taken, accommodations were not discussed by all participating health providers.  
Providers also differed in their confidence in patients’ understanding of complications of 
their condition(s) and the consequences of not taking medication as prescribed. Many physicians 
and nurses did not think patients adequately understood the severity and range of consequences 
they may face as a result of not adequately caring for themselves or adhering to prescribed 
medications. Others felt that, as a physician in the South governorate explained, “some know the 
consequences, but neglect them.” Participants in FGDs with both Lebanese and Syrian refugee 
patients not only reported knowing the consequences of non-adherence, but in many cases named 
specific complications and described experience with these complications, either directly or as 
experienced by family members and neighbors.  
The divergence in emergent themes from FGDs with patients and those with providers 
may reflect providers’ focus on the elements perceived to be more within their ability to affect, 
while overlooking the potential role of factors further from their ability to control directly in the 
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patients’ brief visits, such as psychosocial factors. The range of influences to which healthcare 
providers attributed poor medication adherence among patients reflects the breadth of factors that 
have previously been shown to influence self-management behaviors, including medication 
adherence. Substantial evidence has demonstrated that there is generally no single factor driving a 
patients’ medication use, but rather a complex interplay among numerous domains including, but 
not limited to, medication affordability and availability; health literacy (including patients’ 
understanding of diagnosed conditions, the importance of adherence to prescribed medication(s), 
the consequences of non-adherence, and potential complications); patient-provider relationships; 
patients’ health beliefs; and psychosocial factors such as social support, psychological distress 
(particularly in the case of diabetes), and self-efficacy.225,276,324,331,338,342-345,379,381,382,384,478 
Patient knowledge measured by their ability to identify complications of hypertension 
and diabetes during phone interviews was comparatively low relative to the large proportion of 
FGD participants who demonstrated an understanding of the complications of non-adherence to 
prescribed medication (Table 7-4). During enrollment interviews, only 42.2% (CI: 29.9-55.2%) of 
patients who reported having stopped anti-hypertension medication use for two weeks or longer 
correctly identified stroke as a complication of hypertension, as compared to 64.5% (CI: 60.8-
68.2%) of patients who did not stop medication use in this period (P<0.001). Patients who did not 
stop diabetes medication also correctly identified a larger number of diabetes complications, on 
average, than patients reporting interrupted medication use (1.29 and 0.76, respectively; 
P=0.016). The proportion of patients with type 2 diabetes who were unable to identify any correct 
diabetes complications was larger among those who reported medication interruption (54.5%, CI: 
36.4-71.9%) than among those without interruption (36.9%, CI: 32.5-41.5%) (P=0.043), 
indicating a potential area for intervention in future attempts at improving adherence in these 
populations.  
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7.5. Discussion 
While multiple factors influence medication adherence among Syrian refugees in 
Lebanon, this study suggests that methods for capturing adherence/non-adherence have unstable 
reliability in this context. Nonetheless, these results indicate areas in which targeted interventions 
may reduce gaps in medication use for hypertension, type 2 diabetes, and potentially other 
chronic medical conditions requiring pharmacotherapy. Moreover, study results highlight specific 
methodological concerns that must be considered and addressed in future research and suggest 
substantive areas worthy of further study to strengthen evidence regarding factors influencing 
medication use and adherence in both Syrian refugee and host community populations in 
Lebanon.  
Implications and Recommendations for Intervention 
Among care-seekers at primary health facilities in this study, predictors of interrupted 
medication adherence were somewhat consistent between persons having hypertension and those 
with diabetes. For both hypertension and type 2 diabetes, older age and housing stability, defined 
as having lived in the current residence for longer than one year, were protective against 
interrupted adherence to prescribed medication. Previous studies have determined a clear link 
between housing stability and medication adherence for a number of chronic conditions.479-484 It is 
not apparent from the data what additional factors may be influencing this relationship, though 
conceptually this may be tied to socioeconomic factors or increased awareness of how and where 
to access subsidized care and medications when living in a single location for longer periods. To 
our knowledge, this is the first demonstration of the association between stable housing and 
adherence in a humanitarian setting, providing support for multi-sectoral intervention efforts 
moving forward. 
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Education attainment in this study was also associated with interruption of medication for 
hypertension but not for diabetes and not in the expected direction: higher education attainment 
(i.e. having completed primary education or higher as compared to some primary or no education 
completed) was associated with significantly higher odds of medication interruption. Evidence 
from the literature regarding the association between education attainment and adherence is 
mixed. Most previous studies were unable to confirm a significant relationship, while others 
demonstrated improvement in medication adherence with increased general education.318,329,485-488 
It may be that the analysis categories, which are logically based on the distribution in this 
population, are too broad to detect this difference and that the protective effect of education is 
only present at higher levels of education (e.g. secondary schooling and beyond). Further research 
is warranted to confirm and better understand the mechanism(s) for this association.  
Longer time since initial diagnosis was also associated with increased odds of interrupted 
medication adherence for diabetes, though not for hypertension. This association held despite 
tests of adjustment for the interaction between time since diagnosis and age, suggesting that the 
relationship is not simply an artifact of the association between age and medication adherence, 
which has been shown with mixed results in previous studies.289,293,320-322,324,325  
While further exploration is needed, gaps in medication adherence with longer duration 
of disease may be a consequence of the burden of managing glycemic control and the emotional 
toll of long-term threat of complications, indicating that diabetes distress could expresses itself as 
a cumulative function over time. This possibility, coupled with emergent themes during FGDs 
with patients and health providers suggest that ongoing efforts by local and international 
organizations to mitigate the challenges Syrian refugees with diabetes face in meeting health 
needs (e.g. provider training, patient education, and support) may benefit from taking diabetes 
distress into account. Diabetes distress is a condition involving the specific emotional response to 
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diabetes diagnosis and the associated burden and worries. Distinct from clinical depression, 
distress specifically related to diabetes influences not only behavioral indicators (e.g. diabetes 
self-efficacy, self-management behaviors, and overall quality of life), but also biological 
indicators (e.g. glycemic control).489 Diabetes distress is defined across four main domains: “(i) 
emotional burden (e.g., “feeling overwhelmed by the demands of living with diabetes”), (ii) 
physician-related distress (e.g., “feeling that my doctor doesn’t take my concerns seriously 
enough”), (iii) regimen-related distress (e.g., “feeling that I am not sticking closely enough to a 
good meal plan”), and diabetes-related interpersonal distress (e.g., “feeling that my friends/family 
don’t appreciate how difficult living with diabetes can be”)”.490,491 While diabetes distress and the 
aforementioned psychosocial factors were not measured in our studies, it is possible that 
comments by providers during FGDs about the tendency for some patients to ignore treatment 
instructions despite understanding the consequences of non-adherence may be driven by these 
factors or a combination thereof. The higher prevalence of interrupted medication adherence 
among Syrian refugees than among Lebanese, though certainly reflecting population differences 
in numerous variables, may also be mediated by increased psychological distress brought about 
since the start of the crisis in Syria and continuing as they navigate the challenges of finding their 
way in a new life in Lebanon. 
Diabetes distress can be integrated into existing programs in many ways, ranging from 
“acknowledgement, education and support that considers distress an expected part of diabetes” to 
formal problem solving training related to anticipating and addressing diabetes-related 
stressors.492 Adaptations of existing programs to accomplish this aim require minimal effort and 
funding, and in other settings, have shown to improve patient outcomes in various domains 
including self-efficacy, self-management behaviors, and ultimately blood pressure, HbA1C, and 
related clinical outcomes.490,493  
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Somewhat surprisingly, the odds for interrupted antihypertensive and antidiabetic 
medication use were not associated with hypertension/diabetes comorbidity, knowledge of stroke 
as a complication of hypertension/knowledge of at least one prominent complication of diabetes, 
patient sex, or monthly household expenditures. In addition to the findings discussed above that 
offer insight into potentially beneficial interventions, these and similar null findings, individually 
and collectively, can also guide the nature and focus of interventions to reduce interrupted 
medication adherence in this and similar contexts. 
FGDs conducted with individuals and health care providers participating in the Treatment 
Guidelines study revealed information that reconcile previous suppositions about medication non-
adherence and quantitative study findings. The central insight from FGDs is that non-adherence 
was most often reported for durations of less than two weeks at a time, highlighting the crucial 
shortcoming of quantitative measurement of adherence interruption for longer durations. While 
not counterintuitive, additional themes emerged in FGDs that support specific actionable 
programming interventions to reduce discontinuities in medication use for chronic medical 
conditions in which continuous high adherence to medication is essential to avoid serious 
secondary and tertiary consequences of the underlying disease. For example, limited patient 
understanding of the potential complications if these conditions are not properly managed and 
inconsistent availability of medication in accessible dispensaries. 
Though a causal relationship cannot be demonstrated, both quantitative and qualitative 
findings indicate a possible association between a patient’s knowledge of their pathological 
condition, particularly knowledge of possible complications or consequences of damage to the 
microvasculature, and medication adherence. General education is insufficient to influence 
adherence, condition-specific education is required. Potential strategies to employ could include 
contemporaneous patient health education and targeted health provider training. In particular, 
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increasing employment of community health workers (CHWs) and/or refugee outreach volunteers 
(ROVs) may provide an affordable approach for delivering not only health education, but also 
more continuous monitoring, care, and referral services, for Syrian refugees with chronic health 
conditions. Programs that make use of CHWs and ROVs for community-based implementation 
have shown promising results for improving chronic disease care among Syrian refugees and in 
numerous other contexts.494-502 ROVs are an extension of the CHW concept, where refugee 
volunteers are trained in a variety of areas to provide information and services to other refugees in 
their communities. Expansion of the ROV workforce in Lebanon to provide health education 
sessions and to assist other refugees in accessing essential services for chronic health conditions 
have the potential to provide an affordable solution to the challenges highlighted in this study. 
Given the expectation that the Syrian refugee population will remain in Lebanon for quite some 
time, such community-driven, cost conscious, and sustainable interventions are essential to 
improve health behaviors and access to health care. As an added benefit, ROV programs have 
proven to be beneficial both to refugees with chronic conditions and to UNHCR and 
implementing partners. ROVs provide them with a link to refugee communities, a better 
understanding of the communities they serve, and a sustainable presence to improve 
organizations’ reputation and legitimacy in refugee communities. Moreover, the sustainability of 
such programs is enhanced because they offer opportunities for refugees to “preserve and 
promote their dignity, self-esteem, and productive and creative potential.”503 
The discordance in patients’ understanding of complications and consequences related to 
their condition between discussions with patients themselves versus physicians and nurses also 
raises questions about what measures are in place to support and encourage health providers to 
properly education patients. Health providers’ reports of limited understanding among patients 
while patients directly reported not only knowledge of, but direct experience with consequences 
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of their condition(s) should be emphasized as it has meaningful operational implications. 
Activities to encourage physician compliance with guidelines, including sufficient patient 
education should be supported. 
While more research is needed to explore the context of medication availability, existing 
electronic record systems in many primary health facilities throughout Lebanon and/or the 
mHealth application tested in the parent study can be expanded to include medication stock on-
hand at facilities that include a dispensary. Linking patient health records, which should include 
data on prescribed medication(s), with dispensary stock has the potential to facilitate 
improvements in prescribing practices, communication to patients about stockouts at care 
facilities, and more strategic, informed procurement practices in cases where facilities have 
greater control over procurement. Inventory management systems separate from electronic patient 
records that have proven effective in other settings may also aide in improving stock 
communication and medication procurement in this context. This is particularly the case for 
facilities included in the YMCA program that generally have less control over procurement of 
medicines supplied through the program.504-509   
The factors shown in this study and previously noted to influence medication use among 
Syrian refugees and host Lebanese, such as cost concern, condition understanding, medication 
availability, and side effects, among others, are not unique to this context. Although they may be 
intensified as a result of strain on the Lebanese health system with increased demand from 
refugee patients, or exacerbated by household resource limitations following displacement, the 
reasons for poor adherence in this context follow similar patterns across economic systems. 
Extensive evidence supports the role these factors have in patients’ medication decision-making 
not just in Lebanon or the United States, but globally spanning varied health systems and social, 
cultural, and economic contexts.225,276,278,280,324,425,510   
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Suggested Further Research 
Results indicate a need for further investigation of medication availability and cost on the 
supply side at facilities, as well as on the demand side with patients. Out-of-pocket medication 
costs relative to patients’ self-declared sufficiency of resources would also be informative in 
guiding intervention refinements such as improving targeting criteria and identifying rates for 
subsidized medications reflective of beneficiaries’ means. 
The intermittent and variable nature of medication availability reported in FGDs elevates 
the need for supply-side research. Supply chain management is critical in all health systems, but 
particularly so in systems facing sudden increases in demand by a displaced population of this 
size. Results from FGDs indicate that availability of prescribed medications may be a substantial 
barrier to continued medication adherence; however, additional data is needed to support and 
better understand the factors that determine medication availability and the associated influence 
of availability on patient adherence to prescribed medication(s). A comprehensive assessment of 
pharmaceutical procurement, distribution, and use in health facilities serving large populations of 
Syrian refugees and vulnerable Lebanese is needed to most effectively improve and target current 
interventions. In the interim, training programs based on a systems model of medicine selection, 
procurement, distribution, and use can improve stock availability. Gap analyses can identify 
specific management skill needs and guide targeted educational interventions.511  
Methodological Implications 
The discordance between adherence reported during individual phone interviews with 
study participants and adherence described during FGDs is consistent with the limitation of using 
a single question measure of adherence. Single-item measures often capture only one type or 
stage of adherence, lack the ability to distinguish intentional from unintentional non-adherence, 
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and seldom provide information on reasons for non-adherence such as those raised by focus 
group discussion participants (fear of medication availability for future refills, undesirable side 
effects, and misunderstanding how and precisely why to take prescribed medication, etc.). 
Caution should be taken when interpreting adherence reports from previous studies in which such 
measures are used. Moving forward, efforts should be made to consider the nature of adherence 
captured by available instruments and to utilize measures with increased sensitivity to the 
relevant type(s) of non-adherence (i.e. sporadic versus long-term, intentional versus unintentional, 
etc.) in this and similar contexts.  
Future research in unstable or limited resource settings where the only feasible means of 
assessing medication adherence is through self-report should include more sensitive assessment 
characterized by the ability to capture and distinguish between the varied types of (e.g. more 
recent or shorter periods of non-adherence versus episodic non-adherence and missed or altered 
doses) and reasons for non-adherence. As demonstrated by this study and others with Syrian 
refugee populations in neighboring countries, mixed data collection methods including qualitative 
components can provide more nuanced results. These capture aspects and incidents of non-
adherence possibly missed be by quantitative instruments for individual self-report.426   
Established survey tools include many, but generally not all, of the factors identified in 
this study that influence medication adherence. While creation of a new, highly sensitive tool 
with the aforementioned characteristics would be ideal, taking into account the constraints of data 
collection in humanitarian settings, adapting an existing tool for greater context-specific 
sensitivity may sufficiently improve the quality of adherence measurement. When selecting 
survey instruments to capture medication adherence for future studies, researchers must consider 
the setting in which it will be implemented, the time available for administration, and the aim in 
measuring adherence. Adherence measures may focus on medication-taking behavior, barriers to 
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adherence, or a combination thereof. Some tools are better suited for clinical settings and research 
intended to improve adherence in individual patients than for quantifying population or group 
level adherence measures such as prevalence or informing higher level intervention. The time 
needed for respondents to complete a questionnaire confronts a trade-off with practical time 
limits in field settings. Respondent burden is critical as excessively detailed instruments may be a 
barrier to obtaining sufficient completed questionnaires. The length of and administration time for 
other instruments likely diminishes their practical utility if they are included in much larger 
interview questionnaires.  
Of the validated instruments available, the Adherence to Refills and Medications scale 
(ARMS) is among the best suited to capture the nature of non-adherence among Syrian refugees 
in Lebanon.265 The ARMS incorporates the four items included in the abbreviated MMAS, plus 
four additional items that evaluate how respondents take prescribed medication, including 
skipping and changing doses, which were among the most commonly reported types of non-
adherence raised during FGDs. Another four-item subscale of the ARMS assesses refill 
behaviors, providing granular and actionable information on patient behaviors that directly relate 
to concerns about medication availability that are not included in many other adherence scales.  
Questions in the ARMS are rated using Likert scale responses ranging from “none of the 
time” to “all of the time”, capturing less frequent behaviors that be missed with binary “yes/no” 
response options. Moreover, the scale includes explicit instruction and text to be read prior to 
administering the ARMS. This text is intended to calibrate the respondent and normalize 
adherence, thereby reducing bias in the individual responses. A separate version of the ARMS, 
revised to focus on adherence specific to medication for diabetes includes questions specific to 
insulin therapy and has been validated for use in diabetes-specific research.266 The ARMS is well-
suited for use with vulnerable and displaced populations in Lebanon, ideally with the addition of 
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a question to evaluate reasons for skipped doses and possible further adaptations based on pilot 
test in the field. The validity of the Hill-Bone Compliance to High Blood Pressure Therapy Scale 
(HB-HBP) or the Hill-Bone Medication Adherence Scale (HB-MAS) should also be explored in 
this context for possible use when a wider range of information about overall treatment adherence 
is needed.252-256      
Limitations 
As with all studies, the limitations of the parent studies (Chapter 4 and Appendix B) and 
present analysis must be considered when interpreting results. Differences in recall period will 
almost certainly influence the accuracy of adherence reporting. First, while the longer reference 
time period for having stopped medication use (i.e. six months preceding interview) may offer a 
general view of adherence, it also increases the potential for recall bias compared to shorter recall 
periods. While a shorter recall period may produce more reliable reporting, a longer period 
extends the time in which gaps in adherence could occur without being captured.512-517 
Additionally, the single question adherence measure focuses on capturing medication underuse; 
however, it did not capture other manners of non-compliance (e.g. improper dosage, timing, and 
overuse) nor mitigate occurrences of undetected non-adherence.  
Use of self-report to assess medication adherence is another potential limitation of this 
study. Over-reporting medication adherence via self-report is likely increased due to social 
desirability and recall biases. Use of refill counts or pharmacy fills were not feasible in the study 
context however, limiting the potential for a more accurate and/or comprehensive understanding 
of adherence.  
Other variables previously reported to be associated with adherence, such as specific 
comorbidities, severity of disease, generic versus brand-name medication use, perceptions and 
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beliefs related to diagnosed hypertension/diabetes, and other psychosocial factors, were not 
captured in data collection tools in the interest of maintaining a practical interview length. Thus, 
these variables were not available for the present analysis. Additionally, the parent study design 
precludes causal inference; results identify associations rather than directional causality. Finally, 
the relatively modest sample size, coupled with high overall reporting of adherence, limits the 
ability to detect weaker associations in both datasets.  
7.6. Conclusion 
In conclusion, this study demonstrates the shortcomings of single-measure methods of 
evaluating medication adherence among Syrian refugees and host communities in Lebanon. 
Conflicting reports of adherence during individual phone interviews with study participants and 
adherence described during FGDs is consistent with the limitations of a single question measure 
of adherence to capture sporadic, short-term non-adherence, as well as with the reasons for non-
adherence raised during FGDs. Utilizing multiple methods of data collection, including 
qualitative components, more effectively captures components and occurrences of non-adherence 
that can be missed by quantitative instruments for individual self-report. Alternatively, 
quantitative scales that include more specific content focused on the appropriate type of and 
contributors to non-adherence are likely to yield more reliable estimates of the prevalence of 
medication adherence in similar contexts.  
Results show an association between participation in subsidized medication programs, 
housing stability, and lower education attainment and a reduced risk of interrupted medication 
adherence. Knowledge of complications of hypertension and diabetes were also found to possibly 
influence adherence behaviors. Though further information is needed regarding medication 
availability and its influence on patient adherence to prescribed medication(s), these results, 
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coupled with emergent themes during FGDs with patients and health providers identify areas in 
which targeted interventions may reduce gaps in medication use.  
Effective interventions to improve medication adherence build on applied research, 
understanding patient and provider behaviors, and a systems model of pharmaceutical 
management. Suggested strategies from the present research include continued efforts to scale-up 
employment of CHWs and/or ROVs to provide health education, monitoring, care, and referral 
services to vulnerable populations in Lebanon; consideration of diabetes distress in ongoing 
programming; enhanced pharmaceutical inventory management utilizing electronic health records 
where available to link patient health records with dispensary stock; and physician training and 
support for prescribing practices that consider availability and cost. 
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Table 7-1. Enrolled Sample by Population Group and Diagnosed Condition(s) 
 Hypertension 
Only 
Type 2 Diabetes  
Only 
Hypertension & 
Type 2 Diabetes Total 
Syrian Refugees 325 (51%) 85 (13%) 227 (36%) 637 
Lebanese Host Community 129 (39%) 35 (11%) 166 (50%) 330 
Other Nationalities 16 (37%) 6 (14%) 21 (49%) 43 
Total  470 (47%) 126 (12%) 414 (41%) 1,010 
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Table 7-2. Hypertension and Type 2 Diabetes Medication Prescription and Adherence  
 HYPERTENSION DIABETES 








 (N=463) (N=248) (N=280) (N=188) 
  % (95% CI) % (95% CI) % (95% CI) % (95% CI) 
Medication Prescription     
Ever prescribed medication* 100 (99.2-100) 100 (98.5-100) 100 (98.7-100) 100 (98.1-100) 
Prescribed in Syria† 55.9 (51.3-60.5) -- -- 54.6 (48.6-60.6) -- -- 
Prescribed in Lebanon† 44.1 (39.5-48.7) -- -- 45.4 (39.4-51.4) -- -- 
  (n=462) (n=248) (n=280) (n=188) 
Currently taking medication 98.1 (96.3-99.1) 98.4 (95.9-99.6) 96.8 (94.0-98.5) 97.3 (93.9-99.1) 
 P = 0.751 P = 0.730 
Medication Adherence† (n=463) (n=248) (n=280) (n=188) 
Stopped taking medicines for 
2+ weeks in the past 6 months 13.2 (10.2-16.6) 2.0 (0.7-4.6) 10.0 (6.7-14.1) 2.7 (0.9-6.1) 
 P < 0.001 P = 0.002 
Stopped taking medicines for 
2+ weeks in the past 6 months 
against medical advice 
12.8 (9.9-16.2) 1.6 (0.4-4.1) 10.0 (6.7-14.1) 1.6 (0.3-4.6) 
 P < 0.001 P < 0.001 
When medication was 
stopped‡ (n=59) (n=0) (n=28) (n=0) 
Stopped taking in Syria 13.6 (6.0-25.0) -- -- 21.4 (8.3-41.0) -- -- 
Stopped in Lebanon 49.2 (35.9-62.5) -- -- 57.1 (37.2-75.5) -- -- 
Started in Lebanon but stopped 37.3 (25.0-50.9) -- -- 21.4 (8.3-41.0) -- -- 
Reason for stopping 
medication‡ (n=58) (n=4) (n=28) (n=3) 
HH could not afford medication 72.4 (59.1-83.3) 50.0 (6.8-93.2) 78.6 (59.0-91.7) 66.7 (9.4-99.2) 
Could not find pharmacy with 
the medication 8.6 (2.9-19.0) 0.0 -- 14.3 (4.0-32.7) 0.0 -- 
Symptoms improved/felt better  3.4 (0.4-11.9) 50.0 (6.8-93.2) 0.0 -- 0.0 -- 
Did not like available 
medications 5.2 (1.1-14.4) 0.0 -- 7.1 (0.9-23.5) 0.0 -- 
Did not know where to get the 
medication 5.2 (1.1-14.4) 0.0 -- 0.0 -- 0.0 -- 
Too far to travel to obtain 
medication 1.7 (0.0-9.2) 0.0 -- 0.0 -- 0.0 -- 
Other 3.4 (0.4-11.9) 0.0 -- 0.0 -- 33.3 (0.8-90.6) 
 P = 0.032 P = 0.018 
HH = household. P-value for group comparisons using Pearson's chi-square. Statistical significance indicated in bold 
(P<0.05) and bold italics (P<0.001). 
* As percent of patients with condition diagnosis 
† As percent of patients prescribed medication 
‡ As percent of patients that stopped taking medication in the past six months without instructions from a doctor 
 
 179  
 
Table 7-3. Odds of Interrupted Adherence to Medication for Hypertension and Type 2 
Diabetes Among Syrian Refugee Care-Seekers 
 
Crude Odds P-value Adjusted Odds P-value   OR (95% CI) OR (95% CI) 
HYPERTENSION 
Patient Characteristics     
Age 0.93 (0.90-0.96) <0.001 0.96 (0.93-0.99) 0.025 
Female 1.40 (0.75-2.61) 0.287 1.26 (0.60-2.62) 0.539 
Completed ≥ primary education 2.07 (1.18-3.61) 0.011 2.48 (1.26-4.88) 0.008 
Above median monthly HH 
expenditures* 0.70 (0.40-1.22) 0.206 0.97 (0.52-1.79) 0.913 
In current residence ≤ 1 year 2.59 (1.47-4.55) 0.001 2.70 (1.46-4.99) 0.001 
Clinical Characteristics     
Diabetes comorbidity 0.78 (0.44-1.40) 0.406 1.03 (0.54-1.95) 0.928 
Time since diagnosis (ref: < 5 years)     
5 - 9 years 1.04 (0.57-1.89) 0.909 1.12 (0.58-2.14) 0.734 
≥ 10 years 0.26 (0.11-0.65) 0.004 0.39 (0.15-1.03) 0.058 
Enrolled in YMCA program 0.31 (0.14-0.70) 0.005 0.35 (0.14-0.86) 0.023 
Knowledge of stroke as a 
complication of HT 0.48 (0.27-0.84) 0.010 0.53 (0.28-1.02) 0.058 
DIABETES 
Patient Characteristics     
Age 0.93 (0.88-0.98) 0.005 0.92 (0.87-0.98) 0.011 
Female 1.00 (0.43-2.31) 1.000 0.94 (0.35-2.51) 0.894 
Completed ≥ primary education 1.72 (0.77-3.85) 0.190 2.09 (0.78-5.59) 0.141 
Above median monthly HH 
expenditures* 1.52 (0.68-3.38) 0.304 1.86 (0.76-4.55) 0.172 
In current residence ≤ 1 year 3.11 (1.40-6.91) 0.005 3.46 (1.44-8.34) 0.006 
Clinical Characteristics     
HT comorbidity 1.00 (0.42-2.37) 1.000 1.52 (0.56-4.15) 0.412 
Time since diagnosis (ref: < 5 years)     
5 - 9 years 1.80 (0.68-4.80) 0.239 3.03 (1.03-8.87) 0.043 
≥ 10 years 1.58 (0.58-4.28) 0.374 3.59 (1.14-11.35) 0.030 
Enrolled in YMCA program 0.44 (0.15-1.32) 0.144 0.49 (0.14-1.73) 0.267 
Knowledge of ≥ 1 complication of 
diabetes† 0.58 (0.26-1.28) 0.177 0.41 (0.16-1.05) 0.064 
HH = household; HT = hypertension. Statistical significance indicated in bold (P<0.05) and bold italics (P<0.001). 
Interrupted medication adherence defined as having stopped medication for hypertension/diabetes for two weeks or longer 
in the past six months without instructions from a doctor 
* Relative to median monthly household expenditures reported by Syrian refugees 
† Able to identify at least one complication of diabetes, including eye problems, kidney problems, foot ulcers, and heart 
problems. Reference: not able to identify any complication. 
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Table 7-4. Knowledge of Possible Complications by Interrupted Adherence to Medication 
for Hypertension and Type 2 Diabetes Among Syrian Refugee and Lebanese Host 
Community Care-Seekers  
    Overall Interrupted Adherence 
Uninterrupted 
Adherence P-value 
    Point (95% CI) Point (95% CI) Point (95% CI) 
HYPERTENSION 
Identification of HT 
complications* 
(n=735) (n=64) (n=671) 
 
Stroke 59.0% (55.6-62.3%) 42.2% (29.9-55.2%) 64.5% (60.8-68.2%) <0.001 
None/No risk factors 1.8% (1.1-3.0%) 1.6% (0.0-8.4%) 0.4% (0.1-1.3%) 0.247 
Don't know 8.2% (6.5-10.2%) 28.1% (17.6-40.8%) 6.3% (4.5-8.4%) <0.001 
Other 30.9% (27.9-34.1%) 28.1% (17.6-40.8%) 28.8% (25.4-32.4%) 0.914 
DIABETES 
Identification of specific 
diabetes complications† 
(n=491) (n=33) (n=458) 
 
    
Eye Problems 47.2% (42.9-51.6%) 36.4% (20.4-54.9%) 49.3% (44.7-54.0%) 0.150 
Kidney Problems 31.3% (27.4-35.5%) 18.2% (7.0-35.5%) 31.9% (27.6-36.4%) 0.100 
Foot Ulcers 28.1% (24.3-32.1%) 6.1% (0.7-20.2%) 31.0% (26.8-35.5%) 0.002 
Heart Problems 15.9% (12.9-19.3%) 15.2% (5.1-31.9%) 16.8% (13.5-20.6%) 0.805 
No complications 3.2% (1.9-5.1%) 0.0% (0.0-10.6%) 1.3% (0.5-2.8%) 0.508 
Don't know 28.1% (24.3-32.1%) 33.3% (18.0-51.8%) 27.3% (23.3-31.6%) 0.454 
Number of correctly 
identified complications‡ 
    
Cannot identify any 
complications 39.8% (35.6-44.2%) 54.5% (36.4-71.9%) 36.9% (32.5-41.5%) 0.043 
Identifies 1-2 
complications 44.2% (39.9-48.6%) 42.4% (25.5-60.8%) 46.3% (41.6-51.0%) 
 
Identifies 3+ 
complications 15.9% (12.9-19.3%) 3.0% (0.1-15.8%) 16.8% (13.5-20.6%) 
 
Mean number of 
complications identified 1.22 (1.12-1.33) 0.76 (0.40-1.11) 1.29 (1.18-1.40) 0.016 
Point = point estimate (proportion, mean, or median); HT = hypertension 
Group comparison using Pearson's chi-square. Statistical significance indicated in bold (P<0.05) and bold italics (P<0.001). 
* As percent of patients with hypertension diagnosis 
† Each item as percent of all patients with type 2 diabetes diagnosis able to correctly identify the complication  
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Chapter 8.  Conclusions 
 
The aims of this dissertation were to assess healthcare utilization and medication 
adherence for hypertension and type 2 diabetes among Syrian refugees and host communities in 
Lebanon, and to identify factors associated with care-seeking and medication adherence for these 
conditions among refugees. Paper 1 assessed care-seeking and medication adherence at the 
population level. Papers 2 and 3 examined healthcare utilization and medication adherence, 
respectively, in greater depth among care-seekers at select primary level health facilities, thus 
eliminating questions about initial contact with the health system. Together, these papers reveal 
overall high levels of care-seeking and medication adherence for hypertension and diabetes in 
both refugee and host populations. However, they identify important differences in these 
behaviors between Syrian refugees and host communities. The findings highlight opportunities of 
focus for improving refugee and Lebanese host community health service utilization and 
adherence to medication for hypertension and type 2 diabetes. 
8.1. Summary of Results 
Overall Trends 
Care Utilization and Costs 
Focusing on hypertension and diabetes, Paper 1 demonstrates high care-seeking overall 
at the population level for both refugees and host community members, with more than half 
reporting that they received care for these conditions in the preceding three months. Despite 
overall high care-seeking in both populations, host community cases of hypertension and diabetes 
were more likely to seek care than refugees, and to have done so within the past six months. Cost 
was a priority motivator for refugees’ care-seeking decisions. Conversely, host community cases 
 
 182  
 
primarily utilized private clinics, citing perceived quality of care/continuity of care from the 
family doctor(s) as their predominant motivation for doing so. Greater overall care-seeking and 
out-of-pocket spending were significantly higher in the host community than among refugees, 
reflecting the host community’s greater use of private sector facilities, differential financial 
support available to the two groups, and potentially, varying financial resources for affording 
care.  
The majority of refugee and host community care-seekers incurred out-of-pocket cost for 
their most recent hypertension/diabetes care visit. The average reported consultation costs among 
refugees who received care at primary level health facilities exceed the standard subsidized cost 
of US$2 – US$3. The large proportion of primary level care-seekers reporting costs above the 
standard subsidized rate likely indicates care being sought at facilities outside the Ministry of 
Public Health’s (MoPH) primary healthcare center (PHCC) network or not supported by the 
United Nations High Commissioner for Refugees (UNHCR) or non-governmental organizations 
(NGOs). 
Paper 2 also provides evidence that hospitalization was uncommon for either condition, 
but that care utilization was consistently high among patients who had sought care at select 
primary level health facilities at least one time in the six months preceding study enrollment. 
Although general practitioner (GP) and specialist care are more accessible in Lebanon than in 
nearly any other humanitarian setting, findings from focus group discussions (FGDs) with 
patients and providers revealed that many patients make health facility follow-up visits solely to 
obtain prescribed medication refills. Patient FGD participants reported problems with facilities 
having stockouts and did not see the value in visiting a doctor if medication is not available at the 
health facility. Additional uncertainty about the quality of care at primary level facilities was 
revealed in provider FGDs where GPs also raised concerns about the limits of their training and 
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ability to treat patients with hypertension and/or diabetes. For both hypertension and diabetes, 
refugees were more likely to seek care from GPs and report more frequent GP visits while 
Lebanese patients tended to rely more on specialists’ care (cardiologist for both hypertension and 
diabetes, and endocrinologist for diabetes). 
Medication Prescription and Adherence Interruption 
Evidence from Paper 1 demonstrates that nearly all hypertension and diabetes cases had 
been prescribed medication for their condition and of those patients, few reported having stopped 
medication for two weeks or longer in the preceding year. When there was an interruption, cost 
was the primary reason among both population groups and both conditions, which confirms the 
role of financial burden in healthcare decisions.  
Paper 3 contained relatively low rates of reported interrupted medication adherence 
among Syrian refugee and host community patients for both hypertension and type 2 diabetes. 
However, the actual rates may be higher since qualitative findings indicated that non-adherence 
was often reported for individual doses or a few days at a time, far shorter durations than the two 
weeks or longer specified in the question used to quantify adherence. This reveals a fundamental 
weakness of quantitative measurement of adherence interruption for longer timespans. Additional 
qualitative findings include unreliable availability of medication in accessible dispensaries, and 
discordance in patient-provider understanding of complications and consequences related to these 
conditions. 
Results from Paper 1 also identified higher incidence of interrupted medication use (i.e., 
stopping for two weeks or longer) among refugees than among host community cases. For both 
hypertension and diabetes, interrupted medication use was reported by more than one-quarter of 
refugees, which is more than three times the interruption rate reported by host community cases. 
 
 184  
 
This disparity also held in Paper 3, showing that among patients who had visited a primary 
health facility in the preceding six months, a substantially smaller proportion of host community 
patients reported interrupted medication adherence as compared to refugees. 
Characteristics Associated with Care-Seeking and Interrupted Medication Use 
Few household level predictors of care-seeking or interrupted medication adherence were 
identified among refugees in Paper 1. Care-seeking for hypertension in the preceding three 
months, the only individual level variable retained in its regression analyses, was among the few 
factors significantly associated with the [decreased] odds of interrupted medication adherence 
among hypertension cases. The otherwise null findings illustrate the pitfalls of assuming the 
impact of household characteristics on individual members’ care-seeking and medication use. 
In Paper 2, negative binomial hurdle regression analyses revealed several individual 
level characteristics associated with utilization of GP and specialist care for hypertension and 
type 2 diabetes, and of the number of GP and specialist visits conditioned upon having any care 
visits in the preceding six months. Paper 3 similarly identified individual patient level factors 
associated with interrupted adherence to medication for these conditions. Papers 2 and 3 showed 
that older age and having lived in their current residence for more than one year were associated 
with higher care-seeking and lower odds of interrupted medication adherence among patients 
with type 2 diabetes. While longer time in their current residence was also associated with higher 
care-seeking and decreased odds of medication interruption among patients with hypertension, 
associations between patient characteristics and health behaviors were less consistent for 
hypertension. For example, for patients with hypertension, older age was associated with 
decreased odds of specialist care-seeking but increased number of GP care visits and decreased 
odds of interrupted medication adherence. Conversely, having completed at least primary 
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education was predictive of increased odds of GP care-seeking, and increased odds of interrupted 
adherence to medication. Enrollment in the Young Men’s Christian Association (YMCA) 
medication program was associated with decreased odds of interrupted medication adherence, yet 
lower number of GP visits for hypertension.  
Although not statistically significant in regression analyses, descriptive and qualitative 
findings suggest that knowledge of available services at subsidized rates likely influence refugees 
delaying or not seeking care for hypertension and diabetes, and that knowledge of complications 
of hypertension and diabetes may improve adherence behaviors. 
8.2. Strengths and Limitations 
A key strength of this dissertation is that it provides an assessment of care-seeking and 
health behaviors from a multi-level perspective: first, by understanding larger trends at the 
population level (Paper 1), then by focusing at the individual level (Papers 2 and 3) to understand 
challenges facing patients after they initiate care in Lebanon. Papers 2 and 3 study individuals 
seeking care in a sample of health facilities, which limits representativeness to the subset of the 
population while providing important information about barriers to continued care This 
dissertation is also limited by its use of data collected four years prior to publication. This may 
have implications on the relevance of findings given subsequent changes in the context and the 
introduction of new projects. However, most programmatic changes have been relatively small-
scale and meeting the needs of Syrian refugees and vulnerable host communities remains an 
immense challenge. 
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8.3. Programming Recommendations 
1. Increase refugee knowledge of services available to them and how these services can be 
accessed through continued communication efforts  
Continued communication efforts are recommended to increase refugees’ understanding 
of accessible support and improve utilization of affordable care. Refugees’ difficulty 
distinguishing between PHCCs in the MoPH network, primary care facilities supported by 
UNHCR or NGOs, and private clinics, combined with reports of seeking care at private clinics 
for cost-related reasons suggest inadequate awareness of the support available to them and where 
and how it can be accessed. Confusion or limited knowledge of subsidized health services and 
medication may play a role in cost being the predominant reason for refugees’ delaying or 
avoiding care-seeking. The existence of this knowledge gap is also supported by UNHCR’s 
annual Health Access and Utilization Survey (HAUS), which found that in 2014, immediately 
prior to the time of data collection for this dissertation, just over half of refugees knew they could 
access consultations at PHCCs for approximately US$2-US$ and fewer than one-quarter were 
aware that medication for chronic conditions is available for approximately US$0.66.71 
Communication efforts have improved  refugees’ knowledge of available health services and 
associated costs, but in the 2018 HAUS, 40% of refugees still were not aware of subsidized 
consultation costs.432  These efforts should be expanded to facilitate refugees’ ability to locate and 
access nearby health facilities offering subsidized services, minimizing the impact of geographic 
access and cost on delayed or avoided care-seeking. 
2. Facilitate standard, predictable costs to patients through alternative payment 
arrangements such as bundled service packages or a flat fee model 
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Findings from this dissertation demonstrate a need for minimal and predictable out-of-
pocket payments for health services. Lebanon’s fragmented health system generates wide 
variations in base costs for services, especially diagnostic testing, across facilities. These 
variations contribute to patients’ misunderstanding of cost and interferes with their ability to 
predict out-of-pocket costs prior to seeking care. One consequence of unpredictable costs is 
delayed or avoided care-seeking by patients with limited financial resources. Such deferred care-
seeking may be prevented by providing bundled services at predetermined rates, and effectively 
communicating them to refugees and vulnerable Lebanese prior to their seeking care.  
A 2017 stakeholder acceptability study conducted in Lebanon showed strong public and 
civil society sector support for a health benefits package and numerous ongoing projects such as 
the Emergency Primary Healthcare Restoration Project (EPHRP) and Reducing Economic 
Barriers to Accessing Health Services in Lebanon (REBAHS) are currently piloting alternative 
approaches to out-of-pocket costs, including a subsidized essential healthcare package and a flat 
fee capitation approach.418,419,518 Pending outcome results and feasibility analyses, these 
approaches should be considered for implementation at scale to mitigate the consequences of 
current unpredictable fee schedules across facilities. 
3. Improve quality of care for hypertension and diabetes through large-scale training of 
health providers, particularly GPs, on treatment standards and guidelines, integration 
of collaborative care models, and improved referral system(s) 
Universal delivery of quality care for hypertension and diabetes in Lebanon is hindered 
by provider knowledge and adherence to standard treatment guidelines, public-private sector and 
specialist-generalist physician divides, and discontinuity of care across the health sector. Many 
GPs in primary level health facilities rely on specialist referrals to manage patients with 
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hypertension and diabetes, impeding efficient long-term management of these conditions. 
Increased GP capacity to treat patients with hypertension and diabetes is critical to provision of 
affordable, quality care to refugees and other vulnerable populations in Lebanon. Programs such 
as the MoPH’s initiative for cardiovascular services in the national PHCC network and the 
EPHRP can provide useful experience and lessons regarding the feasibility, implementation, and 
overall effectiveness of healthcare provider capacity building. Improvements based upon these 
experiences and expanding targeted clinical training for primary level health workers is 
recommended to improve the quality of patient care for better health outcomes. 
In addition, integration of a collaborative care approach within and between health 
facilities could further benefit care quality, cost, and long-term control of chronic health 
conditions. Collaborative care approaches have already proved advantageous in Lebanon, with 
notable benefits stemming from increased communication and partnership between general and 
specialist physicians and from overall intra-facility cooperation.470 Expansion of referral system 
linkages between facilities in the MoPH-PHCC network with public hospitals to include facilities 
throughout the Lebanese health system would enhance the continuity of care required for 
managing chronic conditions.  
4. Scale up CHW and ROV use to provide health education, monitoring, care, and referral 
services to vulnerable populations 
Increased use of community health workers (CHWs) and/or refugee outreach volunteers 
(ROVs) via a range of activities including health education and awareness raising, basic condition 
monitoring, and referral to relevant higher-level care providers when appropriate can leverage 
investments and contribute to realizing Lebanon’s health system goals. Community-driven, cost 
effective, and sustainable interventions are essential in this context in view of the expectation that 
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Syrian refugees will remain in Lebanon for the foreseeable future. Community-based 
interventions that employ CHWs and ROVs have shown great potential for improving chronic 
disease care in Lebanon as well as other humanitarian and development contexts.494-502 Expanding 
current use of CHWs and ROVs to provide health education, more continuous monitoring, basic 
care, and service referrals for Syrian refugees and vulnerable Lebanese with chronic health 
conditions address impediments to long-term control of hypertension and diabetes. 
8.4. Recommendations for Future Research 
Findings from this research suggest that quantitative self-reported medication adherence 
measures have unstable reliability among Syrian refugees and vulnerable populations in Lebanon. 
Conflicting reports of adherence during individual patient phone interviews and adherence 
disclosed during FGDs demonstrate the limitations of evaluating medication adherence with 
single-question measures. Adherence reports from previous research in which such measures are 
used should be interpreted with caution given these methodological differences and shortcomings.  
Future research in unstable or limited resource settings should utilize more sensitive 
instruments distinguished by the ability to capture and differentiate between types of non-
adherence (e.g., non-fulfillment, shorter periods of non-adherence, and episodic non-confirming 
including skipped/missed or altered doses). In the context of displaced and vulnerable populations 
in Lebanon, most previously validated adherence measures do not sufficiently evaluate the 
reasons for non-adherence, such as those conveyed by FGD participants, which included fear of 
medication availability for future refills, undesirable side effects, and misunderstanding how and 
why to take prescribed medications. Of the available instruments validated for assessing multiple 
chronic conditions, the Adherence to Refills and Medications scale (ARMS) is likely to provide 
actionable evidence of the contributors to non-adherence among Syrian refugees in Lebanon, 
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though its 14-question length requires adaptation and further testing for feasible use outside of 
studies focused exclusively on chronic conditions to minimize administration time.265 The Hill-
Bone Compliance to High Blood Pressure Therapy Scale (HB-HBP) and the Hill-Bone 
Medication Adherence Scale (HB-MAS) are also worth exploring within this context; however, 
with 14 and 9 items, respectively, these scales require similar administration time and the HB-
HBP’s focus on hypertension hinder its utility for more general use.252-256 This research and 
previous studies with Syrian refugees in neighboring countries also indicate the substantial 
benefit of mixed-methods approaches, which provide a deeper understanding of the context-
specific nuances motivating and characterizing medication adherence and related health 
behaviors. Given the difficulties in accurately quantifying medication adherence, triangulating 
data from multiple sources, including qualitative data, is recommended to reduce the risk of 
mischaracterizing results.426 
Findings from this dissertation suggest several areas to be explored in future research. 
While relatively high care utilization rates were identified, uncertainties about whether this 
represents rational use of the various types of healthcare providers remain. Frequent specialist 
care-seeking may in some cases be appropriate, representing patients who receive care 
commensurate to the complexity of their condition, the presence of complications, and/or overall 
condition control. In other patients, however, it may be unnecessary, more costly, and an 
unnecessary use of specialty resources when GP care could be appropriate.  
There is little documented evidence concerning the quality of care provided for 
hypertension and diabetes at primary level facilities. What constitutes rational use of generalist 
versus specialist care is dependent upon an understanding of the extent and quality of care 
provided by each type of provider. It will also be influenced by their relative cost and 
productivity within overall health sector service demands, as well as financial and personnel 
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constraints. Future research examining rational provider utilization and dimensions of quality care 
at primary level facilities is needed to most effectively plan and deliver interventions. Targeted 
research should investigate and assess both Syrian and Lebanese patients’ perceptions and beliefs 
regarding generalist versus specialist care for these conditions and, in turn, whether GP capacity 
building could be a viable near-term improvement. 
These study results also indicate a need for further investigation of service/commodity 
availability and cost on the supply side at facilities, as well as on the demand side with patients. 
Questions remain about the nature of medication availability, resilience of medications’ supply 
chain, and accessibility of specialist care at primary level facilities. 
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Appendix A. Household Survey of Syrian Refugee Health Status and Access to 
Care in Lebanon: Survey Design and Implementation Methods 
 
A survey of Syrian refugees and Lebanese host communities was conducted in March 
and April 2015 to characterize health-seeking behaviors and health service access. A cluster 
design with probability proportional to size sampling was used to attain a nationally 
representative sample of Syrian refugees living outside of camps. The planned sample was 
increased from the minimum identified size of 900 refugee households to 1400 refugee 
households and 700 Lebanese host community households to provide increased precision of point 
estimates and additional power.  
Sample Size Calculations 
Sample size calculations were based on the study objectives of assessing health status and 
access to health care among Syrian refugees and host communities in the region. A moderate 
level of precision in point estimates was required given that the primary purpose of the study was 
to inform humanitarian programming. Given this and the challenges of data collection in urban 
Syrian refugee populations, a modest sample size was identified. The sample size calculations 
were based on the most conservative prevalence of 50% and assumed 80% power (1-β) and a 
design effect of 2.0 to account for a cluster sample design. The minimum and maximum planned 
sample sizes were increased to account for a 10% non-response rate and the possibility of 
incomplete reporting. The minimum sample size identified was 900 Syrian refugee households, 
which would allow for the characterization of prevalence rates for health access and status with 
±5% precision. Increased precision of point estimates and additional power for comparisons 
between registered and unregistered Syrian refugees, Syrian refugees in different sub-national 
regions, and between Syrian refugee and host community households were considered desirable 
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and a decision was made to increase the sample size. Data collection was planned for 1,400 
Syrian refugee households and 700 host Lebanese households (2:1 ratio of refugee vs. host 
communities) with a final target sample of 2,100 households. The planned sample size was 
sufficient to allow for the detection of differences greater than 11% between Syrian refugees in 
different regions and differences greater than 8% between Syrian refugee and Lebanese host 
community households for dichotomous variables. 
Sample Design 
A multi-stage cluster survey design with probability proportional to size (PPS) sampling 
was used to attain a nationally representative sample. A 100 cluster x 21 household (14 Syrian 
refugee households and 7 host Lebanese households per cluster) design was chosen due to the 
relatively low costs for visiting many locations given the small geographic size of Lebanon and 
the concentration of the Syrian refugee population. PPS sampling was used to assign the number 
clusters to sub-districts using United Nations High Commissioner for Refugees (UNHCR) 
registration data, assuming that non-registered Syrian refugees had similar housing patterns as 
those registered with UNHCR. Lebanese host community households were sampled using a 
neighborhood approach (i.e., households were selected based on proximity to included Syrian 
households) so that the sample reflected Lebanese households from communities most affected 
by the influx of Syrian refugees. It is important to note that sample of Lebanese host community 
households was not designed to be nationally representative of the Lebanese population as a 
whole, but rather as representative of communities whose health services access was most likely 
to be affected by the crisis. 
A multi-stage cluster design was used: clusters were first allocated by governorate, then 
by district, and then by cadastral (similar to municipality and the lowest level administrative unit 
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where UNHCR registration data was available). An overview of the registered Syrian refugee 
population and the final cluster allocation by governorate is summarized in Supplementary Table 
A-1, A-2, and A-3. The original sample was planned using the UNHCR registered population and 
assumed that all cadastrals were accessible.  
The research team was unable to attain permission to conduct the survey in certain 
security sensitive areas as planned, which necessitated a re-draw of 28 clusters that were 
originally assigned to 22 inaccessible cadastrals. Clusters were re-assigned using PPS sampling 
methods based on a revised population of accessible areas. Supplementary Figure A-1 presents 
the administrative units that were accessible and included in the survey. Detailed information on 
the UNHCR registered population, cluster allocation, and sampling by cadastral are presented in 
Supplementary Figures A-2 and A-3. The final sample encompassed all five governorates, 18 of 
26 districts, and 76 of 126 cadastrals; according to UNHCR registration data used for survey 
planning, 52.8% of registered refugees resided in cadastrals included in the survey coverage area 
(inclusive of two clusters in two cadastrals in the South which were later excluded from the 
analysis). 
ArcGIS software was used to randomly allocate cluster start points within cadastrals. 
Coordinates in populated areas were used and the nearest intersection to the start point, usually 
within a half kilometer, was used as the starting survey location. Teams were provided with 
coordinates and satellite imagery maps and were instructed to navigate to start points using 
mapping software such as Google Maps. At the start location, interviewer pairs were sent in 
different directions to locate households; they approached the nearest business likely to be used 
by refugees and asked to be referred to nearby Syrian households. Other key informants, notably 
community residents, were used when there were no nearby shops. Verbal informed consent was 
sought at the beginning of the interview; only consenting households proceeded with interviews. 
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When interviewers reached a household that consented to participate, the first interview in the 
cluster was conducted; upon completion, respondents were asked for a referral or introduction to 
the nearest Syrian household. This referral process was used until 14 Syrian refugee interviews 
were completed. Following every two interviews completed with Syrian refugee households, the 
nearest Lebanese household was approached to complete an interview. To improve 
representativeness and geographic coverage of the sample, no more than three households within 
the same apartment building were included.  
To sample informal settlements, the team estimated the settlement’s overall size and area 
by walking transects and/or the perimeter. When necessary, the settlement was divided into sub-
areas of similar size that were assigned to different interviewers. Interviewers located the middle 
of the settlement/area, spun a pen to select a direction randomly, and then walked in the indicated 
direction counting the number of shelters passed before reaching the edge of the settlement/area. 
A randomly selected number between one and the total number of shelters passed was used to 
identify the starting household. This process was repeated until the necessary number of 
interviews was complete; referrals were not requested in informal settlements to reduce the 
potential for bias.  
Only Syrian households arriving in Lebanon in 2011 or later were eligible to participate, 
as the aim was to capture the experiences of those displaced by the conflict, so the one 
approached household that arrived in Lebanon before 2011 was not included in the analysis. 
Families with both Lebanese and Syrian members were considered Syrian refugees if they arrived 
in Lebanon in 2011 or later and lived in Syria before this time; families who had never lived in 
Syria were considered Lebanese host community households for the survey.  
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Questionnaire Design 
The questionnaire was initially developed for use in Jordan by consensus between the 
World Health Organization (WHO), UNHCR, and Johns Hopkins Bloomberg School of Public 
Health (JHSPH) with the aim of providing a comprehensive assessment of the health of Syrian 
refugees to inform humanitarian assistance planning at local, national and regional levels. To the 
extent possible, existing content from WHO surveys, UNHCR assessments, and other surveys of 
Syrian refugee populations were adapted for use to improve the validity of the tool and 
comparability of results. The Jordan questionnaire was adapted to the Lebanese context by 
consensus between JHSPH, Médecins du Monde (MdM), International Medical Corps, UNHCR, 
and European Civil Protection and Humanitarian Aid Operations (ECHO). Arabic translation of 
the Jordan questionnaire was adapted for Lebanon and a formal pilot test conducted before 
implementation in Lebanon. The final questionnaire focused on four key domains: health service 
utilization, access and barriers to care, children’s health, and non-communicable diseases 
(NCDs).  
To obtain information on access to health services and medications for NCDs, 
respondents were asked about the five conditions reported to be most common among the Syrian 
refugee population in Lebanon: hypertension, cardiovascular disease (including heart failure, 
angina, arrhythmias/irregular heartbeats, a previous heart attack, or previous stroke), diabetes, 
chronic respiratory diseases (including asthma, chronic bronchitis, emphysema, and chronic 
obstructive pulmonary disease), and arthritis.72,519 Diagnosis was self-reported; no documentation 
was required to verify reported conditions. Respondents were asked a series of questions about 
each of these conditions, beginning with the number of people in the household diagnosed with 
the condition organized into four age groups: 17 years and under, 18–39 years, 40–59 years, and 
60 years and over. A series of questions regarding care-seeking, access, and utilization of health 
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services were asked about the experiences of one randomly selected household member who had 
been diagnosed with each of the five conditions. If more than one person in the household had the 
same condition, the person whose birthday was closest to the date of the interview was asked the 
series of questions about care-seeking.  
Survey Implementation 
The survey was conducted by faculty at JHSPH, MdM staff, and hired Lebanese 
interviewers. Interviewers received two days of classroom training that focused on the 
questionnaire, e-data collection, interview techniques, basic principles of human subjects’ 
protections, and sampling, after which two additional days of practical field training were 
completed. To protect the anonymity of respondents, no unique identifiers were recorded, and 
verbal consent was obtained.  
Data were collected electronically on tablets using the Magpi mobile data platform by 
DataDyne LLC (Washington, DC) between March 12 and April 15, 2015 by three teams 
supervised by study team members from MdM and the JHSPH Field Coordinator. Interviews 
were conducted with either the head of household or the caretaker/health decision maker. The 
household head was prioritized as the respondent for some sections of the questionnaire; 
however, questions about hospitalizations and chronic diseases were asked directly to the 
afflicted individual selected, if that person was available, or, if not, another household member 
familiar with the person’s condition or hospitalization. If households were encountered that were 
child-headed or had a child caretaker/health decision maker, the individual was interviewed so 
that this vulnerable population sub-group was not excluded. Because these individuals are acting 
as adults, the same informed consent process was used as in other households. If no one was 
home in an identified household, a second referral from the previously interviewed household 
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was approached. If no interview could be conducted due to the absence of an appropriate 
household decision maker, refusal to participate, or if the household was already interviewed, this 
household was recorded with the appropriate reason for not completing an interview and referral 
to another Syrian household was requested. Interviews lasted an average of 40 minutes and 
typically ranged from 30 to 60 minutes depending on the household size, number of children, and 
number of individuals with chronic medical conditions.  
JHSPH and MdM study team members actively supervised interviewers in the field to 
ensure adherence to data collection procedures and data quality standards. Team leaders reviewed 
all data records for completion and quality before uploading them to Magpi and leaving the 
cluster location. Data quality control included daily uploads from the tablets and overnight quality 
control reviews by the JHSPH field coordinator, with next day feedback to the on-site team for 
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Supplementary Table A- 1. Initial Cluster Allocation by Governorate, District, and 
Cadastral 







Beirut       3 3 
  Beirut Bachoura 0.7% 1 (1%) 1 
Mazraa 1.1% 1 (1%) 1 
Moussaytbeh 0.3% 1 (1%) 1 
Bekaa       35 24 
  Baalbek Al-Nabi Chite 0.3% 1 (1%) 0 
  
 
Al-Qa El-Benjakie 0.9% 1 (1%) 1 
  
 
Arsale 3.6% 4 (4%) 0 
  
 
Baalbek 2.0% 2 (2%) 0 
  
 
Bednayel 0.3% 1 (1%) 0 
  
 
Brital 0.6% 1 (1%) 0 
  
 
Douress 0.3% 1 (1%) 0 
  El-Hermel Hermel 0.5% 1 (1%) 0 
  Rachaya Dahr El-Ahmar 0.2% 1 (1%) 1 
  West Bekaa Al-Marje 1.3% 1 (1%) 1 
  
 
Al-Sawireh 0.5% 1 (1%) 1 
  
 
El-Karaoun 0.3% 1 (1%) 1 
  
 
Ghazzeh 1.2% 1 (1%) 1 
  
 
Haouche-el-Harimeh 0.4% 1 (1%) 1 
  
 
Jib Jehnine 0.7% 1 (1%) 1 
  Zahle Bar-Elias 3.0% 3 (3%) 3 
  
 
Chtaura 0.4% 1 (1%) 1 
  
 
Delhamieh 0.5% 1 (1%) 1 
  
 
Jditah 0.3% 1 (1%) 1 
  
 
Kab Elias 2.4% 2 (2%) 2 
  
 
Kfar Zabed 0.9% 1 (1%) 1 
  
 
Maallaka (Terres) 0.5% 1 (1%) 1 
  
 
Mejdel-Anjar 1.5% 1 (1%) 1 
  
 
Rayak 0.6% 1 (1%) 1 
  
 
Saeid Neil 1.4% 1 (1%) 1 
  
 
Talabaya 1.0% 1 (1%) 1 
  
 
Zahleh Maallaka Kerek 0.5% 1 (1%) 1 
  
 
Zahleh Midan 1.3% 1 (1%) 1 
Mt. Lebanon       24 18 
  Aley Aley 0.6% 1 (1%) 2 
  
 
Aramoun 0.9% 1 (1%) 1 
  
 
Chouaifat Amroussyat 1.7% 2 (2%) 2 
  
 
Chouaifat Qobbat 0.5% 1 (1%) 1 
  Baabda Borge el Baragenat 2.1% 2 (2%) 0 
  
 
Chiah 4.4% 4 (4%) 1 
  
 
Haret Horaeik 0.4% 1 (1%) 0 
  
 
Laylaki 0.3% 1 (1%) 0 
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Supplementary Table A- 1 (continued) 







  Chouf Barja 0.7% 1 (1%) 1 
  
 
Chehime 0.5% 1 (1%) 1 
  
 
Damour 0.3% 1 (1%) 1 
  
 
El Jiyeh 0.2% 1 (1%) 1 
    Naamat 0.5% 1 (1%) 1 
  El Meten Baouchariat 0.6% 1 (1%) 1 
   Borge Hammoud 1.6% 2 (2%) 2 
   Dekouanet 0.3% 1 (1%) 1 
   Senn el Fil 0.3% 1 (1%) 1 
  Kesrwane Djounieh Ghadir 0.2% 1 (1%) 1 
North       25 25 
  Akkar Akroum 0.5% 1 (1%) 1 
  
 
Al-Khraibeh 0.2% 1 (1%) 1 
  
 
Al-Mehamra 0.6% 1 (1%) 1 
  
 
Bebnine 0.5% 1 (1%) 1 
  
 
Berkayel 0.3% 1 (1%) 1 
  
 
Deir-Daloum 0.2% 1 (1%) 1 
  
 
El-Bireh 0.5% 1 (1%) 1 
  
 
Halba 0.9% 1 (1%) 1 
  
 
Machta Hammoud 0.2% 1 (1%) 1 
  
 
Ouadi Khaled 1.4% 1 (1%) 1 
  El Batroun Batroune 0.4% 1 (1%) 1 
  
 
Chekka 0.3% 1 (1%) 1 
  El Koura Ras Maska 0.2% 1 (1%) 1 
  El Minieh-Dennie Al-Beddaoui 1.5% 2 (2%) 2 
  
 
Al-Minieh 1.5% 2 (2%) 2 
  
 
Sir 0.7% 1 (1%) 1 
  Tripoli Al-Kalmoune 0.3% 1 (1%) 1 
  
 
Al-Mina Jardins 0.4% 1 (1%) 1 
  
 
Tripoli Al-Kobbeh 0.9% 1 (1%) 1 
  
 
Tripoli Al-Tabbaneh 0.6% 1 (1%) 1 
  
 
Tripoli Zeitoun 1.6% 2 (2%) 2 
  Zgharta Mehriata 0.2% 1 (1%) 1 
South       13 2 
  Bent Jbeil Bint Jbail 0.1% 1 (1%) 0 
  El Nabatieh Kfar Remmane 0.2% 1 (1%) 0 
  
 
Nabatiyeh El-Faouka 0.2% 1 (1%) 0 
  
 
Nabatiyeh El-Tahta 0.3% 1 (1%) 0 
  Hasbaya Chabaaa 0.3% 1 (1%) 0 
  Marjaayoun El-Khiam 0.2% 1 (1%) 0 
  Saida Bissariat 0.4% 1 (1%) 0 
  
 
Ghazyat 0.5% 1 (1%) 0 
  
 
Saeida Ville 1.3% 1 (1%) 1 
  
 
Sarafend 0.3% 1 (1%) 1 
  
 
Abbassyat 0.2% 1 (1%) 0 
  
 
Borge El-Chehmali 0.2% 1 (1%) 0 
  
 
Sour (Tyr) 0.8% 1 (1%) 0 
Total       100 72 
*Lightly shaded and italicized cadastrals were excluded from data collection 
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Supplementary Table A- 2. Allocation of 28 Replacement Clusters in Permitted Areas by 















Beirut 1     3.8% 4% 1 
    Beirut Moussaytbeh 0.4% 4% 1 





0.6% 4% 1 
  
  
Ghazzeh 1.7% 4% 1 
  
 
  Kherbet Kanafar 0.1% 4% 1 
  
 
Zahle Delhamieh 0.7% 4% 1 
  
  
Kfar Zabed 1.3% 4% 1 
  
  
Mejdel-Anjar 2.1% 4% 1 
  
  
Saeid Neil 2.0% 4% 1 
  
  
Talabaya 1.4% 4% 1 
  
  
Tanaeil 0.4% 4% 1 
  
  
Zahleh Midan 1.9% 4% 1 
Mt. Lebanon 7     25.1% 25% 7 
    Aley Aley 0.8% 4% 1 
  
 
  Bhamdoun 
(Village) 
0.3% 4% 1 
  
 
Chouf Baakline 0.1% 4% 1 
  
 
  Chehime 0.8% 4% 1 
  
 
El Meten Jal-el-Dib 0.1% 4% 1 
  
 
  Senn el Fil 0.4% 4% 1 
  
 
Kesrwane Faraya 0.2% 4% 1 
North 10     35.3% 36% 10 
    Akkar Akkar El-Atika 0.2% 4% 1 
  
  
Bebnine 0.7% 4% 1 
  
  
Deir-Daloum 0.3% 4% 1 
  
 
  Tikrite 0.1% 4% 1 
  
 
El Batroun Tannourine Foka 0.1% 4% 1 
  
 





Bakhoune 0.3% 4% 1 
  
 
  Sir 1.0% 4% 1 
  
 
Tripoli Al-Kalmoune 0.5% 4% 1 
  
  
Tripoli Jardins  0.3% 4% 1 
South 0     2.2% 0% 0 
Total       100.0% 100.0% 28 
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Supplementary Table A- 3. Final Allocation of Survey Clusters by Governorate, District, 
and Cadastral 







Beirut     2% 4% 4% 4  
Beirut Bachoura 1% 1% 1% 1   
Mazraa 1% 1% 1% 1   
Moussaytbeh 0% 2% 2% 2 
Bekaa     20% 34% 34% 34  
Baalbek Al-Qa El-Benjakie 1% 1% 1% 1  
Rachaya Dahr El-Ahmar 0% 1% 1% 1  
West Bekaa Al-Marje 1% 1% 1% 1   
Al-Sawireh 0% 1% 1% 1   
El-Karaoun 0% 1% 1% 1   
Ghazzeh 1% 2% 2% 2   
Haouche-el-Harimeh 0% 2% 2% 2   
Jib Jehnine 1% 1% 1% 1   
Kherbet Kanafar 0% 1% 1% 1  
Zahle Bar-Elias 3% 3% 3% 3   
Chtaura 0% 1% 1% 1   
Delhamieh 0% 2% 2% 2   
Jditah 0% 1% 1% 1   
Kab Elias 2% 2% 2% 2   
Kfar Zabed 1% 2% 2% 2   
Maallaka (Terres) 1% 1% 1% 1   
Mejdel-Anjar 1% 2% 2% 2   
Rayak 1% 1% 1% 1   
Saeid Neil 1% 2% 2% 2   
Talabaya 1% 2% 2% 2   
Tanaeil 0% 1% 1% 1   
Zahleh Maallaka Kerek 0% 1% 1% 1   
Zahleh Midan 1% 2% 2% 2 
Mt. Lebanon     14% 25% 25% 25  
Aley Aley 1% 2% 2% 2   
Aramoun 1% 1% 1% 1   
Bhamdoun (Village) 0% 1% 1% 1   
Chouaifat Amroussyat 2% 2% 2% 2   
Chouaifat Qobbat 1% 1% 1% 1  
Baabda Chiah 4% 1% 1% 1  
Chouf Baakline 0% 1% 1% 1   
Barja 1% 1% 1% 1   
Chehime 1% 2% 2% 2   
Damour 0% 1% 1% 1   
El Jiyeh 0% 1% 1% 1   
Naamat 1% 1% 1% 1  
El Meten Baouchariat 1% 1% 1% 1   
Borge Hammoud 2% 2% 2% 2   
Dekouanet 0% 1% 1% 1   
Jal-el-Dib 0% 1% 1% 1   
Senn el Fil 0% 2% 2% 2  
Jbeil Jbeil 0% 1% 1% 1 
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Supplementary Table A- 3 (continued) 







Kesrwane Djounieh Ghadir 0% 1% 1% 1   
Faraya 0% 1% 1% 1 
North     15% 35% 35% 35  
Akkar Akkar El-Atika 0% 1% 1% 1   
Akroum 1% 1% 1% 1   
Al-Khraibeh 0% 1% 1% 1   
Al-Mehamra 1% 1% 1% 1   
Bebnine 0% 2% 2% 2   
Berkayel 0% 1% 1% 1   
Deir-Daloum 0% 2% 2% 2   
El-Bireh 0% 1% 1% 1   
Halba 1% 1% 1% 1   
Machta Hammoud 0% 1% 1% 1   
Ouadi Khaled 1% 1% 1% 1   
Tikrite 0% 1% 1% 1  
El Batroun Batroune 0% 1% 1% 1   
Chekka 0% 1% 1% 1   
Tannourine Foka 0% 1% 1% 1  
El Koura Enfeh 0% 1% 1% 1   
Ras Maska 0% 1% 1% 1  
El Minieh-
Dennie 
Al-Beddaoui 1% 2% 2% 2  
Al-Minieh 2% 2% 2% 2  
Bakhoune  0% 1% 1% 1   
Sir 1% 2% 2% 2  
Tripoli Al-Kalmoune 0% 2% 2% 2   
Al-Mina Jardins 0% 1% 1% 1   
Tripoli Al-Kobbeh 1% 1% 1% 1   
Tripoli Al-Tabbaneh 1% 1% 1% 1   
Tripoli Jardins  0% 1% 1% 1   
Tripoli Zeitoun 2% 2% 2% 2  
Zgharta Mehriata 0% 1% 1% 1 
South     2% 2% 2% 2  
Saida Saeida Ville 1% 1% 1% 1  
  Sarafend 0% 1% 1% 1 
Total     53%   100% 100 
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Supplementary Figure A- 1. Survey Coverage Area by Cadastral 
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 N % 
Beirut 3% 4 4% 
Bekaa 35% 34 34% 
Mt Lebanon 25% 25 25% 
North 25% 35 35% 
South 12% 2 2% 
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Appendix B. Treatment Guidelines for Hypertension and Type 2 Diabetes in 
Syrian Refugees and Host Communities in Lebanon: Study Design and 
Methods 
The Treatment Guidelines for Hypertension and Type 2 Diabetes in Syrian Refugees and 
Host Communities in Lebanon study was a longitudinal cohort study implemented from 
September 2014 through September 2016 in primary health care settings in Lebanon serving both 
Syrian refugees and host communities with two research aims:  
1. To develop, adapt, and test existing standards and guidelines for treatment, including 
counseling, of persons with hypertension and type 2 diabetes (or both).  
2. To evaluate the effectiveness of an mHealth tool that includes a patient-controlled health 
record (PCHR), which have the potential to improve quality of care, continuity of care, 
health literacy, and health outcomes for patients. This objective focused on supporting 
provider and patient compliance and improving disease control through the introduction 
of the mHealth tool and PCHRs.  
Study Design 
The study used a phased introduction of two interventions over a period of two years with 
longitudinal measurement of outcomes. While randomized control trials are considered the gold 
standard research design, they are often not possible in humanitarian emergencies. In the case of 
this study, randomized and quasi-experimental designs were not feasible at the facility level 
because there are few participating facilities and important underlying differences between the 
facilities and patient populations served. Patient randomization was not possible because of likely 
contamination between groups and difficulties associated with asking providers to manage 
patients differently. A study that included fewer health facilities but provided a more in-depth 
assessment of outcomes from multiple perspectives was preferable to a design that incorporated 
more facilities so that more comprehensive evidence could be generated with a better 
understanding of causal pathways and added value of the interventions. Longitudinal study 
designs are generally preferable to cross-sectional assessments and provide more analysis options. 
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This study design followed the cohort monitoring approach used by United Nations Relief and 
Works Agency for Palestine Refugees in the Near East (UNRWA) to evaluate non-communicable 
disease (NCD) management in Palestinian refugees and proved feasible in this context.520,521  
Study Interventions 
The Treatment Guidelines for Hypertension and Type 2 Diabetes in Syrian Refugees and 
Host Communities in Lebanon study evaluated two interventions with a phased implementation 
design:  
1. Guidelines for Treatment of Hypertension and Type 2 Diabetes in Primary Care 
Facilities were developed based on adaptations to relevant guidelines from international 
sources such as the World Health Organization’s Package of Essential Noncommunicable 
Disease Interventions (WHO PEN), standards from professional societies and authorities 
such as the National Institute for Health and Care Excellence clinical guidelines, and the 
recently updated treatment guidelines by the Lebanese Ministry of Public Health 
(MoPH).522,523 The adapted guidelines are congruent with the Lebanese context, 
applicable beyond the participating health facilities, and generally applicable to other 
humanitarian organizations and crisis settings.  
2. The mHealth intervention is a tablet-based open source software for clinical 
management of hypertension and type 2 diabetes that serves as both electronic medical 
record and a decision support tool for providers with key clinical milestones and tracking 
of what physicians prescribe. The mHealth application also produced a PCHR, exportable 
in paper format and abbreviated SMS format to be provided to patients. The PCHR 
contains a limited disease history, updated every visit with information such as fasting 
blood sugar, blood pressure, medications prescribed, and date of next follow up, as well 
as a risk assessment summary for biometrics and lifestyle (adapted from existing 
resources such as the World Health Professions Alliance Health Improvement Card).523,524 
Basic elements of the record were printed off and given to the patient or transmitted via 
SMS to the patient’s cell phone for an electronic record, which could help patients 
understand and monitor their condition or can provide medical history if the patient 
unexpectedly needs to access care outside their usual providers. In summary, the mHealth 
tool is best conceptualized as tablet-based decision support tool used by medical 
providers that can store patient medical information; an output of the system is a 
summary of the patient’s condition and prescriptions to be provided at each visit either in 
paper or SMS format. 
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Participants and Sample Size Calculations 
Study participants consisted of care-seekers at ten primary health facilities in Lebanon 
supported by the International Organization for Migration (IOM) and International Medical Corps 
(IMC) in the South, Bekaa, Beirut, and Mount Lebanon governorates (Supplementary Figure B-
1). Care-seekers at these locations include Syrian refugees, Lebanese populations, and in smaller 
number, Iraqi refugees and Armenian populations. Individuals without a hypertension or type 2 
diabetes diagnosis, those less than 40 years of age, and adults lacking the capacity to participate 
in interviews independently were excluded from the study.  
The final sample size was dependent on the caseload of diabetes and hypertension 
patients seen at study health facilities. Planned sample sizes were based on the total estimated 
caseload and projected newly diagnosed cases for each study health facility. Initial enrollment 
figures at IOM facilities were substantially below target enrollment numbers, so five additional 
facilities supported by IMC were brought on to participate in the study and participants from 
these sites were recruited. The total initially estimated caseload, as well as the anticipated 
proportion that could be reached by phone (estimated at 80%) and proportion that would consent 
to participate (estimated at 80%) for each facility are presented in Supplementary Table B-1. The 
planned and maximum samples to be enrolled in each facility are also presented; the maximum 
sample size was increased to allow for anticipated community outreach activities that were 
expected to generate additional cases beyond sample size projections from facility information.  
Sample size calculations were based on the main study objective of improving quality of 
care, specifically the proportion of providers who adhere to treatment guidelines. Sample size 
calculations assumed a baseline prevalence rate of 50% for adherence to guidelines, which is the 
most conservative prevalence rate from a statistical perspective that would ensure the ability to 
detect significant differences from all other rates. This is a reasonable assumption given that the 
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proposed guidelines do not differ substantially from other best practice guidelines, thus, some 
providers may already have been adhering to guidelines. Further, sample size calculations 
assumed α = 0.05, β = 0.20 (power = 0.80) and one-sided calculations based on the supposition 
that quality of care would not decrease as a result of the study interventions. Sample size 
calculations were performed using Stata 13. The final sample size in each study phase is 
presented by health facility in Supplementary Table B-2 and by diagnosed condition in 
Supplementary Figure B-2. 
Recruitment and Enrolment Process 
Potential participants were identified using patient lists provided to IOM by the 
participating health facilities. At the beginning of the study, lists of diabetes and hypertension 
patients who visited each facility within the past six months were provided. These lists covered 
most of the existing caseload and served as the patient population initially approached for 
enrollment. Each facility submitted updated patient lists for study recruitment purposes weekly 
through the end of the enrollment period. Enrollment of additional patients continued until the 
first intervention was implemented in the facility. These patients included: 1) those newly 
diagnosed with hypertension and diabetes, 2) those that were unreachable by telephone, and 3) 
those not included in the initial lists but later identified as potentially eligible for enrollment.  
Identified patients were called by interviewers using the primary contact number 
provided, or an alternate number when necessary and available. Interviewers began by reading a 
brief script introducing the reason for the call and providing information about the study and the 
patient’s rights to decline participation. During this call, informed consent was obtained by 
interviewers trained in human subjects research and data collection practices, including the data 
collection tools used for the study.  
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Data Collection  
This study was designed using a mixed-methods approach with both qualitative and 
quantitative data collection. A timeline of study intervention implementation and data collection 
is provided in Supplementary Figure B-3.  
Quantitative Data Collection 
Health facility assessments were performed at baseline to collect information about 
available equipment, drug supplies, and facility conditions. They also included observation of the 
physical space; numbers of providers by type and facility operating hours; records of patients 
seen for the target conditions and related diagnoses and referral; equipment for diagnosis and 
management of hypertension and diabetes; and medicines for the conditions and recent stock 
outs.  
In addition to a facility assessment conducted at the start of the study, a total of four 
instruments were used to collect patient data throughout the study: (i) enrollment interview, (ii) 
patient record review, (iii) exit interviews, and (iv) end of study phase interviews.  
Enrolment interviews were conducted with every patient. These were structured 
interviews conducted by phone at baseline for all participants. In addition to providing consent 
for study participation, key indicators collected through these interviews included patient 
demographic and migration information; medical history and recent care seeking behaviors; and 
knowledge, attitudes, and practices related to diabetes and/or hypertension. 
Medical record reviews were conducted for each patient following enrollment, 
retrospectively at the end of Phase 2, and finally with information from both the mHealth 
application and facility records at the end of Phase 3. Key indicators included in the record 
reviews were related to provider compliance with guidelines and quality of care; frequency of 
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visits; generic patient outcomes (death and loss to follow-up), and disease-specific patient 
outcomes (complications and adverse events of hypertension and diabetes). 
Patient exit interviews were conducted on a subset of enrolled patients that sought care at 
study facilities throughout the study period. Phone interviews with these patients were conducted 
within ten days of a visit to the facility. Key indicators relate to provider trust, counseling 
received, and satisfaction and perceptions of care received during the most recent visit. 
End of study phase interviews consisted of a shortened combination of questions from 
enrollment and exit interviews and were conducted at the end of Phases 2 and 3. Key indicators 
included recent care seeking behaviors; knowledge, attitudes, and practices related to diabetes 
and/or hypertension; and counseling, satisfaction, and perceptions of care received during the 
most recent visit to a study facility. 
All patient interviews were conducted by phone to ensure confidentiality and reduce the 
gratuity bias of interviews performed at health facilities. The approach has been successfully used 
by the United Nations High Commissioner for Refugees (UNHCR) for surveys of Syrian refugees 
in Lebanon with reduced implementation costs and loss to follow-up compared to in-person 
interviews.71,117 Interview and record review data were collected on tablets using the Magpi 
mobile data platform by DataDyne LLC (Washington, DC). 
Qualitative Data Collection 
In addition to quantitative data collected via phone interviews, a total of 19 focus group 
discussions (FGDs) were conducted with Syrian refugees and Lebanese host community 
members enrolled in the study, as well as health care providers working at study health facilities. 
Interview content focused on care-seeking and medication adherence, providing more nuanced 
information regarding barriers to care-seeking, treatment, and medication adherence from both 
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patient and provider perspectives. Two key informant interviews (KIIs) were also conducted with 
staff from humanitarian organizations providing services or programming for NCDs among 
Syrian refugees in Lebanon.  
Qualitative data was collected by local IOM staff with one note-taker and one interviewer 
at each focus group. Oral informed consent was obtained from each participant before initiating 
the group discussion. FGDs were facilitated using semi-structured interview guides and lasted 
between 30 and 90 minutes, depending upon time participants had available and interest in 
participation. 
Separate focus group discussions were conducted for Syrian refugees and Lebanese host 
community members in each geographic region. Groups were then further separated based upon 
whether the participant sought care for hypertension and/or type 2 diabetes in the six months prior 
to FGDs. Supplementary Table B-3 presents the number of FGD participants by location and 
participant group. 
Focus groups were recorded to allow facilitators to more fully engage in discussions 
without compromising documentation. Following each discussion, the interviewer and note-taker 
discussed participants’ contributions, interactions within the group, and how group composition 
or other factors may have influenced participants’ responses. Detailed notes were typed using 
recordings to expand upon notes taken during focus groups, then reviewed by data collection 
team members and translated to English. FGD facilitators also debriefed with the Johns Hopkins 
Bloomberg School of Public Health (JHSPH) field coordinator throughout data collection to 
discuss questions, concerns, challenges faced, as well as strengths and weaknesses of each 
discussion.  
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In addition to FGDs, individual and group KIIs were conducted with staff from various 
humanitarian organizations involved in the provision of services for NCDs to Syrian refugees in 
Lebanon. Interviews with humanitarian actors were semi-structured and conducted by the JHSPH 
field coordinator and the local IOM study coordinator who facilitated FGDs. 
FGD and KII summaries and field notes were analyzed using content analysis methods to 
identify key themes, consensus viewpoints, and viewpoints of a minority within groups, in 
addition to views that were unique to particular contexts or locations. FGD notes were analyzed 
separately for each participant group, after which findings were analyzed across groups to 
examine common themes further. 
Preliminary Data Cleaning 
A sequenced process-based classification used patient records, clinical data, and 
prescriptions to assign a uniform diagnosis category to patients in cases where reporting was 
inconsistent. Eight patients remained with an unclassified diagnosis and were subsequently 
dropped from the final analysis to ensure reliable reporting by condition. A similar process was 
used to classify population group (i.e., Syrian refugee, Lebanese host community, or other 
nationalities) among participants with conflicting reporting across data sources; all participants 
were successfully classified.  
Limitations 
Limiting the study sample to individuals seeking care at study health facilities, while 
necessary for the main study objectives, is a limitation of this research in that it restricts 
representativeness to a small subset of the population of Syrian refugees and host communities in 
Lebanon who sought care in these locations. The prevalence of hypertension and type 2 diabetes 
is likely to be much higher in the community than only those recruited for the study without 
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additional screening of the general population, and persons receiving care from private clinics, 
pharmacies, or Syrian doctors may well have different findings. As such, results are not 
necessarily applicable to all individuals with hypertension or diabetes who are not receiving care 
or who receive care at different types of health facilities or in other geographic areas of Lebanon. 
This is limiting because outcomes among patients not receiving care could presumably be far 
worse than in patients receiving some level of care; however, results from this research can 
neither confirm nor preclude those assumptions. 
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Supplementary Table B- 1. Sample Size and Power Calculations 









IOM Supported Facilities 
Tyre 123 74 197 158 142 
Msayleh 193 116 309 247 223 
Nabatiyeh 140 84 224 179 161 
Bar Elias N/A N/A 125 100 90 
Taalabaya 16 18 34 27 25 




324 259 233 
Tayouneh 183 183 146 132 
Fanar 50 50 40 36 
Mrayje 72 72 58 52 
Karagheusian 715 715 572 515 
Maximum Planned Sample  1,609 
*estimated by taking 10% of the current caseload as newly identified cases monthly and extrapolating this out for a 
6-month period during Phase 1; and † 80% of the estimated cases; and ‡ estimated at 80% of the reachable cases  
 
 
Supplementary Table B- 2. Final Study Sample by Health Facility and Study Phase 




End Phase 2 
(N=830) 






Msayleh (IOM) 116 93 113 88 
Nabatiyeh (IOM) 67 62 64 62 
Tyre (IOM) 83 65 81 64 
Bekaa Governorate 
Bar Elias (IOM)  105 86 92 81 
Taalabaya (IOM) 193 163 185 158 
Saadnayel (IMC) 95 88 91 83 
Beirut/Mt. Lebanon Governorates 
Tayouneh (IMC)  9 8 9 8 
Fanar (IMC) 12 9 11 9 
Mrayje (IMC) 49 50 48 48 
Karagheusian (IMC) 281 206 269 203 
Total  1,010 830 963 804 
* Complete follow-up indicates data collected from at least one instrument (i.e. participant interview and/or record 
review) in each study phase 
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Mt. Lebanon Bekaa South Total 
Health Care Providers     
Physicians 2 3 6 11 
Nurses 3 4 4 11 
Pharmacists 0 0 2 2 
Total Provider FGD Sample 5 7 12 24 
Patients     
Syrian Refugees     
Recently sought care 11 9 3 23 
Did not recently seek care 12 8 8 28 
Lebanese Host Community     
Recently sought care 8 3 2 13 
Did not recently seek care 4 3 4 11 
Total Patient FGD Sample 35 23 17 75 
 
Supplementary Figure B- 1. Study Facilities by Geographic Area 
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Supplementary Figure B- 2. Final Study Sample by Condition and Study Phase 
 
 
Supplementary Figure B- 3. Data Collection and Study Intervention Timeline 
Year 2014            2015               2016 
Month 9 10 11 12 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3 4 5 6 7 8 
Study Intervention Implementation 
Treatment 
guidelines 
                        
mHealth app                         
Data Collection  
Facility 
assessments                                                 
Enrollment 
interviews                                                 
Record reviews                                                 




Baseline / Enrollment 
(N = 1,010) 
Hypertension only = 470 Hypertension & Diabetes = 414 Diabetes only = 126 
Guidelines Implementation (Phase 1) 
(N = 829) 
Hypertension only = 392 Hypertension & Diabetes = 336 Diabetes only = 101 
mHealth Implementation (Phase 2) 
(N = 960) 
Hypertension only = 450 Hypertension & Diabetes = 395 Diabetes only = 115 
Complete Follow-Up 
(N = 804) 
Hypertension only = 379 Hypertension & Diabetes = 329 Diabetes only = 96 
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Appendix C. Explanatory Variables 
Multicollinearity among explanatory variables was explored in each dataset using 
variance inflation factor (VIF) scores, which measure the extent of inflation in a regression 
coefficient’s variance due to multicollinearity in the model. In the case of models in all three 
papers, VIF scores were all below 1.75, indicating no multicollinearity concerns relative to 
conventional thresholds. 
Paper 1 
Explanatory variables used in analyses are summarized in Supplementary Table C-1 
below and included: (i) any care visit for the condition of interest in the three-month period prior 
to interview (no/yes; only included in models for odds of interrupted medication adherence); (ii) 
region of residence (Beirut or Mt. Lebanon/Bekaa/North); (iii) female-headed household 
(no/yes); (iv) highest level of education completed by the household head (less than 
primary/primary or higher); (v) household expenditure category (measured as below/above the 
median monthly household expenditures reported by Syrian refugees); (vi) year of arrival in 
Lebanon (2011-2012/2013-2015); and (vii) receipt of any cash/voucher assistance from a United 
Nations agency, non-governmental organization (NGO), or other religious or community group in 
the month preceding interview (no/yes). Distributions of explanatory variables are provided in 
Supplementary Table C-2 stratified by households with members diagnosed with hypertension 
and those with diabetes.  
Paper 2 
Explanatory variables used in analyses are summarized in Supplementary Table C-3 
below. Patient demographic characteristics in this analysis include: (i) age (40-50 years/51-60 
years/older than 60 year); (ii) sex (male/female), (iii) highest level of education completed (less 
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than primary/primary or higher), (iv) household expenditure category (below/above the median 
monthly household expenditures reported by refugees); and (v) duration of time in current 
residence location (longer than one year/one year or less). Age was categorized into wider 
intervals due to imprecision in self-report.  
Clinical characteristics include: (i) comorbid hypertension and diabetes diagnoses 
(no/yes); (ii) time since diagnosis (less than 10 years/10 years ago or longer); (iii) patient 
enrollment in the YMCA chronic medications program (no/yes); and (v) knowledge of 
complications of the condition of interest (hypertension and/or type 2 diabetes). As with age, time 
since diagnosis is analyzed as a dichotomous variable because of imprecise patient reporting of 
disease duration; the division of 10 year disease duration for categories was selected based upon 
the distribution of reported continuous time since diagnosis, and to reflect distinctions between 
patients likely to have had established care and treatment routines prior to the start of the Syrian 
conflict versus those either diagnosed after the start of the crisis or close enough that they are not 
expected to have acclimated to the diagnosis and settled into a care routine. A descriptive 
overview of explanatory variables stratified by condition is provided in Supplementary Table C-
4. 
Paper 3 
Explanatory variables used in analyses are summarized in Supplementary Table C-5 
below. Patient demographic characteristics in this analysis include: (i) age (in years); (ii) sex 
(male/female), (iii) highest level of education completed (less than primary/primary or higher), 
(iv) household expenditure category (below/above the median monthly household expenditures 
among refugees); and (v) duration of time in current residence location (longer than one year/one 
year or less).  
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Clinical characteristics include: (i) diagnosed hypertension and diabetes comorbidity 
(no/yes); (ii) time since diagnosis (10 years or fewer /more than 10 years); (iii) patient enrollment 
in the YMCA chronic medications program (no/yes); and (v) knowledge of complications of the 
condition of interest (hypertension or type 2 diabetes; no/yes). 
Distributions of explanatory variables stratified by diagnosed condition are provided in 
Supplementary Table C-6. 
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Supplementary Table C- 1. Individual and Household Characteristics Included as 
Explanatory Variables in Paper 1 Regression Analyses 
Variable Variable Type Description 
Individual Characteristics 
Recent care visit Dichotomous Defined as any care received for hypertension/diabetes in 
the three months preceding interview (no/yes) 
Household Characteristics 
Year of arrival in 
Lebanon 
Categorical Categorized as: 2011-2012/2013-2015 
Region of residence Categorical Defined as the region of current residence. Categorized as: 
Beirut/Mt Lebanon, South, or Bekaa 
Female-headed 
household 
Dichotomous Categorized as: no/yes 
Highest education 
level completed 
Categorical Defined as highest level of education completed by the 





Dichotomous Defined as having self-reported monthly household 
expenditures below/above the median amount reported by 
Syrian refugees  
(Median = 986,750 LBP/US$654.5) 
Receipt of any 
cash/voucher 
assistance 
Dichotomous Defined as receipt of any cash or voucher assistance 
received from a United Nations agency, NGO, or other 
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Supplementary Table C- 2. Paper 1 Explanatory Variable Distributions by Household 
Members Diagnosed with Hypertension and/or Diabetes 
 
1+ HH Member with 
Hypertension* 




Any care visit for condition in past 3 months 145 (51.4%) 84 (61.8%) 
Year of arrival in Lebanon   
2011 – 2012 123 (43.6%) 68 (50.0%) 
2013 – 2015 159 (56.4%) 68 (50.0%) 
Region of residence   
Beirut/Mt. Lebanon 68 (24.1%) 35 (25.7%) 
Bekaa 97 (34.4%) 45 (33.1%) 
North 117 (41.5%) 56 (41.2%) 
Female-headed household 45 (16.0%) 23 (16.9%) 
Household head completed primary education 
or higher 216 (76.6%) 113 (83.1%) 
Above median monthly household 
expenditures† 168 (59.6%) 73 (53.7%) 
Receipt of cash/voucher assistance‡ 219 (77.7%) 104 (76.5%) 
Presented as frequency (%). HH = household 
* Condition classification not mutually exclusive; households with any member(s) diagnosed with both conditions 
are included in both condition groups 
† Relative to median monthly expenditures reported by Syrian refugee households 
‡ Includes cash or voucher assistance received from a United Nations agency, NGO, or other religious or 
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Supplementary Table C- 3. Clinical and Demographic Characteristics Included as 
Explanatory Variables in Paper 2 Regression Analyses 
Variable Variable Type Description 
Demographic Characteristics 
Age Categorical Categorized as: 40-50 years / 51-60 years / older than 60 
years 
Sex Dichotomous Male/female 
Highest education 
level completed 
Categorical Defined as highest level of education completed by the 





Dichotomous Defined as having self-reported monthly household 
expenditures below/above the median amount for Syrian 
refugee patients. (Median = 932,000 LBP/US$618) 
Time in current 
residence location 
Binary Defined as having lived in current residence for one year 





Dichotomous Defined as formal diagnosis of both hypertension and 
diabetes (no/yes) 
Time since diagnosis Dichotomous Defined as the amount of time since initial condition 
diagnosis 
Categorized as: less than 10 years / 10 years or longer 
Medication 
assistance 
Dichotomous Defined as enrollment in the YMCA chronic medications 
program, which provides medications for chronic 
conditions at a nominal cost through select 






For patients with hypertension, defined as reported 
knowledge of stroke as a complication of hypertension 
(no/yes) 
For patients with diabetes, defined as reported 
knowledge of at least one complication of diabetes 
including eye problems, kidney problems, heart 
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Supplementary Table C- 4. Distribution of Paper 2 Explanatory Variables by Diagnosed 
Condition Among Syrian Refugees 
 
Hypertension Type 2 Diabetes 
  (N=552) (N=312) 
Patient Characteristics     
Age   
 
40 – 50 years 167 (30.8%) 96 (31.4%) 
51 - 60 years 176 (32.4%) 103 (33.7%) 
> 60 years 200 (36.8%) 107 (35.0%) 
Female 370 (67.0%) 216 (69.2%) 
Completed ≥ primary education 160 (29.5%) 87 (28.6%) 
Above median monthly household expenditures* 273 (51.4%) 152 (50.8%) 
Lived in current residence location ≤ 1 year 151 (28.7%) 93 (31.7%) 
Clinical Characteristics     
Hypertension/diabetes comorbidity 227 (41.5%) 227 (73.2%) 
>10 years since diagnosis 129 (27.7%) 79 (30.0%) 
Enrolled in YMCA Program 148 (27.3%) 79 (25.9%) 
Knowledge of complication(s) of condition† 281 (51.8%) 161 (52.8%) 
Presented as frequency (%) 
Condition classification not mutually exclusive; participants with dual diagnoses included in both condition groups 
* Relative to median monthly household expenditures reported by Syrian refugees 
† Defined for hypertension patients as identifying stroke as a complication and for diabetes patients as identifying at least 
one complication of diabetes, including eye problems, kidney problems, foot ulcers, and heart problems. Reference: not 
able to identify any complication of diabetes 
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Supplementary Table C- 5. Clinical and Demographic Characteristics Included as 
Explanatory Variables in Paper 3 Regression Analyses 
Variable Variable Type Description 
Demographic Characteristics 
Age Ordinal In years 
Sex Dichotomous Male/female 
Highest education 
level completed 
Categorical Defined as highest level of education completed by the 





Dichotomous Defined as having self-reported monthly household 
expenditures below/above the median amount Syrian 
refugee patients.  
(Median = 932,000 LBP/US$618) 
Time in current 
residence location 
Binary Defined as having lived in current residence for one year 





Dichotomous Defined as formal diagnosis of both hypertension and 
diabetes (no/yes) 
Time since diagnosis Categorical Defined as the amount of time since initial condition 
diagnosis 
Categorized as: less than five years / five to nine years / 
ten years or longer 
Medication 
assistance 
Dichotomous Defined as enrollment in the YMCA chronic medications 
program, which provides medications for chronic 
conditions at a nominal cost through select 




Dichotomous For patients with hypertension, defined as reported 
knowledge of stroke as a complication of hypertension 
(no/yes) 
For patients with diabetes, defined as reported 
knowledge of at least one complication of diabetes 
including eye problems, kidney problems, heart 
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Supplementary Table C- 6. Distribution of Paper 3 Explanatory Variables by Diagnosed 
Condition Among Syrian Refugees 
  Hypertension Type 2 Diabetes 
  (N=552) (N=312) 
Patient Characteristics 
  
Age (years) 57.2 (9.9) 56.6 (9.2) 
Sex   
 
Male 182 (33.0%) 96 (30.8%) 
Female 370 (67.0%) 216 (69.2%) 
Completed ≥ primary education 160 (29.5%) 87 (28.6%) 
Above median monthly household expenditures* 273 (51.4%) 152 (50.8%) 
Lived in current residence location ≤ 1 year  151 (28.7%) 93 (31.7%) 
Clinical Characteristics 
  
Hypertension / diabetes comorbidity 227 (41.5%) 227 (73.2%) 
Time Since Diagnosis   
 
< 5 years 201 (43.1%) 106 (40.3%) 
5 - 9 years 136 (29.2%) 78 (29.7%) 
≥ 10 years 129 (27.7%) 79 (30.0%) 
Enrolled in YMCA Program 148 (27.3%) 79 (25.9%) 
Knowledge of complication(s) of condition† 281 (51.8%) 161 (52.8%) 
Presented as mean (standard deviation) for continuous variables and frequency (%) for dichotomous/categorical variables 
Condition classification not mutually exclusive; participants with dual diagnoses included in both condition groups 
* Relative to median monthly expenditures reported among those in the same population group 
† For hypertension: Defined as able to identify stroke as a complication of hypertension. 
  For diabetes: Defined as able to identify at least one complication of diabetes, including eye problems, kidney problems, 

























































































































































































   
   
   
   
   
   




   
   
   
   
   
   
   




   
   




   
   








































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Appendix E. Paper 2 Care Utilization Model Comparison and Selection 
Methods 
Physician utilization outcome variables in these analyses are count data (i.e., non-
negative integers). Overdispersion, or greater variability than would be expected relative to the 
mean, is common in count data due to excess zeros relative to standard distributions, and/or from 
unexplained heterogeneity.455 This violates the assumption of equidispersion necessary for the 
Poisson model; however, the negative binomial regression model (NB) includes a parameter for 
dispersion and thus is able to account for over-dispersion resulting from unobserved 
heterogeneity and/or temporal dependency.525  
In the case of overdispersion due to excess zeros, zero-inflated and hurdle models are 
most often utilized.526 These models frequently produce comparable fit statistics, but 
conceptually, they contain related yet different reports of excess zero concerns. Zero-inflated 
models are commonly used for data with both structural and sampling excess zeros, while hurdle 
models are used in data that contain only sampling excess zeros. Use of hurdle models has gained 
favor in health research, mainly for their ability to facilitate interpretations that reflect the “dual 
decision structure” of health service utilization.527 
Model selection for Paper 2 began by assessing equidispersion using the Lagrange 
Multiplier test, which identified overdispersion both in the number of visits to a general 
practitioner (GP) and in visits to a relevant specialist (endocrinologist and/or cardiologist).410 To 
identify the analytical technique best suited to the data structure, Poisson and NB models were 
compared, along with zero-inflated Poisson (ZIP), zero-inflated negative binomial (ZINB), 
Poisson hurdle (PH), and negative binomial hurdle (NBH) models for each of the utilization 
outcome variables included in this analysis. Both the Akaike (AIC) and Bayesian information 
criterion (BIC) were considered in determining the best-suited model for the data, though 
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qualitative consideration was also given to assumptions about excess zeros in the data and 
interpretation of model results. Goodness of fit statistics comparing the tested models are 
provided in Supplementary Table E-1. 
Both AIC and BIC indicated a preference for NBH models in all outcome variables. 
Moreover, excess zeros in the data are believed to contain only sampling zeros rather than both 
sampling and structural zeros, further supporting the conclusion that hurdle models are better 
suited to these data than zero-inflated models. Because study participants were recruited using 
lists of patients who had received care at any of the ten study health facilities in the six months 
prior to enrollment, it is assumed that all study participants are “at risk” or capable of having one 
or more visits to any given provider type in the same period of time used as a reference period 
during interviews. Although patients were placed on recruitment lists regardless of whether they 
visited a study health facility to receive care from a physician or a nurse, to have laboratory tests 
performed, or simply to refill a prescription, it is assumed that by virtue of having visited a 
facility, all enrolled patients were “at risk” for visiting any given type of health provider in the 
future, particularly at the study health facilities. Consequently, the final analyses employed four 
distinct NBH models: (i) GP care utilization among patients with hypertension, (ii) specialist care 
utilization among patients with hypertension, (iii) GP care utilization among patients with type 2 
diabetes, and (iv) specialist care utilization among patients with type 2 diabetes.  
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Supplementary Table E-1. Multivariate Models of Care Utilization by Syrian Refugee 
Patients: Goodness of Fit Comparisons for All Utilization Outcome Models 
 Poisson NB ZIP ZINB PH NBH 
HYPERTENSION 
GP Visits 
AIC 2075.59 1766.54 1956.45 1788.06 1922.64 1745.24 
BIC 2157.73 1852.79 2120.73 1956.45 2004.78 1831.49 
Specialist Visits 
AIC 1968.87 1788.44 1926.23 1797.81 1887.53 1777.78 
BIC 2051.01 1874.69 2090.51 1966.20 1969.67 1864.03 
TYPE 2 DIABETES 
GP Visits 
AIC 1064.89 941.09 1027.90 952.39 989.75 937.29 
BIC 1135.15 1014.87 1168.44 1096.44 1060.02 1011.07 
Specialist Visits 
AIC 1251.92 1115.56 1225.33 1125.63 1186.57 1099.20 
BIC 1322.19 1189.34 1365.87 1269.68 1256.84 1172.98 
AIC = Akaike Information Criterion; BIC = Bayesian Information Criterion 
Poisson = Poisson regression model; NB = negative binomial regression model; ZIP = zero-inflated Poisson model;  
ZINB = zero-inflated negative binomial model; PH = Poisson hurdle model; NBH = negative binomial hurdle model 
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Appendix F. Validity of Single-Question Medication Adherence Measure 
The single-question measure of interrupted medication adherence used in this paper 
(“Within the last six months, have you had to stop taking [medicines prescribed for 
hypertension/diabetes] for two weeks or more?”)  has been used previously in research with 
refugee populations; however, its validity as an informative measure in these settings was not 
previously evaluated.72 Consequently, in the final two follow-up data collection periods of the 
Treatment Guidelines for Hypertension and Type 2 Diabetes in Syrian Refugees and Host 
Communities in Lebanon study, the four-item Morisky Medication Adherence Scale (MMAS-4) 
was included in survey instruments to evaluate the validity of the single-question adherence 
measure. In the final two data collection periods, the single-question adherence measure reference 
period was three months preceding interview, whereas the question referred to the prior six 
months in the enrollment interview. In all data collection periods, the single-question measure 
asked about medication interruption of two weeks or longer. The validity of the MMAS-4 and the 
original eight-item version (MMAS-8) have been established in multiple international settings 
and are among the most widely accepted and utilized measures of medication adherence, 
particularly among those with chronic health conditions.222,528,529  
Paper 3 used baseline data from the Treatment Guidelines study to assess and model (i) 
medication adherence, (ii) group differences in adherence, and (iii) factors associated with 
adherence. The validity of the single-question adherence measure was first assessed using 
responses to this question and to the MMAS-4 adherence classifications collected in subsequent 
cohort study data collection periods. Most patients were classified as having high medication 
adherence according to the MMAS-4 regardless of medical condition or study phase. Ranging 
from zero to four with higher values indicating lower medication adherence, the mean MMAS-4 
score among patients with hypertension was 0.19 (CI: 0.15-0.23) following the guidelines phase 
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and 0.15 (CI: 0.12-0.18) following the mHealth phase.530 Similar mean MMAS-4 scores were 
observed among patients with type 2 diabetes (0.17, 95: CI: 0.12-0.21 following the guidelines 
phase and 0.12, CI: 0.08-0.15 after the mHealth phase). Of the individual items on the MMAS-4, 
sometimes forgetting to take medication was the most commonly reported item in all study 
phases for both conditions. The three remaining MMAS-4 items (carelessness in taking 
mediation, stopping when the patient felt better, and stopping when the patient felt worse) were 
reported by a similar proportion of patients in both study phases for hypertension and type 2 
diabetes.  
One or more of the individual MMAS-4 items were reported by a larger proportion of 
individuals than was interrupted adherence as measured by the single question “Have you stopped 
taking your hypertension/diabetes medication for two weeks or longer in the past three months?” 
in both study phases for both conditions.  
An overview of MMAS-4 results are presented in Supplementary Table F-1 stratified by 
report of interrupted medication use in the single-question adherence measure. The sensitivity and 
specificity of the single-question medication adherence measure against the MMAS-4 are also 
provided in Supplementary Table F-2.  
Hypertension 
Following implementation of the treatment guidelines, 64.6% (CI: 49.5-77.8%) of 
patients with hypertension who reported interrupted adherence were nonetheless also classified as 
having high adherence using the MMAS-4 as compared to 84.1% (CI: 80.8-87.1%) among 
patients who did not report interrupted adherence (P<0.001). Following implementation of the 
mHealth application, high MMAS-4 scores were observed in 60.0% (CI: 42.1-76.1%) of patients 
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with hypertension who reported interrupted adherence versus 78.2% (CI: 73.7-82.3%) of those 
who did not report interrupted adherence (P <0.001).  
Among patients with hypertension, the single-question measurement of interrupted 
adherence in the prior three-month period had 16.2% (CI: 9.7%-24.7%) sensitivity and 93.8% 
(CI: 91.3%-95.7%) specificity compared to the validated MMAS-4 scale. These calculations 
consider patients with low or medium medication adherence based upon MMAS-4 scores as 
“non-adherent” and are based on data collected following guideline implementation. Relying on 
data collected after implementation of the mHealth application, the single-question measure had 
14.6% (CI: 8.2%-23.3%) sensitivity and 93.4% (CI: 90.0%-95.8%) specificity among patients 
with hypertension.  
Type 2 Diabetes 
Among patients with type 2 diabetes, high medication adherence (measured using the 
MMAS-4) was observed in 64.3% (CI: 44.1-81.4%) of those reporting interrupted adherence and 
86.1% (CI: 82.1-89.6%) of those not reporting interrupted adherence following guideline 
implementation (P <0.001). After mHealth implementation, 64.3% (CI: 35.1-87.2%) of those 
with interrupted adherence to their type 2 diabetes medication were classified as having high 
adherence according to the MMAS-4 versus 82.0% (CI: 76.7-86.6%) of those who did not report 
interrupted adherence (P <0.001).  
Among patients with type 2 diabetes, the single-question measurement of interrupted 
adherence had 16.9% (CI: 8.4%-29.0%) sensitivity and 94.4% (CI: 91.3%-96.7%) specificity 
compared to the validated MMAS-4 scale following guideline implementation. After mHealth 
implementation, the single-question measure had 10.2% (CI: 3.4%-22.2%) sensitivity and 95.7% 
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Supplementary Table F- 2. Sensitivity and Specificity of Single-Question Medication 
Adherence Measure Against the MMAS-4 
  Sensitivity (95% CI) Specificity (95% CI) 
Hypertension   
Guideline Implementation  
(Study Phase II) 16.2% (9.7-24.7%) 93.8% (91.3-95.7%) 
mHealth Implementation 
(Study Phase III) 14.6% (8.2-23.3%) 93.4% (90.0-95.8%) 
Type 2 Diabetes   
Guideline Implementation 
(Study Phase II) 16.9% (8.4-29.0%) 94.4% (91.3-96.7%) 
mHealth Implementation 
(Study Phase III) 10.2% (3.4-22.2%) 95.7% (92.0-98.0%) 
MMAS-4 scores ranging from 1 – 4 are classified as “non-adherent” and MMAS-4 scores of 0 are classified as 
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Appendix G. Paper 3 Additional Results 
Medication Prescription Documented in Patient Health Records 
Hypertension 
Based on patient health records, the most frequently prescribed medications for patients 
with hypertension were beta blockers (48.6%, CI: 44.2-53.1%), though calcium channel blockers 
and angiotensin-converting-enzyme inhibitors/angiotensin II receptor blockers were each 
prescribed for nearly one-third of patients. Just over half (53.0%, CI: 48.5-57.4%) of all patients 
with hypertension were also prescribed cardiac medication, primarily Acetylsalicylic 
acid/Aspirin*, though Clopidogrel/Plavix®, Molsidomine/Corvasal®, and various others were 
also prescribed to a smaller number of patients. The most commonly prescribed antihypertensive 
medications among enrolled patients were Bisoprolol Fumarate/Concor® and 
Amlodipine/Amlor® (Supplementary Table G-1).  
Type 2 Diabetes 
The most frequently prescribed medication for patients with type 2 diabetes reported in 
patient health records was Metformin/Glucophage®, which was prescribed for 84.4% (CI: 79.8-
88.2%) of enrolled patients at enrollment (Supplementary Table G-2). Glimepiride/Amaryl® was 
the second most frequently prescribed medication for patients with type 2 diabetes, though it was 
only prescribed for 40.4% (CI: 34.9-46.1%) of all patients with diabetes. Similar proportions of 
Syrian refugees and Lebanese host community members were prescribed each of these 
medications. 
 
                                                     
* The original spelling of medication names in the Lebanese context is retained in the current work 
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Supplementary Table G- 1. Hypertension Medication Prescription Extracted from Patient 
Records of Enrolled Syrian Refugee and Lebanese Host Community Care-Seekers at Study 
Primary Health Facilities 
    Overall Syrian Refugees Host Community 
P-value 
  
(N=718) (N=489) (N=229) 
    Point (95% CI) Point (95% CI) Point (95% CI) 
Proportion of all hypertension 
patients prescribed medication 
for condition 
69.9% (66.4-73.3%) 66.5% (62.1-70.6%) 77.3% (71.3-82.6%) 0.003 
Number of 
medications reported 
in medical record* 
  (n=502) (n=325) (n=177)  
Median 2 2 2  
Mean 1.79 (1.71-1.86) 1.70 (1.61-1.79) 1.95 (1.81-2.09) 0.002 
Proportion of patients with any 
newly prescribed medication* 30.3% (26.3-34.5%) 38.8% (33.4-44.3%) 14.7% (9.8-20.8%) < 0.001 
Prescribed medication class† (n=502) (n=325) (n=177)  
Beta Blockers 48.6% (44.2-53.1%) 46.8% (41.2-52.4%) 52.0% (44.4-59.5%) 0.265 
Calcium Channel Blockers 32.7% (28.6-37.0%) 29.8% (24.9-35.1%) 37.9% (30.7-45.4%) 0.068 
ACEi/ARBs‡ 30.9% (26.9-35.1%) 32.6% (27.5-38.0%) 27.7% (21.2-34.9%) 0.253 
Diuretics 3.8% (2.3-5.8%) 5.5% (3.3-8.6%) 0.6% (0.0-3.1%) 0.005 
Cardiac§ 53.0% (48.5-57.4%) 48.6% (43.1-54.2%) 61.0% (53.4-68.2%) 0.008 
Other 0.8% (0.2-2.0%) 0.9% (0.2-2.7%) 0.6% (0.0-3.1%) 0.666 
Prescribed antihypertensive 
medication† 
    
Bisoprolol Fumarate/Concor 41.8% (37.5-46.3%) 39.7% (34.3-45.2%) 45.8% (38.3-53.4%) 0.188 
Amlodipine/Amlor 32.3% (28.2-36.6%) 29.8% (24.9-35.1%) 36.7% (29.6-44.3%) 0.115 
Captopril/Capoten 9.8% (7.3-12.7%) 9.8% (6.8-13.6%) 9.6% (5.7-14.9%) 0.931 
Ramipril/Tritace 8.4% (6.1-11.1%) 8.0% (5.3-11.5%) 9.0% (5.3-14.3%) 0.688 
Andesart 8.4% (6.1-11.1%) 10.8% (7.6-14.7%) 4.0% (1.6-8.0%) 0.008 
Atenolol/Tenormin 6.4% (4.4-8.9%) 7.4% (4.8-10.8%) 4.5% (2.0-8.7%) 0.209 
Valsartan/Diovan 4.8% (3.1-7.0%) 4.6% (2.6-7.5%) 5.1% (2.4-9.4%) 0.814 
Esidrex 3.8% (2.3-5.8%) 5.5% (3.3-8.6%) 0.6% (0.0-3.1%) 0.005 
Propranolol/Inderal 0.8% (0.2-2.0%) 0.0% -- 2.3% (0.6-5.7%) 0.007 
Diltiazem/Tildiem 0.6% (0.1-1.7%) 0.0% -- 1.7% (0.4-4.9%) 0.019 
Other 0.8% (0.2-2.0%) 0.9% (0.2-2.7%) 0.6% (0.0-3.1%) 0.666 
Prescribed cardiac medication†     
Acetylsalicylic acid/Aspirin 49.8% (45.3-54.3%) 46.2% (40.6-51.7%) 56.5% (48.9-63.9%) 0.027 
Clopidogrel/Plavix 5.2% (3.4-7.5%) 3.1% (1.5-5.6%) 9.0% (5.3-14.3%) 0.004 
Molsidomine/Corvasal 4.8% (3.1-7.0%) 2.8% (1.3-5.2%) 8.5% (4.8-13.6%) 0.004 
Digoxin/Lanoxin 0.8% (0.2-2.0%) 1.2% (0.3-3.1%) 0.0% -- 0.138 
Acenocoumarol/Sintrom 0.2% (0.0-1.1%) 0.0% -- 0.6% (0.0-3.1%) 0.175 
Isosorbide Dinitrate/Isordil 0.2% (0.0-1.1%) 0.0% -- 0.6% (0.0-3.1%) 0.175 
Amiodarone/Cordarone 0.0% -- 0.0% -- 0.0% -- --- 
Point = point estimate (proportion, mean, or median) 
Group comparison using Pearson's chi-square for proportions and t-test for means. Statistical significance indicated in bold (P<0.05) 
and bold italics (P<0.001). 
* Among patients with a prescription recorded 
† Each as a proportion of all patients with hypertension and a prescription recorded 
‡ ACEi = angiotensin-converting-enzyme inhibitor; ARB = angiotensin II receptor blockers 
§ Including Acetylsalicylic acid/Aspirin, Clopidogrel/Plavix, Molsidomine/Corvasal, Digoxin/Lanoxin, Acenocoumarol/Sintrom, 
Isosorbide Dinitrate/Isordil, and Amiodarone/Cordarone 
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Supplementary Table G- 2. Type 2 Diabetes Medication Prescription Extracted from 
Patient Records of Enrolled Syrian Refugee and Lebanese Host Community Care-Seekers 
at Study Primary Health Facilities 
    Overall Syrian Refugees Host Community 
P-value 
  
(N=431) (N=277) (N=154) 
    Point (95% CI) Point (95% CI) Point (95% CI) 
Proportion of all diabetes 









Number of medications 
reported in medical 
record* 
  (n=307) (n=197) (n=110)  
Median 1 1 1  
Mean 1.43 (1.37-1.49) 1.44 (1.36-1.51) 1.41 (1.31-1.51) 0.659 
Proportion of patients with any 











































Point = point estimate (proportion, mean, or median) 
Group comparison using Pearson's chi-square for proportions. Statistical significance indicated in bold (P<0.05) and bold 
italics (P<0.001). 
* Among patients with a prescription recorded  
† Each as a proportion of all patients with type 2 diabetes and a prescription recorded 
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